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 « Je suis de ceux qui pensent que la science est d’une grande beauté. Un scientifique dans son laboratoire est 
non seulement un technicien : il est aussi un enfant placé devant des phénomènes naturels qui 
l’impressionnent comme des contes de fées. Nous ne devrions pas laisser croire que tout progrès scientifique 
peut être réduit à des mécanismes, des machines, des rouages, quand bien même de tels mécanismes ont eux 
aussi leur beauté. Je ne crois pas non plus que l’esprit d’aventure risque de disparaître dans notre monde. Si 
je vois quelque chose de vital autour de moi, c’est précisément cet esprit d’aventure, qui semble qui me 
paraît indéracinable et s’apparente à la curiosité. Sans la curiosité de l’esprit, que serions-nous ? Telle est 
bien la beauté et la noblesse de la science : désir sans fin de repousser les frontières du savoir, de traquer les 
secrets de la matière et de la vie sans idée préconçue des conséquences éventuelles. » 
Marie Skłodowska Curie 
Ève Curie, Marie Curie, éd. Da Capo Series in Science, p. 341 
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1 ABSTRACT 
Mutations in Bicaudal C1 (BICC1), an RNA binding protein involved in translational regulation, have been 
associated with cystic kidney disease both in humans and in mice. Since kidney cysts associate with 
pancreatic defects in several human syndromes, we investigated the function of BICC1 in pancreas 
development. We found that pancreatic expression of BICC1 was restricted to the bipotent progenitors from 
E12.5 and later to the ducts. Deletion of Bicc1 caused pancreatic cysts, starting with duct dilation at E14.5. 
Around birth, ductal cells were hyperproliferative. However, the mitotic index was not increased at E14.5, 
arguing that the proliferation is not the cause of cyst formation. The expression of PKD2, which is mutated 
in 15% of the patients with autosomal polycystic kidney disease, was downregulated already before ducts 
start to enlarge, consistent with a role downstream of BICC1 that has been reported in kidney and in 
osteoblasts. Conversely, two other targets of BICC1 in kidneys, ADCY6 and PKIA, were not affected by 
Bicc1 deletion in E15.5 pancreata. In addition, after E14.5, but still before birth, Bicc1 deletion led to a 
decrease in the number of endocrine cells. Only half of the normal numbers of beta, delta, PP, and epsilon 
cells were present in Bicc1 KO pancreata. Alpha cells were reduced by 20%. Neither proliferation nor 
survival of the endocrine cells was affected in Bicc1 KO pancreata. Instead, we observed in Bicc1 KOs a 
reduction of the production of endocrine progenitor cells expressing NEUROG3+, a major regulator of 
endocrine cell differentiation. Bicc1 deletion reduced the activity of Neurog3 promoter. Therefore, direct 
translation regulation of Neurog3 by BICC1 can be ruled out. However, the transcriptional activators of 
Neurog3 promoter, HNF1B, ONECUT1, PDX1, FOXA2, SOX9 and its transcriptional repressor, HES1, 
were unaffected by Bicc1 deletion, arguing that they unlikely mediate BICC1 regulation of NEUROG3+ cell 
production. Finally, new BICC1 variants have been uncovered in patients with cystic kidneys, and the two 
oldest diabetes. Contrary to what has been observed with previously reported mutations, the variants did not 
affect the ability of BICC1 to inhibit canonical WNT signaling. In conclusion, this study showed that BICC1 
is important to maintain duct homeostasis and endocrine progenitor production. BICC1 may thus be a 
susceptibility factor for diabetes when it is mutated. 
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2 RESUME 
La polykystose rénale chez la souris et la dysplasie rénale multikystique chez l’humain peuvent être 
associées à la perturbation ou l’inactivation de Bicaudal C (BICC1), une protéine liant l’ARN et régulant la 
traduction des RNA messagers. En raison de l’existence de syndromes associant des kystes rénaux et un 
dysfonctionnement du pancréas, nous nous sommes intéressés à la fonction de BICC1 durant l’organogenèse 
pancréatique. Chez la souris, le domaine d’expression de BICC1 est restreint aux progéniteurs à double 
potentialités à 12 jours et demi après la fertilisation et par la suite aux canaux pancréatiques. Dans le 
pancréas, l’absence de Bicc1 provoque la formation de kystes commençant par une dilatation des canaux à 
14 jours et demi. Aux alentours de la naissance, les cellules canalaire prolifèrent plus activement. Cependant, 
l’augmentation de la prolifération n’est pas la cause initiale des kystes car la proportion des cellules qui se 
divisent n’est pas accrue à 14 jours et demi. Par contre, on a observé, avant même l’élargissement des 
canaux, une diminution de l’expression de PKD2. Hors, 15% des cas de polykystoses rénales autosomiques 
dominantes sont causés par une mutation dans le gène de PKD2. De plus, chez la souris, il a été découvert 
que son expression est régulée par BICC1 dans les ostéoblastes et dans les reins. En revanche, dans le 
pancréas des mutants à 15 jours et demi, je n’ai pas observé de changement de l’expression de deux autres 
protéines, ADCY6 et PKIA, elle aussi régulée par BICC1 dans les reins. Par ailleurs, à la naissance, le 
nombre de cellules endocrines bêta, delta, PP et epsilon est réduite de moitié alors qu’il y a que 20% de 
cellules alpha en moins chez les mutants Bicc1. Ces déficits ne sont pas observés à 14 jours et demi et ne 
sont pas causés par une diminution de leur survie ou de leur capacité à proliférer. Cependant, l’aptitude des 
progéniteurs à se différentier en progéniteurs endocrines exprimant Neurog3, un facteur de transcription 
nécessaire pour continuer la différentiation en cellule endocrine, est réduite chez les mutants. La régulation 
par BICC1 de la traduction de Neurog3 peut être exclue puisque l’absence de BICC1 affecte l’activité du 
promoteur de Neurog3. Néanmoins, l’expression des activateurs transcriptionnels de Neurog3, HNF1B, 
ONECUT1, PDX1, FOXA2, SOX9, et de son répresseur transcriptionnel, HES1, ne change pas chez les 
mutants Bicc1. Ils ne relayent donc pas la régulation par BICC1 de la production de cellules positive pour 
NEUROG3. Pour finir, de nouveaux allèles de BICC1 ont été identifiés chez des patients présentant des 
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kystes rénaux et pour certains d’entre eux, un diabète. Nonobstant ce qui a été observé avec les premières 
mutations de BICC1 découvertes, la capacité de BICC1 d’inhiber la voie de signalisation canonique de WNT 
n’est pas altérée par les nouveaux variants de BICC1. Pour conclure, cette étude montre que BICC1 est 
essentiel pour l’homéostasie des canaux pancréatiques et promeut la production des progéniteurs endocrines. 
En raison de cette capacité, des mutations affectant la fonction de BICC1 pourraient être un facteur de 
susceptibilité au diabète. 
Mots-clefs : Bicaudal C1, protéine liant l’ARN, embryon, pancréas, progéniteurs endocrines, cellules 
endocrines, MODY, kystes 
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3 ABBREVIATIONS 
Table 1: list of the abbreviation used in this work and their meaning 
Abbreviation Meaning 
% percent or g per 100ml 
°C celsius degree 
3D 3 dimensions 
3'-UTR 3'- untranslated region 
Ac Tub acetyl tubulin 
ADCY adenylate cyclase 
ADPKD autosomal dominant polycystic 
kidney disease 
Al488 alexa488 
Al568 alexa568 
Al647 alexa647 
ANOVA analysis of variance 
ARPKD autosomal recessive polycystic 
kidney disease 
ATP Adenosine triphosphate 
bHLH basic helix-loop-helix 
Bicc1 Bicaudal C1 
BMP bone morphogenetic protein 
bTC beta cell line 
C2H2  paired cystine and histidine type 
C6FeK3N6, Potassium ferricyanide 
C6FeK4N63H2O Potassium ferrocyanide trihyrate 
Ca2+ calcium ion 
cAMP cyclic adenosine monophosphate 
cDNA complementary deoxyribonucleic 
acid 
CCR4-NOT CCR4 deadenylase complex 
COPII Coat protein II 
DAPI 4′,6-Diamidino-2-phenyindole 
DBA Dolichos Biflorus Agglutinin  
DBA dolichos biflorus agglutinin 
DESeq Differential expression analysis for 
sequence count data 
DVL Dishevelled 
Abbreviation Meaning 
E embryonic day 
e. g. exempli gratia 
ECL enhanced chemiluminescence 
EGF epithelium growth factor 
EGTA Ethylene Glycol Tetraacetic Acid 
ESRD end stage renal disease 
FDR false discovery rate 
FGF fibroblast growth factor 
FZD frizzled receptor 
g/l gram per litre 
Gcg Glucagon 
Ghr ghrelin 
H2O water 
HA-tag Influenza Hemagglutinin peptide-
tag 
HEK293T cell human embryonic kidney 293 cell 
HES family hairy and enhancer of split family 
factors  
HNF hepatic nuclear factor 
Hprt1 Hprt 
HRP horseradish peroxydase 
i. e. id est 
Ins Insulin 
K+ potassium ion 
KCl potassium chloride 
KH K homology RNA-binding domain 
KO knockout 
M Molar 
mA milliAmper 
MAPK 
(signaling) 
pathway 
MAP kinase signaling pathway 
MgCl2 Magnesium Chloride 
Mir17-92  miR-17~92 miRNA cluster  
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Abbreviation Meaning 
ml millilitre 
µm micrometer 
mM milliMolar 
mRNA RNA messenger 
n number of specimens 
Na+  sodium ion 
Na+K+ATPase  sodium potassium pump 
NaCl sodium chloride 
Neurog3 Neurogenin3 
ng nanogram 
NOTCH notch family 
OCT Optimal cutting temperature 
P postnatal day 
PBS phosphate buffer saline 
PCP planar cell polarity pathway 
PDE1 phosphodiesterase 1 (a, b and c) 
PFA paraformaldehyde 
pH potential of hydrogen 
PHH3 Phospho-histone H3 
phospho- phosphorylated 
PKA protein kinase A, cAMP dependent 
PKC Protein kinase C 
PKD polycystic kidey disease 
Pkd1 polycystic kidney disease 1 
homolog 
Pkd2 polycystic kidney disease 2 
Pkhd1 polycystic kidney and hepatic 
disease 1 
PNDM permanent neonatal diabetes 
Abbreviation Meaning 
polyA Polyadenylic acid  
Ppy pancreatic polypeptide 
Q-PCR quantitative real time polymerase 
chain reaction 
RFP red fluorescent protein 
RNA ribonucleic acid 
rpkm read per kilobase per million 
SAM sterile alpha motif 
SDS Sodium dodecyl sulfate 
SMART simple molecular architecture 
research tool 
Sst somatostatin 
SUR sysematic uniform random 
sampled 
TBST Tris buffer saline Triton 
TBSTw Tris buffer saline Tween20  
TNDM transient neonatal diabetes 
Tris Tris(hydroxymethyl)aminomethane 
TUNEL terminal deoxynucleotidyl 
transferase-dUTP nick end labeling 
assay  
VANGL VANGL1 and VANGL2 
vs versus 
WNT WNT family members 
WT wild-type 
X-gal 5-bromo-4-chloro-3-indolyl-beta-
D-galacto-pyranoside 
YFP yellow fluorescence protein 
Some of the most important genes are included in this table. All the other gene symbols present in this work are listed 
with their full official name in Table 11 in the Appendix.  
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5 PREAMBLE 
There are several syndromes which associate kidney cysts and diabetes. For instance, young adults with 
HNF1B mutations have MODY5, a syndrome characterized by renal cysts and diabetes. Similarly newborns 
without functional GLIS3 develop neonatal diabetes with hypothyroidism, and some of them harbor cysts in 
the kidneys (Lindner et al., 1999; Senée et al., 2006). Therefore genes endowed with a role in kidney 
homeostasis may be important for beta cell generation and function or vice versa. Moreover, the renal-
hepatic-pancreatic dysplasia syndrome associating fibrosis and cysts in the kidneys, the liver, and the 
pancreas (Ivemark et al., 1959). In mice, the inactivation of Pkd1 or Pkd2 associate cystic kidney disease and 
pancreatic cysts, suggesting similar mechanisms of ductal homeostasis in both organs (Wu et al., 2000; Lu et 
al., 2001; Wu et al., 2002). BICC1 mutation has been recently associated with human kidney dysplasia 
(Kraus et al., 2012), and Bicc1 mutant mice have been used as a model for autosomal recessive polycystic 
kidney disease (Nauta et al., 1993; Flaherty et al., 1995). Moreover, targeted deletion of Bicc1 in mice results 
in cysts in kidneys and in the pancreas (Tran et al., 2010; Piazzon et al., 2012). 
Prompted by the idea that genes involved in the formation of kidney cysts could be associated to defects in 
beta cells, leading to diabetes and/or to cysts in the pancreas, my PhD project has focused on the role of 
BICC1 during murine pancreas development, principally on its role in ductal homeostasis and endocrine cell 
differentiation. In addition, I have started to characterize the functionality of new BICC1 variants identified 
by the groups of Pr. Bingham, Pr. Ellard, and Pr Hattersley, in patients with renal cysts kidneys and, for the 
oldest patients, diabetes. The majority of the results have been recently published in (Lemaire et al., in press) 
with the exception of the characterization of E12.5 Bicc1 KO pancreata, the microRNA sequencing 
performed on E13.5 Bicc1 KO and WT pancreatic dorsal buds and, the study of human BICC1 variants. 
During my PhD, I have also characterized two mouse lines, a transgenic Neurog3-RFP line and a knock-in 
Sox17CREGFP line. The corresponding articles are provided in the Appendix (Choi et al., 2012; Kim et al., 
2015).  
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6 INTRODUCTION 
6.1 Pancreas physiology and Diabetes 
6.1.1 Pancreas physiology 
The pancreas is an abdominal organ with a dual function. It is involved in digestion by secreting pancreatic 
enzymes from the acini. The exudates are collected by a ductal network and converge in the duodenum with 
bile fluid.  
 
Fig. 1: Scheme representing the adult pancreas  
Pancreas is an abdominal organ. It is composed of an acinar compartment (blue) connected by ducts (green) to the 
duodenum, and the islets of Langerhans (light blue, red, pink and purples) are scattered in the exocrine compartment 
(color code corresponds to Fig. 2). 
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The islets of Langerhans provide the other function. They are composed of 5 different cell types. Beta cells, 
the most numerous, secrete insulin (INS). Alpha cells secrete glucagon (GCG). Delta cells secrete 
somatostatin (SST). These hormones are involved in blood glucose homeostasis, with insulin lowering 
glycemia, glucagon having the opposite effect and somatostatin controlling, in a paracrine manner the 
secretion of INS and GCG. SST also controls the secretion of growth hormones, among other functions. PP 
cells secrete pancreatic polypeptide (PPY) that is involved in digestion and food intake regulation as well as 
mood control. Epsilon cells secrete ghrelin (GHR) also to stimulate food intake (Fig. 1) (Norris and Carr, 
Chemical Regulation of Feeding, Digestion and Metabolism, in Vetebrate Endocrinology, 2013).  
6.1.2 Diabetes mellitus 
Diabetes is one of the most challenging diseases of the 21st century. 390 million people suffer from diabetes 
worldwide and 4.9 million died of a consequence of diabetes in 2014 (International Diabetes Federation, 
2014 update, in IDF Diabetes Atlas, 2014). It is characterized by hyperglycemia due to a defect in glucose 
homeostasis. Hyperglycemia causes polydipsia and polyuria associated with glycosuria distinguishes it from 
diabetes insipidus. The long term complications associated with diabetes mellitus include cardiovascular 
diseases and kidney failure (Scobie and Samaras, Chapter 3: Type 1 diabetes and Chapter 4: Type 2 diabetes, 
in Fast facts: Diabetes mellitus, 2014) 
The different types of diabetes are classified based on their etiology and time of apparition. Type II diabetes 
is the most prevalent accounting for nearly 90% of all diabetic cases. It mainly appears in adulthood between 
40 and 60 years of age. It is a metabolic disease caused by the inability of peripheral cells to respond to 
insulin and, thus, reduce blood glucose level. In response to such peripheral resistance, beta cells increase 
their insulin secretion until they slowly die of exhaustion (Scobie and Samaras, Chapter 4: Type 2 diabetes, 
in Fast facts: Diabetes mellitus, 2014b). Treatment of type II diabetes is initially by an adapted diet and by 
drugs that normalize glycemia by inhibiting liver neoglucogenesis or by promoting insulin secretion. But as 
beta cells become dysfunctional insulin injections are needed to lower the glycemia (Inzucchi et al., 2015). 
Type I diabetes, the second most common type, is an autoimmune disease characterized by immune attack 
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against the beta cells leading to their destruction. It is thus directly insulin dependent. Patients developing 
type I diabetes are also younger, being in their childhood or their early twenties (Scobie and Samaras, 
Chapter 3: Type 1 diabetes, in Fast facts: Diabetes mellitus, 2014a).  
6.1.2.1 Monogenic diabetes 
The etiology of type I and type II diabetes is multifactorial as it involves both complex genetic predisposition 
and environmental cues. By contrast, other more rare forms of diabetes are monogenic, which means that 
they are caused by a mutation in only one gene. Monogenic forms of diabetes are usually characterized by an 
absence of autoimmune reaction, and their onset is earlier than type II diabetes. Mature onset diabetes of the 
young (MODY) syndromes are characterized by an onset before the age of 25, even though some patients 
may develop it later (reviewed in Ashcroft and Rorsman, 2012). Rare infants (1/400000 birth) develop 
diabetes in the first months of life. The disease is called neonatal diabetes, and is either transient neonatal 
diabetes (TNDM), when babies recover, or permanent (PNDM) (reviewed in Polak and Shield, 2004). The 
monogenic causes of diabetes not only shed important light on pathogenesis and beta cell physiology, but 
also on beta cell ontogeny, as some of the genes mutated in monogenic diabetes regulate beta cell formation. 
They also give insight on the similarities and discrepancies between human and mouse models as the mouse 
model do not always recapitulate the corresponding human disease. Forms of monogenic diabetes are 
reviewed in Tables 2 and 3. 
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Table 2: MODY 
Name Muta-
tion 
Transmission 
mode 
Other 
defect 0F1 
Mouse phenotype 1F2 References2F3 
Altröm 
disease 
ALMS1 Recessive Yes* Type II diabetes (Collin et al., 2002; Hearn et al., 
2002; Collin et al., 2005) 
MODC3F4 GATA4 dominant Yes Ventral pancreas agenesis 
(tetraploid 
complementation) 
(Watt et al., 2007; Shaw-Smith 
et al., 2014) 
MODY KCNJ11 Dominant, 
relapse from 
TNDM 
Yes Neonatal diabetes (gain of 
function)  
 
(Koster et al., 2000; Flanagan et 
al., 2007) 
 
MODY ABCC8 Dominant, 
relapse from 
TNDM 
Yes impaired glucose 
tolerance  
(Seghers et al., 2000; Flanagan 
et al., 2007; Bowman et al., 
2011) 
MODY 6q22-23 Imprinted gene, 
paternal 
inheritance 
relapse from 
TNDM 
Yes Overexpression: neonatal 
hyperglycemia, adult 
glucose intolerance 
(Shield et al., 1997; Ma et al., 
2004) 
MODY1 HNF4A Dominant 
 
No Embryonic lethal 
Impaired glucose 
tolerance (pancreas 
specific deletion) 
(Chen et al., 1994; Yamagata et 
al., 1996; Gupta et al., 2005) 
MODY2 GCK Dominant No Glucose intolerance  (Vionnet et al., 1992; Terauchi 
et al., 1995) 
MODY3 HNF1A Dominant No Diabetes (Yamada et al., 1997; Pontoglio 
et al., 1998) 
MODY4 PDX1 Dominant No Pancreas agenesis (Offield et al., 1996; Stoffers et 
al., 1997a) 
MODY5 HNF1B Dominant Yes * Neonatal diabetes 
(pancreas specific 
deletion) 
(Horikawa et al., 1997; Lindner 
et al., 1999; De Vas et al., 2015) 
MODY6 NEURO
D1 
Dominant No Neonatal diabetes  (Naya et al., 1997; Malecki et 
al., 1999) 
MODY7 KLF11 Dominant No Impaired INS secretion, 
no diabetes 
(Neve et al., 2005; Bonnefond et 
al., 2011) 
MODY8 4F5 CEL Dominant Yes No glucose intolerance 
phenotype 
(Ræder et al., 2005; Vesterhus et 
al., 2010) 
MODY9 PAX4 Dominant No Neonatal diabetes based 
on observed symptoms 
(Sosa-Pineda et al., 1997; 
Plengvidhya et al., 2007) 
MODY10 INS Dominant No Diabetes at week 7 
(Dominant negative of 
Ins2)  
(Yoshioka et al., 1997; Edghill 
et al., 2007) 
MODY11 BLK Dominant No Not reported (Texido et al., 2000; Maciej et 
al., 2009) 
Wolfram 
syndrome 
(MODY 
before 15 year 
old) 
WFS1 Recessive 
 
Yes Impaired glucose 
tolerance 
(Inoue et al., 1998; Ishihara et 
al., 2004) 
Classification based on OMIM (http://www.ncbi.nlm.nih.gov/omim/). 
                                                     
1
 * kidney defects 
2
 If not stated, KO 
3
 First mutation described 
4
 Onset in childhood 
5
 diabetes and exocrine pancreatic dysfunction 
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Table 3: Transient and permanent neonatal diabetes mellitus 
Name Muta-
tion 
Transmission 
mode 
Other 
defect 5F
6
 
Mouse phenotype 6F7 References7F8 
Fanconi-
Bickel 
syndrome: 
(PNDM) 
SLC2A2 Recessive 
 
Yes Diabetes (Guillam et al., 1997; Yoo et al., 
2002) 
IPEX 
(PNDM –
Type I 
diabetes) 
FOXP3 X linked Yes Earlier diabetes onset in 
NOD background than 
NOD mice 
(Wildin et al., 2001; Chen et al., 
2005) 
PNDM ABCC8 Recessive Yes impaired glucose 
tolerance  
(Seghers et al., 2000; Ellard et 
al., 2007) 
Dominant Yes (Babenko et al., 2006)  
PNDM GCK Recessive 
 
Yes Neonatal diabetes (Terauchi et al., 1995; Njølstad 
et al., 2001) 
PNDM GATA4 Dominant Yes Ventral pancreas agenesis 
(tetraploid 
complementation)  
(Watt et al., 2007; Shaw-Smith 
et al., 2014) 
PNDM-
Pancreas 
agenesis 
GATA6 Dominant 
 
Yes Ventral pancreatic 
agenesis (tetraploid 
complementation)  
(Watt et al., 2007; Lango Allen 
et al., 2011) 
PNDM GLIS3 Recessive Yes* Neonatal diabetes  (Senée et al., 2006; Kang et al., 
2009b) 
PNDM INS Recessive No Neonatal diabetes  (Duvillie et al., 1997; Garin et 
al., 2010) 
Dominant No Diabetes at week 7 
(Dominant negative Ins2)  
(Yoshioka et al., 1997; Støy et 
al., 2007) 
PNDM KCNJ1
1 
Dominant Yes Neonatal diabetes (GOF) (Koster et al., 2000; Gloyn et al., 
2004) 
PNDM MNX1 Recessive 
 
Yes Dorsal lobe agenesis, less 
insulin cell (relative) 
(Harrison et al., 1999; 
Bonnefond et al., 2013; 
Flanagan et al., 2014) 
PNDM NEURO
G3 
Recessive Yes Neonatal diabetes  (Gradwohl et al., 2000; Rubio-
Cabezas et al., 2011) 
PNDM NEURO
D1 
Recessive Yes Neonatal diabetes  (Naya et al., 1997; Rubio-
Cabezas et al., 2010) 
PNDM NKX2.2 Recessive Yes Neonatal diabetes  (Sussel et al., 1998; Flanagan et 
al., 2014) 
PNDM PAX6 Recessive Yes Glycemia not tested 
 
(St-Onge et al., 1997; Solomon 
et al., 2009) 
  
                                                     
6
 * kidney defect 
7
 If not stated, KO phenotype 
8
 First mutation described 
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PNDM with 
or without 
pancreas 
agenesis 
PDX1 Recessive 
 
Yes Pancreas agenesis  (Offield et al., 1996; Stoffers et 
al., 1997b; Nicolino et al., 2010) 
PNDM PTF1A Recessive 
 
Yes Pancreas agenesis  (Krapp et al., 1998; Sellick et al., 
2004) 
PNDM RFX6 Recessive Yes No Insulin cells, 
glycemia not tested  
(Smith et al., 2010)  
Thiamine-
responsive 
megaloblastic 
anemia with 
diabetes and 
deafness 
(PNDM) 
SLC19A
2 
Recessive Yes Diabetes after 2 weeks on 
thiamin free diet, no 
phenotype on normal diet  
(Oishi et al., 2002; Olsen et al., 
2007) 
TNDM1 6q22-23 
regions 
Imprinted 
genes, paternal 
inheritance 
Yes Overexpression: neonatal 
hyperglycemia, adult 
glucose intolerance 
(Temple et al., 1995; Temple et 
al., 1996; Ma et al., 2004) 
TNDM2 ABCC8 dominant Yes impaired glucose 
tolerance 
(Seghers et al., 2000; Babenko et 
al., 2006; Proks et al., 2006) 
TNDM3 KCNJ1
1 
dominant Yes Neonatal diabetes (gain 
of function)  
(Koster et al., 2000; Gloyn et al., 
2004) 
Wolcott-
Rallison 
syndrome 
(PNDM) 
EIF2AK
3 
Recessive Yes Diabetes  (Delépine et al., 2000; Harding 
et al., 2001) 
Classification based on OMIM (http://www.ncbi.nlm.nih.gov/omim/). 
6.2 Pancreas organogenesis 
6.2.1 Pancreatic epithelium morphogenesis 
In mouse, two regions of the foregut become committed to a pancreatic fate at E8. The first sign of pancreas 
formation is their thickening, which occurs for the dorsal bud at E9 and for the ventral bud at E9.5 The 
epithelium then evaginates into the surrounding mesenchyme, forming a bud (Wessells and Cohen, 1967; 
Spooner et al., 1970)8F9. At E10.5, the bud is mainly composed of multipotent progenitors able to give rise to 
endocrine cells, acinar cells and ductal cells (Fig. 2, 3) (Pan et al., 2013). 
                                                     
9
 Spooner et al describe the formation of the ventral bud in rats. 
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Fig. 2: Pancreas morphogenesis 
(A) The pancreas is specified in two regions of the foregut (brown) at E8. They grow and bud into the surrounding 
mesenchyme (light yellow). A few endocrine progenitors (yellow) and GCG+ cells (red) are already present. Around 
E11.5, microlumens form, and fuse. The plexus then rearranges to form the pancreatic tree composed of a trunk of 
bipotent progenitors (light green) and ended by acinar progenitors (light blue). After the secondary transition has 
started, bipotent progenitors differentiate more into endocrine progenitors (yellow) that leave the ducts, and differentiate 
further into endocrine cells (red and turquoise blue). The bipotent progenitors, which did not become endocrine 
progenitors, differentiate into ductal cells (dark green). The acinar progenitors (light blue) have differentiated into 
acinar cells (dark blue). Endocrine cell clusters (red, light pink, fuchsia, purple and turquoise blue) present at earlier 
stages aggregate and reorganize to form the mature islet of Langerhans around birth. 
(B) The color code depicting the different cell types. 
The cells in the epithelial bud will then rearrange. Apical polarity cues start to be targeted to one side of the 
cells, in a coordinated manner between cells, resulting in the formation of microlumens. Lumens 
progressively fuse to form a tubular plexus at E12.5 (Kesavan et al., 2009; Villasenor et al., 2010). The 
plexus is composed of tubules ending by tips forming a tree-like structure. The pancreas is still mainly 
composed of multipotent pancreatic progenitors, with few endocrine progenitors and endocrine cells (Fig. 2, 
3) (Georgia et al., 2006; Seymour et al., 2007). Dorsal and ventral buds fuse around E13 (Villasenor et al., 
2010). 
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Fig. 3: Pancreatic cell lineage ontogeny  
Multipotent progenitors can give rise to all cell lineages in the pancreas. After the specification of the tip vs trunk 
domain, acinar progenitors at the tips give rise to acinar cells, while bipotent progenitors differentiate into endocrine 
progenitors, or adopt a ductal cell fate. The former leave the trunk domain and differentiate into the five endocrine cell 
types present in the pancreas. Ontogeny has been inferred from lineage tracing experiments using reporters or a CRE 
recombinase under the promoter of a gene of interest (Gu et al., 2003; Zhou et al., 2007; Pan et al., 2013) as well as KO 
data analysis. 
The cell color code is the same as used in Fig. 2.  
After E13.5, the plexus reorganization starts (Villasenor et al., 2010). Endocrine cells differentiation is 
greatly enhance; it is the so-called secondary transition (Mori and Haga, 1960; Rutter et al., 1968). The cells 
present in the distal domain, also called tips, restrict their potency, and by E13.5, become committed to the 
acinar fate (Zhou et al., 2007; Schaffer et al., 2010; Pan et al., 2013). Progenitors present in the proximal 
domain, referred to trunk, become bipotent, and give rise to either ductal cells or endocrine progenitor cells 
expressing NEUROG3, a major transcription factor for the endocrine differentiation program (Gradwohl et 
al., 2000; Schaffer et al., 2010). The endocrine progenitors born in the epithelial layer lining ducts 
delaminate, while they differentiate into the different endocrine cell types (Fig. 2, 3) (Gouzi et al., 2011).  
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There is scant information on how cells choose to differentiate into one or the other endocrine cell type. It 
has been reported than endocrine progenitors are unipotent. However, they rarely divide (Desgraz and 
Herrera, 2009; Miyatsuka et al., 2011). It is thus logical that one pancreatic progenitor gives rise to one type 
of endocrine cells. The different endocrine cell types do not arise at the same time. Indeed, they are produced 
in different overlapping waves, suggesting that their progenitors are competent to give rise to different cells 
at different moments (Johansson et al., 2007). The first endocrine cells expressing GCG are already present 
at E9.5 (Pictet et al., 1972; Rall et al., 1973). The GCG+ cell production becomes minor by E14.5. INS+ cells 
are produced from E10.5 forward. However, the first are immature in the sense that they produce low levels 
of INS, that they miss many molecular hallmarks of beta cells, and that they co-express GCG. PP cells start 
to be produced from the same stage while delta cells arise only later, from E14.5 onward (Johansson et al., 
2007). The endocrine cells are scattered between the bipotent progenitor cords, or form small clusters during 
embryonic development. Around birth, endocrine cells reorganize to form the mature islets of Langerhans 
with beta cells in the center surrounded by the other endocrine cells types in mice (Fig. 2, 3) (Pictet et al., 
1972; Herrera et al., 1991). During development, the expansion in size of the islets is mainly due to the 
convergence of endocrine cells, and, for a small part, to the ability of endocrine cells to proliferate in the late 
developmental stages (Pictet et al., 1972; Deltour et al., 1991; Finegood et al., 1995; Jensen et al., 2000a). 
After birth, massive expansion of the islets is due to proliferation (Finegood et al., 1995; Georgia and 
Bhushan, 2004). 
6.2.2 Pancreatic stroma formation 
The pancreatic stroma is composed of blood vessels, mesenchymal cells, neurons and immune cells. 
6.2.2.1 Mesenchymal cells in pancreatic organogenesis 
The mesenchymal cells of the pancreas originate from the splanchnopleura of the lateral plate mesoderm 
(Wessells and Cohen, 1967). At E8.5-9.5, they are still in lateral position and they are not yet in contact with 
the dorsal pancreas anlage, which initially abuts the notochord and subsequently the dorsal aorta, as it fuses 
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medially from the two lateral aortas (Wessells and Cohen, 1967). The splanchnopleural mesodermal cells 
will migrate along the lateral side of the gut towards the dorsal pancreas primordium and separate it from the 
dorsal aorta. At E10.5 they surround the pancreatic buds (Wessells and Cohen, 1967). Thereafter, the 
mesenchyme is intermingled between the ducts and around the epithelium (Villasenor et al., 2010). The 
proportion of mesenchyme vs epithelium is progressively reduced and, at E18.5, represents 5% of the total 
pancreas (Landsman et al., 2011). In its absence, neither growth nor branching occurs at early stages 
(Golosow and Grobstein, 1962; Edsbagge et al., 2005). At later stages, the mesenchymal cells also promote 
growth of progenitors without affecting differentiation (Landsman et al., 2011). This is due to the secretion 
of signaling factors by mesenchymal cells and their molecular nature is further discussed on p 47. After birth, 
some pancreatic stellate cells, the fibroblasts mainly present around the acini, originate from these 
mesenchymal cells, while others come from the bone marrow (Apte et al., 1998; Watanabe et al., 2009). 
They play important roles in extracellular matrix maintenance and therefore pancreas homeostasis (reviewed 
in Masamune and Shimosegawa, 2013). 
6.2.2.2 Blood vessels in pancreas organogenesis 
Blood vessels have a complex role during pancreas organogenesis. After the specification of the dorsal 
pancreas primordium and initial induction by signals from the notochord, the dorsal aorta is required for the 
dorsal pancreas development. It induces and maintains the expression of  pancreas progenitor markers, such 
as PDX1 and PTF1A. Furthermore, it has indirect activities by promoting the survival of the pancreatic 
mesenchyme, which is necessary for pancreas development (Lammert et al., 2001; Yoshitomi and Zaret, 
2004; Jacquemin et al., 2006). It is unclear whether there are similar signals acting on the ventral pancreas, 
but the vitelline veins contacting it do not appear necessary in early organogenesis (Yoshitomi and Zaret, 
2004).  
At E10.5, blood vessels surround the buds. At E11.5, when the pancreatic epithelium starts to reorganize, 
blood vessels invade the buds. Initially, they are close to the pancreatic proximal domain, and are excluded 
from the distal domain (Pierreux et al., 2010). The presence of blood vessels in the proximal domain 
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promotes pancreatic growth, in part via a decrease in pancreas progenitor proliferation (Magenheim et al., 
2011b; Sand et al., 2011) and because of their negative influence on acinar differentiation (Pierreux et al., 
2010; Magenheim et al., 2011b).  
Their effect on endocrine differentiation is more controversial. Blood vessels may have no effect (Sand et al., 
2011), or inhibit it (Magenheim et al., 2011b). On the contrary, Pierreux and co-workers suggest that blood 
vessels might even promote endocrine differentiation (Pierreux et al., 2010). In line with this observation, 
Lammert and colleagues observed ectopic INS+ cells in the presence of an excess of blood vessels (Lammert 
et al., 2001). These discrepancies may be caused by the fact that endocrine and endothelial cells influence 
each other, or may be due to the embryonic stage of observation. For example after birth, endothelial cells 
are tightly associated with beta cells, and promote both their function and their proliferation (Duvillié et al., 
2002; Brissova et al., 2006; Nikolova et al., 2006). 
6.2.2.3 Glial and Neural cells in pancreas organogenesis 
Pancreatic neural and glial cells originate from the neural crest (Nekrep et al., 2008). Neural crest cells arrive 
in the pancreas at E10.0 (Plank et al., 2011). In the absence of neural crest cells, no neurons or glial cells are 
observed in the pancreas. Consequently, the beta cell mass expands excessively due to an increase of beta 
cell proliferation. However, the resulting beta cells are not mature, indicating that glial cells and/or neurons 
promote beta cell differentiation (Plank et al., 2011). Nevertheless, the signals mediating this potent 
influence on beta cell proliferation are elusive. 
6.2.2.4 Immune cells in pancreas organogenesis 
Immune cells marked by PTPRC, also called CD45, are already present in the E12.5 pancreas (Geutskens et 
al., 2005; Sand et al., 2011). Macrophages positive for EMR1, also called F4/80, are first detected at E14.5 
(Banaei-Bouchareb et al., 2004; Geutskens et al., 2005). However, there is a paucity of information about the 
function of macrophages or more generally immune cells, in this organ. Beta cell proliferation, and therefore 
beta cell mass, is impaired in mice deficient for CSF1 which have extremely few to no EMR1+ macrophages. 
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This result is in line with in vitro observations. The expansion of macrophage population by CFS1 increases 
the beta cell mass, in pancreatic explants (Banaei-Bouchareb et al., 2004; Geutskens et al., 2005). However, 
as these studies relied on the depletion or addition of CSF1 to control the macrophage number, one cannot 
rule out the possibility that CFS1 may also directly affect the beta cell mass. Dendritic cell numbers were 
minimal in the developing pancreas (Banaei-Bouchareb et al., 2004), and no other immune cell type has been 
described during pancreas organogenesis. 
6.2.3 Transcriptional control of pancreas development 
Transcription factors play an important role in pancreas organogenesis, as they drive the differentiation 
cascades. Thereafter, the same transcription factors are required for the function of the different cell types. 
Many of these transcription factors form highly interconnected networks that presumably stabilize specific 
cellular states. In some instances, a given factor has different functions depending on the stage of 
development and the cell type. In addition, different factors may regulate targets together. For instance, 
during proximal distal domain boundary establishment, PTF1A and NKX6.1, initially co-expressed in 
multipotent progenitors antagonize each other and respectively segregate to distal acini and proximal 
bipotent progenitors. PTF1A specifies acinar progenitors while NKX6.1 promotes bipotent progenitor fate 
(Schaffer et al., 2010). Other transcription factor interactions in multipotent or bipotent progenitors are 
depicted in (Fig. 4). Their interactions aim to principally stabilize pancreatic progenitor identity and are 
discussed in details in the subsequent sections. 
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Fig. 4: Gene regulatory network in multipotent progenitors and bipotent progenitors. 
Transcription factor relationships in multipotent progenitors are represented by green arrows for the activation of gene 
expression and red arrows for the repression of the expression. Dashed arrows denote evidence of interaction without 
direct activation or repression. During the establishment of the proximal distal domain boundaries, PTF1A and NKX6.1 
antagonize each other (orange arrows). Gray transcription factors are absent in bipotent progenitors. The inhibition of 
HNF1B by SOX9 and the promotion of the expression of ONECUT1 have only been found in vitro (Dubois et al., 
2011). 
When NEUROG3 starts to be expressed, it promotes its own expression (light green arrow) and represses at least SOX9 
(light red arrow) to enable endocrine cell differentiation. 
The scheme is adapted from the review (Arda et al., 2013), and based on the following refrences (Jacquemin et al., 
2003a; Pedersen et al., 2005; Wiebe et al., 2007; Oliver-Krasinski et al., 2009; Schaffer et al., 2010; Dubois et al., 2011; 
Yang et al., 2011; Ahnfelt-Rønne et al., 2012; Kim et al., 2012; Shih et al., 2012; Thompson et al., 2012; Ejarque et al., 
2013; De Vas et al., 2015) 
The main transcription factors involved in pancreas organogenesis, with emphasis on those used in this 
study, are reviewed here. 
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6.2.3.1 PDX1 
PDX1 is a homeodomain protein (Ohlsson et al., 1993). Its expression starts at E8.5 in the prospective 
pancreatic regions. It is expressed in the multipotent progenitors from E9.5. From E16.5, its expression is 
reduced in the acinar cells, where it remains only at low levels in adults. At E18.5 its expression is largely 
restricted to beta cells and a subset of delta cells (Ohlsson et al., 1993; Guz et al., 1995; Wu et al., 1997; 
Wescott et al., 2009). It is noteworthy that the expression level of PDX1 varies depending on its function. 
Low expression is sufficient for its activity in the stomach and the duodenum, where it is also expressed. 
Higher expression is required in the bipotent progenitors and the highest level is required in beta cells, as 
shown in elegant studies controlling Pdx1 dosage (Guz et al., 1995; Fujitani et al., 2006). 
Pancreatic progenitors 
PDX1 is necessary for the maintenance of the pancreatic progenitor pool. Indeed, mice homozygote for a 
Pdx1 null allele have a highly hypoplastic pancreas and die shortly after birth (Jonsson et al., 1994; Offield et 
al., 1996). The remnant pancreas comes from the dorsal pancreas and is composed of a poorly branched 
epithelium lacking acinar cells. In these mutants, GCG+ cells form normally until E9.5, but are reduced at 
later stages, while the other endocrine cells are absent. PDX1 is not necessary for the specification of either 
dorsal or ventral buds, as their size is unchanged at E9.5 in Pdx1 KOs (Offield et al., 1996). Indeed, the 
absence of PDX1 from E12.5 causes the same phenotype. PDX1 is later involved in the production of mature 
ducts (Hale et al., 2005). It is indeed able to bind and activate Foxa2 and Hnf1b promoters, while it indirectly 
regulates Onecut1 and Sox9. All of them are transcription factors important for the pancreatic progenitor and 
ductal identity (Oliver-Krasinski et al., 2009). In addition, the inactivation of Pdx1 from E13.5 highlights a 
function in acinar differentiation as it results in a more mature and branched epithelium but with few and 
highly immature acini (Hale et al., 2005). 
PDX1 also plays a role in endocrine cell differentiation. Hypomorph Pdx1 homozygote pancreata have less 
endocrine progenitors and therefore a global decrease of endocrine cells. It is caused by the ability of PDX1 
to activate the Neurog3 promoter (Oliver-Krasinski et al., 2009).  
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Beta cells 
PDX1 is also required for beta cell function. Beta-cell specific deletion of Pdx1 causes diabetes in mice 
(Ahlgren et al., 1998). Moreover INS secretion is already impaired if beta cells only express half of the 
normal dose of PDX1 or express the hypomorphic Pdx1 allele. Mice carrying these mutations thereby 
become glucose intolerant over time (Ahlgren et al., 1998; Oliver-Krasinski et al., 2009). 
6.2.3.2 HNF1B 
Hnf1b is already detected in the gut at E8.5 (Poll et al., 2006). It is expressed from E9.5 in the multipotent 
progenitors of the dorsal and ventral pancreas. After E13.5 it is restricted to the bipotent progenitors. At 
E18.5 and after birth, it remains in a subset of ductal cells (Maestro et al., 2003; Haumaitre et al., 2005). 
HNF1B plays several roles during development. Its deletion causes peri-implantation lethality due to its 
importance in visceral endoderm formation (Barbacci et al., 1999; Coffinier et al., 1999b). Specific Hnf1b 
deletion in kidneys causes cyst formation (Gresh et al., 2004). HNF1B is present from E9.5 in the 
mesonephros. It is subsequently present in the tubule epithelium but not in glomeruli. It is also necessary for 
liver organogenesis, where it starts to be expressed from E9.5 (Barbacci et al., 1999; Coffinier et al., 1999a; 
Coffinier et al., 2002). 
Specification 
Using tetraploid aggregation chimera to circumvent early lethality, it has been shown that HNF1B is 
important for pancreatic specification. In the mutants, the dorsal bud is smaller and the ventral does not form. 
In Hnf1b absence, Onecut1, one of its direct targets, is lost in the prospective regions of the pancreas, 
causing this specification defect (Haumaitre et al., 2005; Poll et al., 2006). 
Pancreatic progenitors 
HNF1B is important for maintaining the identity of the multipotent progenitors. The dorsal bud of the 
tetraploid complementation chimeras mentioned above fails to grow, and regress by E13.5. Before complete 
regression, pancreatic progenitors do not correctly express factors necessary for their function, Ptf1a and 
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Onecut1, while Pdx1 is not affected. Hnf1b KOs fail to produce endocrine progenitors and subsequently 
endocrine cells (Haumaitre et al., 2005). Upon inactivation of HNF1B from E12.5 in the pancreatic 
epithelium, the defects are less severe, even though the pancreas is highly hypoplastic at birth, revealing later 
functions of HNF1B. The acinar cells fail to differentiate properly. Hnf1b mutant pancreata have a near 
complete loss of endocrine cells due to the failure to produce endocrine progenitors. Indeed HNF1B is able 
to activate the Neurog3 promoter (De Vas et al., 2015). 
Ductal cells 
HNF1B also has a role in ductal homeostasis. If it is absent from E12.5, cysts start to form from E14.5. They 
are characterized by a reduction of ductal markers such as HNF6 and MUC1 but also the loss of primary 
cilia. Major genes involved in cystic diseases such as Cys1, Pkhd1, Glis3, Bicc1, Pkd2 and Pkd1 are 
dysregulated. Some of them are directly activated by HNF1B (De Vas et al., 2015). The pancreatic ductal 
cystic phenotype reminds of the kidney phenotype observed when Hnf1b is specifically deleted in kidneys. 
Cysts in different organs are discussed in depth from p 53. In Hnf1b kidney mutants, cysts appear from P0 
and, cystic associated gene expression is also altered. However, contrary to the pancreatic deletion, Pkd2 is 
downregulated and Pkd1 is unchanged, suggesting that although HNF1B controls the kidney and pancreatic 
ductal homeostasis, its downstream effectors may vary between both organs (Gresh et al., 2004) 
6.2.3.3 PTF1A 
PTF1A is a bHLH transcription factor forming a heterooligomer. Its transcriptional activity depends on its 
different binding partners (Roux et al., 1989; Krapp et al., 1996; Beres et al., 2006; Masui et al., 2007). It is 
expressed from E8.5 in the prospective ventral pancreas and 0.25 days later in the prospective dorsal 
pancreas. PTF1A is expressed in the multipotent progenitors. From E12.5-E13.5, its expression is restricted 
to the distal tips. At the end of gestation PTF1A is expressed in the acinar cells (Hald et al., 2008). 
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Multipotent progenitors 
PTF1A is important for the multipotent progenitor identity. Its deletion causes drastic dorsal pancreas 
hypoplasia while the ventral bud fails to grow. Fewer endocrine progenitors and subsequently endocrine cells 
are present in Ptf1a KO pancreata (Krapp et al., 1998; Kawaguchi et al., 2002; Burlison et al., 2008). PTF1A 
appears to strengthen a pancreas identity initially specified by PDX1 and possibly other genes. In the absence 
of PTF1A, the cells of the ventral bud, which forms, are incorporated into the duodenum (Kawaguchi et al., 
2002; Burlison et al., 2008). In multipotent progenitors, PTF1A interacts with RBPJ, a transcription activator 
of the NOTCH signaling pathway, to induce gene expression (Masui et al., 2007). Together, they activate 
Pdx1, Onecut1 and Nkx6.1 (Thompson et al., 2012). Inhibition of PTF1A binding to RBPJ by point 
mutations causes the same phenotype as Ptf1a deletion, arguing that the early role of PTF1A involves RBPJ 
(Masui et al., 2007).  
Pdx1 and Ptf1a epistasis 
Pdx1 KO and Ptf1a KO have a similar phenotype i. e. hypoplasia. However, the Pdx1 KO phenotype is more 
severe and double KOs for Pdx1 and Ptf1a have the same phenotype than the single Pdx1 KO (Burlison et 
al., 2008). Moreover, pancreas morphogenesis is rescued in animals expressing PDX1 under the promoter of 
Ptf1a (Kawaguchi et al., 2002). It argues that PDX1 acts upstream of PTF1A. However, a feedback loop 
does exist, since PTF1A is able to activate the Pdx1 promoter. Moreover, PDX1 is not the only input 
promoting PTF1A expression, since Ptf1a is still expressed, albeit at lower levels in Pdx1 KOs (Burlison et 
al., 2008; Thompson et al., 2012).  
Acinar cells 
Ptf1a KO pancreata do not develop any acinar compartment (Krapp et al., 1998). The switch between a 
multipotent pancreatic progenitor program to an acinar differentiation/function program is operated by 
swapping RBPJ for RBPJL (Beres et al., 2006). Rbpj is progressively down-regulated while Rbpjl is 
upregulated at the same time as PTF1A is restricted to the distal domain of the pancreatic epithelium. A 
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heterooligomer with RBPJL and PTF1a is able to activate acinar genes and RBPJL thus maintaining the 
acinar identity (Masui et al., 2007). 
6.2.3.4 SOX9 
SOX9 is expressed from E9.5 in the pancreatic buds. It is expressed in the multipotent progenitors, and 
thereafter, its expression is restricted to the bipotent progenitors by E15.5, as it becomes progressively 
excluded from the distal domain. While a subset of endocrine progenitors expresses SOX9, it is turned down 
as they differentiate into endocrine cells (Lynn et al., 2007; Seymour et al., 2007; Dubois et al., 2011). 
Multipotent and bipotent progenitors 
The absence of SOX9 during early pancreas development causes pancreatic hypoplasia. The remnant 
pancreas is cystic and fewer acini are present. Multipotent progenitor proliferation and survival are impaired, 
resulting in smaller buds at E11.5 (Seymour et al., 2007). Progenitors also lose their identity, and start to 
express liver markers (Seymour et al., 2012). Sox9 KOs progenitors lose the expression of PDX1 while 
ONECUT1 and HNF1B remain unaffected, even though there is some in vitro evidence that they are SOX9 
direct targets (Lynn et al., 2007; Dubois et al., 2011). In Sox9 KOs, endocrine cells are nearly absent due to 
the lack of endocrine progenitor differentiation (Seymour et al., 2007; Shih et al., 2012). Indeed, SOX9 is 
able to activate Neurog3 promoter, promoting, thus, endocrine progenitor production (Lee et al., 2001; 
Seymour et al., 2008). In support of this idea, all endocrine progenitors come from SOX9+ cells in mosaic 
pancreata formed of WT and Sox9 KO cells (Shih et al., 2012). In Sox9 heterozygotes, endocrine progenitors 
and their endocrine cell progeny are reduced by half, leading to glucose intolerance in the adult (Lynn et al., 
2007; Seymour et al., 2008; Dubois et al., 2011). 
Ductal cells 
Like HNF1B, SOX9 is important for ductal cell identity. Ducts are enlarged and later become cystic in 
pancreata in which Sox9 is deleted from E12.5 (Dubois et al., 2011; Shih et al., 2012). The ductal cells fail to 
express key ductal markers such as PKD2. They also have less primary cilia (Shih et al., 2012). HNF1B 
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expression is not affected in Sox9 KO pancreata and vice versa. Therefore, they likely function in parallel 
pathways (Shih et al., 2012; De Vas et al., 2015). 
6.2.3.5 ONECUT1 
ONECUT1 is a transcription factor containing a single cut domain and a homeodomain. It was first identified 
in the liver, where it is expressed from E8.5 (Lemaigre et al., 1996; Jacquemin et al., 2003a). During 
pancreas organogenesis, it is expressed from E8.5 in the prospective dorsal and ventral pancreas, before 
PDX1 starts to be expressed. While before E13.5 it is expressed in the multipotent progenitors, it is then 
restricted to the bipotent progenitors and later to the ducts. While endocrine progenitors express ONECUT1, 
like HNF1B, it declines when they differentiate toward endocrine cells (Jacquemin et al., 2003a; Zhang et 
al., 2009; Pierreux et al., 2010). 
Specification 
ONECUT1 is important for pancreatic specification. It enables the expression of PDX1, one of its direct 
targets. In its absence, fewer cells express PDX1 in the prospective ventral and dorsal pancreas and therefore 
commit to a pancreatic fate, even though other specification markers, such as Foxa2, are unaffected. Onecut1 
KO pancreata are consequently hypoplastic (Jacquemin et al., 2003a). 
Bipotent progenitors 
Early endocrine cells expressing GCG do not require ONECUT1 but it is important for the commitment of 
pancreatic progenitors towards all endocrine progenitors at later stages. After the secondary transition has 
started, few endocrine progenitors with low levels of Neurog3 are produced as it is a direct target of 
ONECUT1. This defect causes a nearly complete loss of endocrine cells (Jacquemin et al., 2000; Zhang et 
al., 2009).  
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Ductal cells 
In the absence of ONECUT1, ducts become cystic from E15.5 (see also p 64). Cysts may be lined by a 
multilayer epithelium instead of a cuboidal epithelium, and endocrine cells can also be detected in this 
epithelium (Pierreux et al., 2006; Zhang et al., 2009). Aberrant proliferation and disturbed WNT signaling, 
which are associated with cyst formation, are not detected (Pierreux et al., 2006). Nevertheless, primary cilia, 
whose lack or malfunction can cause cysts, are absent. HNF1B expression is also altered. Pkhd1, and Cyst1, 
two cyst-associated genes, are downregulated while Pkd1, Pkd2 and Ift88 are unaffected, suggesting that 
SOX9, HNF1B, and ONECUT1 regulate ductal homeostasis in parallel (Maestro et al., 2003; Pierreux et al., 
2006; Shih et al., 2012; De Vas et al., 2015). 
ONECUT2 
Onecut2 is a paralog of Onecut1 (Jacquemin et al., 2003b). It starts to be expressed after ONECUT1 in the 
prospective liver and pancreatic epithelium (Jacquemin et al., 2003b; Pierreux et al., 2004). In the liver, they 
act redundantly (Clotman et al., 2005). In the pancreas, Onecut2 deletion does not lead to an obvious 
phenotype. Moreover, ONECUT2 does not compensate for Onecut1 deletion as the phenotype of Onecut1; 
Onecut2 double KOs is only slightly enhanced as compared to Onecut1 KOs. However, in vitro studies have 
showed that ONECUT2 is able to activate the Neurog3 promoter (Vanhorenbeeck et al., 2007). 
6.2.3.6 FOXA2 
FOXA2 is already expressed in the definitive endoderm (Ang et al., 1993). It continue to be expressed in all 
cells of the developing and adult pancreatic epithelium (Ahlgren et al., 1996; Sund et al., 2001; Besnard et 
al., 2004; Lee et al., 2005). Foxa2 is also expressed in the node, and its deletion precludes node and, 
therefore, notochord formation. Foxa2 KO embryos die around E10 (Ang et al., 1993; Ang and Rossant, 
1994; Weinstein et al., 1994) 
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Pancreatic progenitors 
Although endoderm specific deletions of Foxa2 or Foxa1 do not cause pancreatic morphogenesis defects, the 
double deletion of Foxa2 and Foxa1 in the pancreatic epithelium causes a similar phenotype as Pdx1 KOs 
(Kaestner et al., 1999; Lee et al., 2005; Gao et al., 2008). The pancreas is hypoplastic and cystic. The 
remnant epithelium lacks endocrine and acinar cells. Furthermore, PDX1 is absent of the pancreatic 
epithelium already at E10.5 arguing that FOXA2 and FOXA1 are major activators of  the Pdx1 promoter 
(Gao et al., 2008). FOXA2 is also able to induce Sox9 expression while Foxa2 is activated by SOX9, PDX1, 
and HFN1B (Lynn et al., 2007; Oliver-Krasinski et al., 2009). They therefore form a feedforward loop to 
maintain progenitor identity (Fig. 4). In addition, FOXA2 is able to activate Neurog3 promoter. It can also 
synergize with NEUROG3 to promote Neurog3 expression (Lee et al., 2001; Ejarque et al., 2013). 
Endocrine cells 
Endoderm deletion of Foxa2 causes a specific loss of alpha cells (Lee et al., 2005). Nevertheless, FOXA2 is 
necessary to maintain the beta cell identity. Beta cell deletion of Foxa2 causes hypoglycemia due to 
hyperinsulinemia. FOXA2 activates Pdx1 expression in beta cells, as well as the expression of Kcjn11 and 
Abcc8, two genes involved in insulin release regulation (Wu et al., 1997; Sund et al., 2001; Lee et al., 2002; 
Lantz et al., 2004). 
6.2.3.7 GLIS3 
GLIS3 is a C2H2 krüppel-like zinc finger transcription factor (Kim et al., 2003). It has a role in the kidney 
homeostasis as its absence causes cyst formation (Kang et al., 2009a). It is expressed in the pancreatic 
epithelium from E11.5. It is restricted to the bipotent progenitors. At birth it is expressed in beta cells as well 
as in the ducts (Kang et al., 2009b). 
Bipotent progenitors 
Bipotent progenitors do not seem to be affected by Glis3 deletion. However, in its absence, the commitment 
toward endocrine progenitor fate is affected. Glis3 KO pancreata thus have less endocrine cells. GLIS3 
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promotes endocrine progenitor differentiation by activating Neurog3 promoter either alone or synergistically 
with ONECUT1 or FOX2A (Kang et al., 2009b; Yang et al., 2011; Kim et al., 2012). 
Beta cells 
GLIS3 is also able to activate Ins promoter. The more extensive reduction of beta cells as compared to the 
other endocrine cells in Glis3 KOs may be linked to a lower INS production, and therefore, the inability to 
detect beta cells (Kang et al., 2009b; ZeRuth et al., 2013). 
Ductal cells 
Glis3 KOs also develop pancreatic cysts. They are associated with less primary cilia in the cystic ducts but 
not in the non-cystic ducts of Glis3 KOs, arguing for a secondary effect rather than the initial cause of cyst 
formation (Kang et al., 2009b). 
6.2.3.8 NKX6.1 and NKX6.2 
NKX6.1 and NKX6.2 are expressed in the multipotent progenitors at E10.5 and E12.5. At E14.5 NKX6.1 is 
excluded from the distal domain while NKX6.2 becomes restricted to the distal domain. Contrary to 
NKX6.2, NKX6.1 is also expressed in the endocrine progenitors and some cells differentiating toward 
endocrine cells (Sander et al., 2000; Henseleit et al., 2005). At E18.5 and in the adult, NKX6.1 is expressed 
in the beta cells (Sander et al., 2000; Nelson et al., 2007).  
Multipotent and bipotent progenitors 
NKX6.1 and NKX6.2 act redundantly in the multipotent progenitors. Inactivation of both Nkx6 factors 
causes a drastic decrease of alpha and beta cells while the other endocrine cells are not affected (Henseleit et 
al., 2005). This is due to a reduction of endocrine progenitors at E10.5 and E12.5 while their number is 
normal afterward (Schaffer et al., 2010).  The deficient multipotent progenitors express more Ptf1a, and are 
more prone to differentiate into acinar progenitors, leading to an increase of the acinar compartment after the 
proximal-distal domains have been segregated. Indeed the overexpression of PTF1A converts the pancreatic 
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epithelium into acinar cells at E14.5. The overexpression of NKX6.1 in the pancreatic epithelium has the 
opposite effect, the acinar compartment is reduced and more cells adopt an endocrine fate (Schaffer et al., 
2010).  
Differentiation toward endocrine lineage and beta cells 
Deletion of Nkx6.1 in endocrine progenitors causes beta cell underrepresentation in the islet. Conversely, 
overexpression of Nkx6.1 in NEUROG3+ cells has the opposite effect. As no cell death or proliferation 
defects in beta cells are observed, it suggests the importance of NKX6.1 for beta cell production. Indeed 
NKX6.1 is able to directly inhibit the expression of Arx, a transcription factor important for alpha cell 
production. NKX6.1 is also important for maintaining the beta cell identity as beta cells convert into SST-
expressing cells in the absence of Nkx6.1 (Schaffer et al., 2013). 
6.2.3.9 NEUROG3 
NEUROG3 is a bHLH transcription factor expressed in cells scattered in the pancreatic epithelium (Sommer 
et al., 1996). The pancreatic expression pattern of NEUROG3 is biphasic. It is first observed in a few cells 
from E8.25. NEUROG3+ cells increase until E10.5. At E11.25, no more cells express NEUROG3. Cells 
expressing NEUROG3 reappear at E12. Their number peaks at E15.5 and decreases thereafter. At E18.5, 
only a few NEUROG3+ cells are still in the ducts or in their vicinity (Schwitzgebel et al., 2000; Villasenor et 
al., 2008). NEUROG3 is also detected at low level in the islets after birth (Wang, S. et al., 2009). 
Endocrine progenitors 
NEUROG3 is a major regulator of endocrine progenitors, and is used to identify them. It is the only gene 
absolutely required for endocrine cell generation, as no endocrine cells or factors associated with endocrine 
differentiation are present in Neurog3 KO pancreata (Gradwohl et al., 2000). It is sufficient to induce 
endocrine cell differentiation, as its overexpression in pancreatic cells differentiates them all into endocrine 
cell (Apelqvist et al., 1999; Schwitzgebel et al., 2000). It is noteworthy that, contrary to mice, NEUROG3 is 
not absolutely required for endocrine cell differentiation in humans and in zebrafish (Flasse et al., 2013; 
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Rubio-Cabezas et al., 2014). It is to put in line with the presence of a few GCG+ cells in Neurog3 KO 
pancreata before E15.5 (Wang, S. et al., 2008). 
Several transcription factors, i. e. PDX1, SOX9, HNF1B, ONECUT1, GLIS3 HNF1A, ONECUT2, and 
FOXA2, have been identified as inducers of Neurog3 expression. In addition, NEUROG3 itself  is able to 
induce its own expression (Jacquemin et al., 2000; Lee et al., 2001; Lynn et al., 2007; Vanhorenbeeck et al., 
2007; Yang et al., 2011; Ejarque et al., 2013). Neurog3 is repressed by the transcription factor HES1 (Jensen 
et al., 2000b). After NEUROG3 expression starts, it represses Sox9 expression (Magenheim et al., 2011a; 
Shih et al., 2013). On the contrary, ONECUT1 is required for the differentiation of NEUROG3+ cells 
towards the endocrine lineage, as less endocrine cells are observed when Onecut1 is deleted in NEUROG3+ 
cells (Zhang et al., 2009). NEUROG3 expression is also reinforced by endocrine differentiation factors. 
MYT1 and NKX2.2 are able to promote its expression, although it is not clear if they are able to directly 
activate Neurog3. Moreover, INSM1 is able to promote the splicing of Neurog3 into its coding mRNA 
(Osipovich et al., 2014). 
The expression level of NEUROG3 is critical to elicit the endocrine differentiation program. In Neurog3 
heterozygote animals the amount of NEUROG3 per cell is reduced, and the number of endocrine cells is also 
reduced, while more cells are prompted to commit towards an endocrine fate (Wang et al., 2010). The 
Neurog3-expressing cells that fail to further differentiate into endocrine cells are redirected toward an acinar 
or ductal fate (Schonhoff, S. E. et al., 2004; Wang et al., 2010). The ability to adopt one or the other depends 
on the potency of the cells of origin. Before E12.5, the endocrine progenitors arise from multipotent 
progenitors, and have the capacity to be redirected toward an acinar fate. Thereafter, they can only adopt a 
ductal fate (Beucher et al., 2012).  
Ductal homeostasis 
NEUROG3+ cells feedback to the surrounding pancreatic progenitors to maintain ductal homeostasis. In 
Neurog3 KOs, all cells activating the Neurog3 promoter fail to become endocrine. The majority of these 
cells stays in the pancreatic proximal domain, and becomes ductal cells. They accumulate in the ducts 
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causing the formation of a poorly branched and dilated network (Wang et al., 2010; Magenheim et al., 
2011a). 
Endocrine cells 
NEUROG3 has also been involved in endocrine cell function in the adult mouse. Indeed, deletion of 
Neurog3 in beta cells impairs their function. Mutant mice have a higher fasting glucose and an impaired 
glucose tolerance. Mutant pancreata express less INS, MYT1, NEUROD1, PAX4, and PDX1 (Wang, S. et 
al., 2009). 
6.2.3.10 Final steps toward endocrine cells 
For the subsequent pancreatic differentiation steps, the hierarchy of the transcription factors involved in the 
completion of the endocrine differentiation program is difficult to establish. Nevertheless, the loss of ISL1, 
ARX, PAX4, PAX6, and NEUROD1 expression upon Neurog3 deletion shows that they function 
downstream (Gradwohl et al., 2000; Collombat et al., 2003; Mastracci et al., 2011). The time sequence of 
gene expression is also informative. NEUROG3 is turned off after 24h of expression. It also has been 
reported that it only takes 10 hours for a cell to become endocrine after Neurog3 has been switched off 
(Beucher et al., 2012). A subset of NEUROG3+ cells expresses NEUROD1, INSM1, MYT1, and PAX4 
These genes are directly activated by NEUROG3 (Huang et al., 2000; Jensen et al., 2000a; Schwitzgebel et 
al., 2000; Smith et al., 2003; Mellitzer et al., 2004; Wang et al., 2004; Wang et al., 2007). PAX6 is also 
expressed in a subpopulation of NEUROG3+ cells even though it has not been reported as a direct 
NEUROG3 target (Maestro et al., 2003). On the contrary, no NEUROG3+ cells express ISL1 (Schwitzgebel 
et al., 2000).  
However, other factors such as NKX2.2 and NKX6.1 are first expressed in the multipotent or bipotent 
progenitors. They continue to be expressed in the cells adopting an endocrine cell fate, indicating their 
multiple roles during pancreas organogenesis (Sander et al., 1997; Sussel et al., 1998).  
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It is difficult to disentangle the function of each factor as they may play several roles in a redundant fashion. 
Moreover, no marker has been identified to highlight hierarchical precursors enabling the distinction 
between different populations. Nevertheless, single and compound KO analyses have provided cues to the 
mechanisms behind endocrine cell differentiation (Fig. 5). 
The absence of NEUROD1, PAX6, or ISL1 causes a global and drastic reduction of endocrine cells (Ahlgren 
et al., 1997; Naya et al., 1997). NEUROD1 is also important for beta cell maturity while ISL1 is important 
for endocrine cell proliferation and survival (Du et al., 2009; Gu et al., 2010). Insm1 deletion also causes a 
global endocrine cell reduction. Insm1 KO cells accumulate in an immature state without expressing 
hormones (Gierl et al., 2006). Conversely, Myt1 deletion does not cause a drastic endocrine cell decrease but 
endocrine cells are polyhormonal. The effect of the loss of function of Myt1 is surprising, as its ectopic 
expression is sufficient to induce Neurog3 expression and produce GCG+ cells (Wang et al., 2007; Wang, S. 
et al., 2008). 
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Fig. 5: endocrine progenitor differentiation toward endocrine cells. 
Endocrine progenitor differentiation towards the different endocrine cell types is indicated by black arrows. 
Transcription factors present in the cells are contained in the color boxes referring to a given cell type (same color code 
as in Fig. 2). Some transcription factors (dashed box) are present only in a subset of the endocrine progenitors 
(NEUROG3+ cells). Fewer factors are present in epsilon cells due to poor description of these cells. 
Green arrows indicate factors promoting a differentiation path while red arrows indicate factors repressing a 
differentiation path. Arrow length is not scaled with the differentiation duration. X represents unknown factors.  
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The absence of other transcription factors causes the decrease of specific populations, usually compensated 
by an increase in another endocrine cell type or the apparition of immature cells, suggesting bifurcations in 
the differentiation path. As previously mentioned, the deletion of Nkx6.1 causes a beta cell decrease. The 
deletion of Nkx2.2 causes beta, alpha and PP cell reductions with the apparition of GHR+ cells expressing 
alpha and beta cell markers (Sussel et al., 1998; Kordowich et al., 2011; Schaffer et al., 2013). The absence 
of PAX4 leads to a beta and delta cell decrease with a GCG+ GHR+ cell increase (Sosa-Pineda et al., 1997; 
Collombat et al., 2005). Conversely, in Arx KO pancreata, alpha cells are decreased, and the delta cell 
population is increased. The effect of Arx deletion on the beta cell mass is controversial, as the beta cells are 
either unaffected or increased by the loss of Arx (Collombat et al., 2003; Kordowich et al., 2011). The 
opposing effects of the deletion of Pax4 and of Arx are explained by the ability of the factors to repress each 
other (Collombat et al., 2003; Collombat et al., 2005). Ectopic expression of Pax4 converts endocrine cells 
into beta cells, while ectopic expression of Arx causes beta and delta cell conversion into alpha and PP cells 
(Collombat et al., 2007; Collombat et al., 2009). PAX4 also directly represses Ghr expression (Fig. 5) 
(Wang, Q. et al., 2008). 
A second layer of information is added by the study of double KO embryos. Double deletion of Arx and 
Pax4 causes a drastic alpha and beta cell decrease. The cells adopt an immature delta cell fate coexpressing 
PPY (Collombat et al., 2005). Conjoint deletion of Arx and Nkx2.2 causes an absence of beta and alpha cells. 
They are replaced by GHR+ SST+ cells also expressing alpha and beta cell markers (Kordowich et al., 2011). 
These studies suggest that cells adopt an epsilon cell fate in the absence of NKX2.2. Moreover, PAX4 and 
ARX antagonize each other. If the cell expresses ARX, the cell becomes either PPY or alpha, maybe 
depending on the stage of development. Otherwise, in the presence of PAX4, the cell adopts a beta-delta 
common precursor fate. The cell further differentiates toward a beta cell unless PAX4 is repressed (Fig. 5). 
6.2.4 Signaling pathways involved in pancreas development 
The organogenesis of the pancreas is coordinated with the development of the neighbouring organs. The 
proliferation and differentiation of the pancreatic cells also depend on the other cell types present in the 
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developing pancreas at a given time point. These interactions are mediated by extracellular signals, which 
activate several signaling pathways. As signaling pathways often interact, the outcome of an input can 
depend on other signaling cues, on the cell type that receives it, and the stage of development. Signaling 
pathways may also act redundantly making them more difficult to decipher. 
6.2.4.1 NOTCH signaling regulates different aspects of pancreas development 
This pathway is extremely important to balance pancreas expansion and differentiation. Signal sending cells 
express NOTCH ligands, DLL1 to DLL4, JAG1, and JAG2. The signal receiving cells express NOTCH 
receptors, NOTCH1 to NOTCH4. The ligands bind to NOTCH receptors, and, thereby, trigger a change in 
their conformation. It is followed by a series of cleavages of NOTCH receptor. The latter is mediated by 
gamma secretase. The intracellular domain of NOTCH is thereby released in the cytoplasm. NOTCH 
intracellular domain is exported to the nucleus, and associates with cofactors, such as RBPJ and MAML1. 
They then activate gene expression. Several NOTCH targets are transcriptional repressors of the HES family. 
HES family factors repress among others the expression of NOTCH ligands, forcing the cell into the 
dichotomic choice of being NOTCH-sending or NOTCH-receiving cell. This process of cell segregation is 
called lateral or trans- inhibition. In the absence of NOTCH, RBPJ interacts with co-repressors, and inhibits 
transcription (Fig. 6) (reviewed in Kandachar and Roegiers, 2012). Moreover, ligand-independent activation 
of NOTCH has been observed in Drosophilae. This mode of activation requires the endocytosis of NOTCH 
followed by its intracellular activation (reviewed in Hori et al., 2012). 
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Fig. 6: Notch signaling pathway 
(A) In absence of binding of NOTCH ligand to NOTCH receptor (NOTCH OFF), target genes of the NOTCH signaling 
pathway are repressed. 
(B) When NOTCH ligand binds its receptor (NOTCH ON), the latter is cleaved and its intracellular domain is released 
in the cytoplasm. It migrates to the nucleus where it activates gene expression, such as Hes1 with its cofactors such as 
MAML and RBPJ 
(C) Legend of the different proteins depicted in the cartoons. 
In the pancreas, the expression pattern of NOTCH signaling components is highly dynamic, highlighting the 
complexity of the pathway. The NOTCH ligand, Dll1, is first detected in a few cells of the dorsal pancreas at 
E9. Half a day later, it is expressed in a salt and pepper manner in the dorsal bud. At E10.5, Dll1 starts to be 
expressed in the ventral bud (Ahnfelt-Rønne et al., 2012). Dll1 expression then goes down but it is still 
present in acinar cells after E13.5 (Apelqvist et al., 1999). JAG1 becomes the major NOTCH ligand 
expressed in the pancreatic epithelium from E12.5. However, its expression pattern is unclear. It has been 
found to be progressively restricted to the ducts and beta cells at birth (Jensen et al., 2000b; Golson et al., 
2009). On the contrary, other studies found that Jag1 is detected in the endothelial cells from E15.5, 
(Lammert et al., 2000; Norgaard et al., 2003). Finally, Apelqvist and colleges reported that Jag1 is present in 
the acini and not the trunk at E13.5 (Apelqvist et al., 1999). 
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NOTCH intracellular domain is already present in a few pancreatic cells at E9.0 indicating that the NOTCH 
signaling pathway is active at that stage (Jensen et al., 2000b), although Notch1 and Notch2 are first reported 
at E9.5 in a salt and paper manner (Apelqvist et al., 1999). They are broadly expressed at E10.5 in the 
pancreatic epithelium (Lammert et al., 2000). From E13.5, Notch1 and Notch2 are present in the progenitors 
which lined the ducts (Apelqvist et al., 1999).On the contrary, Notch3 and Notch4 are present in the 
surrounding mesenchyme at E10.5. Thereafter, they are localized in the endothelial cells (Lammert et al., 
2000).  
HES1, a NOTCH target gene, is expressed from E9.0 in the dorsal bud. HES1 colocalized with Dll1 and 
PTF1A at E10.5. It is also present in the surrounding mesenchyme (Lammert et al., 2000; Ahnfelt-Rønne et 
al., 2012). At E15.5, HES1 is expressed in the bipotent progenitors, but is excluded from the endocrine 
progenitors (Shih et al., 2013). At E18.5, HES1 is only expressed in scattered ductal cells (Norgaard et al., 
2003; Kopinke et al., 2011). However, Apelqvist and colleagues found Hes1 in pancreatic tips at E13.5 
(Apelqvist et al., 1999). Indeed, HES1+ cells are still able to give rise to acinar cells at E15.5 (Kopinke et al., 
2011). 
Maintenance of progenitor identity by NOTCH signaling 
NOTCH signaling is required to maintain the identity of the multipotent progenitors and, subsequently, of 
the bipotent progenitors. Indeed, inactivation of the NOTCH signaling pathway leads to the precocious 
differentiation of the multipotent progenitors into endocrine cells (Fig. 7) (Apelqvist et al., 1999; Jensen et 
al., 2000b; Ahnfelt-Rønne et al., 2012). 
45 
 
 
Fig. 7: Different roles of the Notch pathway during pancreas organogenesis 
NOTCH signaling inhibits endocrine progenitor (orange) differentiation in multipotent progenitors (brown). During the 
tip trunk domain specification, around E12.5, NOTCH signaling inhibits acinar progenitor (blue) fate while it promotes 
bipotent progenitor (light green) fate. Thereafter, it inhibits endocrine progenitor differentiation and promotes ductal 
identity (dark green). 
On the contrary, forced activation of NOTCH, by overexpressing its intracellular domain, causes the 
abrogation of endocrine cell differentiation. The epithelium remains immature. For example, it maintains 
PDX1 expression at late stages of development. It also reduces the ductal network branching and increases 
ductal cell proliferation (Hald et al., 2003; Murtaugh et al., 2003; Schaffer et al., 2010). Moreover, after the 
secondary transition has started, high NOTCH signaling induces both the expression of HES1 and SOX9. 
High NOTCH signaling therefore maintains the bipotent progenitor state, and precludes the differentiation 
toward endocrine cells. The cells expressing both HES1 and SOX9 then adopt a ductal fate (Fig. 7)  (Shih et 
al., 2012) 
Cis inhibition versus lateral inhibition 
It is believed that lateral inhibition by NOTCH signaling is used to control the number of cells committing to 
the endocrine lineage (Apelqvist et al., 1999). It is hypothesized that when a cell starts to express 
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NEUROG3, it induces the expression of NOTCH ligand DLL1 (Shih et al., 2012). Then, NEUROG3+ cells 
signal to the neighbouring cells expressing NOTCH receptors. The receiving cells induce HES1 expression, 
and, thereby, inhibit the expression of Neurog3. Therefore the receiving cells maintain their progenitor 
identity (Lee et al., 2001). The hypothesis is mainly supported by the absence of HES1 expression in 
endocrine progenitors as well as the presence of DLL1 in these cells (Apelqvist et al., 1999; Shih et al., 
2012). It is also based on the KO phenotypes of the different NOTCH components and the ectopic activation 
of NOTCH signaling (cf. above).  
However, a recent study challenges the lateral inhibition mechanism (Ahnfelt-Rønne et al., 2012). DLL1 is 
initially expressed in all multipotent progenitors and not only in NEUROG3+ cells. Afterwards, it is also 
expressed in more cells than just NEUROG3+ cells. Dll1 is induced by PTF1A and by HES1. If DLL1 was 
simply driving lateral inhibition, more endocrine cells would be expected in Dll1 KOs. However, although 
Dll1 KOs have more endocrine progenitor cells at E9, they have less at E9.5, contrary to other models of 
NOTCH signaling inactivation. This suggests that DLL1 plays an important role in endocrine progenitor 
production from E9.5. Consequently, a new picture emerges. In this model, NEUROG3 induces high levels 
of DLL1. High DLL1 then inhibits NOTCH receptors that are present in the same cell and not the 
neighbouring cells. Thereby the inhibition promotes endocrine differentiation program in a cell autonomous 
manner. This mechanism of inhibition is called cis-inhibition (Ahnfelt-Rønne et al., 2012). 
Segregation of the proximal and distal domains by NOTCH signaling 
The NOTCH pathway also has an important role in defining the boundaries between distal (acinar) and 
proximal (bipotent progenitors) domains. NOTCH inhibition models have an impaired acinar compartment 
due to the drastic and precocious endocrine differentiation, while NOTCH activation models also have 
defective or no acinar compartment (Apelqvist et al., 1999; Jensen et al., 2000b; Hald et al., 2003; Murtaugh 
et al., 2003). Two recent studies better decipher this role by studying the effects of NOTCH signaling 
impairment at later stages. Deletion of Mib1, a positive regulator of NOTCH signaling, causes a loss of beta 
cells and ductal cells, while the acinar compartment is increased. It is associated with an increase of the 
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NKX6.1- PTF1A+ cell population, corresponding to the acinar or distal domain, at the expense of the 
NKX6.1+ PTF1A- cells, which correspond to the bipotent progenitors, explaining why no endocrine 
progenitors or endocrine cells are generated at later stages (Horn et al., 2012). The imbalance between 
NKX6.1- PTF1A+ cells and NKX6.1+ PTF1A- cells was also observed in Hes1 KOs and a model of ectopic 
expression of dominant negative Maml1 (Horn et al., 2012). Upon NOTCH activation, the converse was 
seen. The whole pancreatic epithelium continued to express NKX6.1 at late stages, while it was devoid of 
PTF1A, even though HES1 is necessary for PTF1A expression at E9.5 (Schaffer et al., 2010; Ahnfelt-Rønne 
et al., 2012). It has thus been proposed that, in the absence of Notch signaling, multipotent progenitors adopt 
an acinar cell fate or distal domain fate (Horn et al., 2012).  
The case of RBPJ, the cofactor of NOTCH intracellular domain  
Contrary to other NOTCH inhibition models, Rbpj KOs have less endocrine cells. They also harbor no acinar 
cells at late stages and immature ducts. Depending of the promoter used to drive the Cre recombinase that 
delete Rbpj locus, Rbpj KO pancreata may recover (Fujikura et al., 2006; Fujikura et al., 2007). The Rbpj KO 
phenotype is similar to Ptf1a KOs and could be explained by the interaction between PTF1A and RBPJ in 
multipotent progenitors (Kawaguchi et al., 2002; Masui et al., 2007; Burlison et al., 2008). 
6.2.4.2 FGF signaling promotes early pancreatic progenitor growth and identity 
FGF signaling is also relevant to pancreas development. FGF ligands bind to FGFR, a family of tyrosine 
kinase receptors. They then activate different downstream signaling pathways such as the MAPK pathway, 
AKT pathway or PKC pathway (reviewed in Dorey and Amaya, 2010). Although FGF signaling plays an 
important role in pancreas development, little is known about its downstream effectors due to their 
redundancy.  
FGF10 is expressed in the mesenchyme surrounding the pancreatic epithelium from E9.5. At E11.5, it is 
restricted to the mesenchyme between the stomach and the dorsal pancreas (Bhushan et al., 2001). Other 
FGF ligands have been detected by PCR but specific information on their expression pattern in different cell 
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types is scarce (Dichmann et al., 2003). FGFR2 is expressed in the pancreatic epithelium from E9.5 to E15.5 
(Hart et al., 2003). Fgfr4 and other Fgf receptors are also expressed in the pancreas (Dichmann et al., 2003; 
De Vas et al., 2015). 
Mesenchymal-derived FGF10 promotes pancreas bud expansion. Indeed, deletion of either Fgf10 or Fgfr2 
causes pancreatic hypoplasia due to a proliferation defect. The effect on endocrine or acinar differentiation is 
less clear, showing little impact in the case of Fgfr2 KOs or a drastic reduction for Fgf10 KOs, suggesting 
redundancy with other receptors (Bhushan et al., 2001; Pulkinnen et al., 2003). The loss of endocrine and 
acinar differentiation is associated with a conversion of the multipotent progenitors to a hepatic progenitor 
fate (Seymour et al., 2012). Conversely, when FGF10 is overexpressed, the pancreatic size is increased. The 
pancreata are also devoid of endocrine and acinar cells. Even at late stages, the pancreatic epithelial cells co-
express multipotent progenitor markers including SOX9, PDX1, PTF1A, NKX6.1, and ONECUT1. NOTCH 
signaling is also upregulated (Hart et al., 2003; Norgaard et al., 2003; Kobberup et al., 2010). The inhibition 
of the ectopic expression of Fgf10 at E13.5 rescues the endocrine cell production. However, the endocrine 
cell production is not rescued after E15.5, suggesting a loss of endocrine commitment after E15.5 upon 
FGF10 expression. The acinar compartment is rescued whenever the ectopic FGF10 expression is inhibited 
(Kobberup et al., 2010). Overexpression of Fgf4 causes a similar phenotype. Although this FGF is not 
expressed in the pancreas, it may trigger the same response (Dichmann et al., 2003).  
Interplay between transcription factors and Fgf signaling 
The hypoplasia observed in Hnf1b KO pancreata has been associated with Fgfr4 downregulation, although 
the role of Fgfr4 in the pancreas is unexplored. However, HNF1B is able to bind the Fgfr4 promoter in the 
developing pancreas, suggestion a role of the latter in pancreas organogenesis (De Vas et al., 2015). 
Multipotent progenitors devoid of SOX9 adopt a liver fate, which is also observed in Fgf10 KOs. It may be 
due to the ability of SOX9 to regulate FGFR2 (Seymour et al., 2012). Since both HNF1B and SOX9 are 
expressed in multipotent progenitors, this control may ensure that the progenitor cells respond to 
mesenchymal FGF10.  
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6.2.4.3 Role of canonical and non-canonical WNT signaling during pancreas development 
Although there is evidence for the importance of several WNT signaling pathways in the pancreas, their 
activity remains quite obscure. WNT ligands can trigger different intracellular pathways depending on the 
type of WNTs and the components expressed in the receiving cell. The most studied is the canonical 
signaling pathway. In brief, in the absence of WNT ligand, CTNNB1, also called β-catenin, is 
phosphorylated by GSK3B, which is stabilized by APC and AXIN2. This phosphorylation leads to the 
degradation of CTNNB1 by the proteasome. When WNT ligands bind to the FZD receptor and the LRP5/6 
co-receptor, it leads to the recruitment of DVL. DVL destabilizes the CTNNB1 - APC - AXIN2 - GSK3B 
complex, releasing CTNNB1. CTNNB1 migrates to the nucleus and activates transcription in the presence of 
cofactors such as TCF7 or LEF1. In the absence of CTNNB1, these cofactors are associated with repressors 
(Fig. 8) (reviewed in Niehrs, 2012). 
 
Fig. 8: canonical WNT signaling 
(A) In absence of WNT, CTNNB1 is phosphorylated by the GSK3B complex and directed for degradation by the 
proteasome. Target genes are repressed by TCF or LEF.  
(B) When WNTs binds to FZD, DVL is recruited and destabilizes GSK3B complex leading to the release and 
accumulation of CTNNB1. CTNNB1 is translocated to the nucleus, and activates gene expression together with the 
cofactors, TCF and LEF. 
50 
 
Non-canonical WNT signaling is induced by the binding of non-canonical WNT ligands to non-canonical 
FZD receptors. These FZD can also interact with VANGL receptors on neighbouring cells, an interaction 
that is stabilized by transmembrane proteins, CELSR1, CELSR2 or CELSR3. FZD then elicits a response 
that can either be transcriptional via the activation of MAPK8, also called JNK, or structural by modifying 
the actin cytoskeleton (reviewed in Seifert and Mlodzik, 2007; Niehrs, 2012). 
Several WNT as well as FZD are detected during development pancreatic development such as Wnt4, Wnt5b, 
Wnt7b. Fzd2, Fzd3 and Fzd7 (Heller et al., 2002; Papadopoulou and Edlund, 2005; Afelik et al., 2015). 
Nevertheless, canonical WNT signaling activity patterns are controversial. Using mouse reporters, it is 
detected in the mesenchyme as well as in GCG+ cells while immunostaining for active CTNNB1 suggests 
that it is active in the pancreatic epithelium. These discrepancies may be due to the different techniques used 
for the detection (Dessimoz et al., 2005; Murtaugh et al., 2005). 
Canonical WNT signaling is involved in progenitor proliferation 
Absence of CTNNB1 in the pancreatic epithelium causes pancreatic hypoplasia due to a proliferation defect. 
A dominant negative FZD8 inhibiting canonical WNT signaling confirms the involvement of WNT signaling 
in the proliferation of the pancreatic progenitors (Dessimoz et al., 2005; Murtaugh et al., 2005; 
Papadopoulou and Edlund, 2005; Wells et al., 2007; Baumgartner et al., 2014). In Ctnnb1 mutant, only cells 
that do not have a recombined Ctnnb1 locus are able to differentiate into acinar cells (Dessimoz et al., 2005; 
Murtaugh et al., 2005; Wells et al., 2007). A recent study has shown that CTNNB1 is necessary to maintain 
acinar identity, but their specification is not altered. Inhibition of NOTCH signaling rescues the acinar 
compartment, suggesting that CTNNB1 inhibits NOTCH signaling (Baumgartner et al., 2014). However, the 
outcome on endocrine differentiation is unclear. Only two studies report an absolute endocrine cell decrease, 
but are backed-up by FZD8 inhibiting canonical WNT signaling (Dessimoz et al., 2005; Papadopoulou and 
Edlund, 2005; Baumgartner et al., 2014). However, it cannot be excluded that endocrine cells require the 
adhesive function of CTNNB1 rather than its role in canonical WNT signaling. In addition, this difference 
may be due to the competitive disadvantage of the mutant cells or the strategy used to inactivate Ctnnb1 
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(Dessimoz et al., 2005; Murtaugh et al., 2005; Papadopoulou and Edlund, 2005; Wells et al., 2007). WNT7B 
is one of the WNTs acting on early pancreatic proliferation. Its deletion of Wnt7b causes pancreatic 
hypoplasia due to multipotent progenitor proliferation defects, while differentiation is not affected (Afelik et 
al., 2015).  
It is noteworthy that stabilizing CTNNB1 before E11.5 or overexpressing Wnt1 in the pancreatic epithelium 
also causes a hypoplastic phenotype (Heller et al., 2002; Heiser et al., 2006). The hypoplasia observed in 
stabilized Ctnnb1 mutants is associated with decreased FGF10 in the mesenchyme and increased SHH 
signaling in the epithelium. Remnant pancreata are cystic and fibrotic while no acinar or endocrine cells are 
observed. Later CTNNB stabilization in pancreatic epithelium causes the converse phenotype. In mutant 
animals, pancreata are hyperplastic. Cell proliferation is globally increased, whereas acinar cells are the 
major contributor of hyperplasia (Heiser et al., 2006). The time-dependent WNT activity is reinforced by 
Wnt7b gain of function experiments. When Wnt7b is overexpressed until E11.5, pancreata are cystic, even 
though the size of the pancreatic epithelium does not seem affected. Multipotent progenitors of the mutant 
pancreata differentiate into ductal cells with loss of endocrine and acinar cells. However, when Wnt7b is 
overexpressed from E11.5, mutant pancreata are hypoplastic with a loss of acinar cells and gain of 
mesenchymal tissue (Afelik et al., 2015). The activity of the pathway is thus expected to be different at 
different phases and to be cell-context dependent. 
Non canonical WNT signaling is important for endocrine cell formation 
Deletions of Celsr2 and Celsr3 do not cause a pancreatic size defect or ductal cyst formation as could be 
expected with PCP mutants. Their absence causes a failure to produce half of the endocrine cells from the 
endocrine progenitors. These defects are associated with a decrease of MAPK8 activity, and inhibition of 
MAPK8 recapitulates the phenotype in vitro (Cortijo et al., 2012). 
Two studies investigated the role of the WNT ligand, WNT5A, in pancreas development. The 
overexpression of Wnt5a, in pancreatic epithelium, induces hypoplasia. However as mentioned above, 
overexpression of WNT1, a canonical WNT, causes the same hypoplastic phenotype while the surrounding 
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organs are differently affected. It suggests therefore a toxic effect in the pancreas linked to the high transgene 
expression (Heller et al., 2002). Indeed, the analysis of Wnt5a KO pancreata does not show an effect on the 
size of the pancreas. However, the islets are closer to the ducts in Wnt5a KO pancreata compare to WTs, 
suggesting that the endocrine cell migration is impaired (Kim et al., 2005). 
6.2.4.4 Role of TGFB in pancreas development and in adult pancreatic stroma homeostasis 
TGFB signaling is poorly characterized during pancreas development. However, due to its major role in 
fibrosis, the role of the TGFB pathway in pancreas organogenesis is reviewed. TGFB signaling components 
are expressed in a dynamic pattern during pancreas development. TGFBR1 and TBFR2 are mainly expressed 
in the epithelium until E16.5. At E18.5, they are present in the blood vessels. ACVRL1 is expressed from 
E16.5 in the blood vessels (Tulachan et al., 2007). 
It is difficult to extract a global picture from the experiments carried out so far on this pathway in the 
pancreas, because the inactivation of different ligands and receptors appear to have unrelated phenotypes. 
For example, expression of a dominant negative form of TGFBR2 causes an increase of endocrine cells 
associated with an increase of endocrine progenitors. Hyperplastic ducts and blood vessels are also observed 
(Wescott et al., 2009). However, deletion of Gdf11, a TGFB ligand, causes endocrine cell decrease 
associated with a partial replacement of beta cells by alpha cells, while endocrine progenitor number is 
increased. The control of the endocrine progenitor production is independent of NOTCH signaling, as HES1 
is not affected in the mutant. Smad2 heterozygotes partially recapitulate the phenotype, as beta cell mass is 
reduced, and endocrine progenitors production is enhanced (Harmon et al., 2004). 
In the adult, stroma homeostasis requires tight regulation of TGFB signaling. Both inactivation and 
overactivation of the pathway cause fibrosis with immune cell infiltration, loss of acinar tissue, and its 
replacement by adipose tissue (Lee et al., 1995; Böttinger et al., 1997). 
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6.2.4.5 Other signaling pathways acting during pancreas development 
BMP signaling components, another major branch of TGFB ligand superfamily, and BMP signaling 
activities are also detected during pancreas development (Lyons, K. M. et al., 1995; Dichmann et al., 2003; 
Ahnfelt-Rønne et al., 2010). However, their exact role is still unclear, as studies bring contradictory 
conclusions (Dichmann et al., 2003; Ahnfelt-Rønne et al., 2010).  
The EGF pathway is  involved in pancreas organogenesis. It promotes both pancreatic size and beta cell 
mass (Miettinen et al., 2000; Huotari et al., 2002). 
Finally SHH signaling pathway inhibition is essential for pancreas specification (Apelqvist et al., 1997). 
Although some SHH compounds are present at later stages, inactivation of SHH signaling pathway does not 
cause any obvious phenotype, arguing that it is not essential during pancreas organogenesis, or that its 
components are redundant (Hebrok et al., 2000; Cervantes et al., 2010). 
6.3 Cystic syndromes 
Cyst is a broad term in biology and medicine that is used to define a closed pocket or pouch of tissue filled 
with air, fluid, or other material (http://www.ncbi.nlm.nih.gov/pubmedhealth). Cysts may arise in any kind of 
tissue, such as the skin, muscle, brain, liver, kidney.., and they have various origins, such as infection or duct 
obstruction. Cysts may be further defined as any fluid-filled closed cavity or sac lined by an epithelium. 
Moreover cyst may be formed of normal, abnormal or neoplastic tissues 
(http://www.ncbi.nlm.nih.gov/mesh). Such cyst may thus arise in any epithelium composed organs such as 
kidneys, ovaries, breast, liver, pancreas, lungs, and salivary glands. It is noteworthy that these definitions do 
not include any size criteria. Cysts in kidneys are largely studied as they cause renal failure. Pancreatic cysts 
are less studied, and they are often associated with neoplastic or pre-neoplastic lesions. 
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6.3.1 Human cystic kidney diseases and kidney dysplasia 
Autosomal dominant polycystic kidney disease (ADPKD), which occurs in around 1:1000 births, is the 
major cystic kidney disease. Patients develop multiple cysts in both kidneys, and as many as half of these 
will develop end-stage renal disease (ESRD) that leads to kidney failure. ADPKD is caused in 85% of the 
cases by a mutation in PKD1 and in 15% by a mutation in PKD2. Autosomal recessive polycystic kidney 
disease (ARPKD) arises in 1:20000 births and is caused by a mutation in PKHD1. It differs from ADPKD in 
that it causes death at neonatal period in nearly half of the cases due to lung failure, and up to 45% of the 
patients develop ESRD in childhood (reviewed in Wilson and Goilav, 2007). Another major difference is the 
origin of the cysts, in ADPKD they start in foci in the nephron, while in ARPKD collecting ducts and 
nephrons dilate and become cystic (Ockenden and Blyth, 1971). Nephronophthisis are recessive diseases that 
are also characterized by cysts in the kidneys in association with other organ defects, depending of the 
affected gene that codes for ciliary proteins. Therefore, these diseases are called ciliopathies (reviewed in 
Wilson and Goilav, 2007). In rare monogenic syndromes renal dysplasia usually associated with other organ 
defects is observed. It is characterized by cysts and fibrosis, as in the case of renal-hepatic-pancreatic 
dysplasia or cystic renal dysplasia (Ivemark et al., 1959; Cole et al., 1976; Frank et al., 2013). 
6.3.2 Cyst formation in polycystic kidney diseases 
The study of patient’s mutations, and also modeling of the disease in animals, combined with the use of 
patient cells have shed light on the genetic, molecular and cellular mechanisms of cyst formation. However, 
translating these findings into treatments has been achieved with relatively little success (reviewed in Riella 
et al., 2015). 
6.3.2.1 Frequent genetic causes of polycystic kidney disease (PKD) 
More than 1000 mutations have been reported in PKD1 and more than 200 in PKD2, causing ADPKD 
(http://pkdb.mayo.edu.). As only one allele is affected in patients, it has been suggested by Reeders that the 
second allele is mutated somatically in a nephric cell. Once the second allele is mutated, the nephric cell 
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expands clonally and form a cyst (Reeders, 1992). Indeed, loss of heterozygosity has been observed both for 
PKD1 and PKD2 in humans, although it may happen that the cells in the cyst do not carry all the same 2nd 
mutation (Qian et al., 1996; Torra et al., 1999). Pkd2 KO mice develop kidney cysts from E15.5. They 
harbor cysts in other organs, and exhibit multiple developmental defects. They die in utero, or shortly after 
birth, mimicking the early lethality and organ defects, e. g. heart, that may be observed in ARPDK (Wu et 
al., 2000). The effect of Pkd1 gene alteration is more complex. PKD1 is absent when the gene is disrupted in 
exon 1 or exon 4. The deletion of exon 34 leads to a smaller protein. The three homozygote mutants have a 
similar phenotype: they develop cysts, and in utero death is associated with edema (Lu et al., 1997; Lu et al., 
2001; Wu et al., 2002). However, the deletion of the exon 17 to 21 causes earlier lethality due to cardiac 
defects precluding the observation of any renal cyst (Boulter et al., 2001). Aged Pkd2 or Pkd1 heterozygotes 
also develop renal cysts although mice are correspondingly older than human ADPKD onset average (Lu et 
al., 1999; Wu et al., 2000). In addition, the majority of the cysts formed in Pkd2 heterozygote mice and some 
Pkd1 heterozygotes mice are devoid of PKD2 or PKD1 respectively (Wu et al., 1998; Lu et al., 1999; Wu et 
al., 2002). Furthermore the pace of cyst formation in Pkd2 heterozygotes is slower than in compound 
heterozygotes with an unstable allele and a null allele (Wu et al., 1998; Wu et al., 2000). Therefore, these 
mouse data support a 2-hit mutation theory in ADPKD (Reeders, 1992). 
In contrast, it appears that even a severe reduction in Pkd1 levels is sufficient to cause cysts. Mice expressing 
only 20% of normal PKD1 level develop cysts in both kidneys (Lantinga-van Leeuwen et al., 2004; Jiang et 
al., 2006). Cysts grow at a slower pace than in Pkd1 KO and the mice survive more than a year. They also 
develop dilated pancreatic and liver bile ducts as well as other defects found in ADPKD patients (Lantinga-
van Leeuwen et al., 2004; Jiang et al., 2006). Hypomorphic alleles likely exist in human since studies of 
ARPKD patients identified compound heterozygous PKD1 mutations correlating with early onset of the 
disease and in utero organ defects (Rossetti et al., 2009; Vujic et al., 2010). In good agreement, animals 
carrying one Pkd1 null allele and a human mutation in the other Pkd1 allele develop a rapid onset of the 
disease (Hopp et al., 2012). Conversely, mice overexpressing Pkd1 or Pkd2 develop cysts (Thivierge et al., 
2006; Park et al., 2009). These findings highlight the tight level regulation of PKD1 and PKD2 required for 
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kidney homeostasis and suggest that the impact of any given PKD1 or PKD2 mutation on disease 
progression cannot be predicted a priori without detailed analysis. 
The cystic outcome for different organs may also depend of the expression level of the affected gene. Indeed, 
while the Pkhd1 KO is used as models of ARPKD, Pkhd1 hypomorphs do not develop kidney cysts. They 
develop cysts and fibrosis in the pancreas and/or in the liver pancreas, highlighting again the importance of 
expression level in disease susceptibility (Moser et al., 2005; Gallagher et al., 2008; Williams et al., 2008). 
Finally, the time of onset of the mutation is important. Indeed studies using different genetic models show 
that gene inactivation before postnatal day 14 (P14) causes massive cyst formation while after P14, the onset 
of the disease is much slower (Davenport et al., 2007; Piontek et al., 2007; Verdeguer et al., 2010). This 
developmental switch may be linked to the proliferative status of the kidney, as suggested by Verdeguer and 
colleagues (Verdeguer et al., 2010; Sharma et al., 2013). However forced proliferation is not sufficient to 
induce cyst formation in adult mice that do not have cilia (Verdeguer et al., 2010; Sharma et al., 2013). It has 
also been suggested that the acquisition of a more mature transcriptome, mainly linked to changes in 
metabolism, may switch the kidneys from a cystogenic state to a cyst refractory state (Menezes et al., 2012).  
6.3.2.2 Cellular defects associated with cyst formation in PKD 
PKDs have been associated with several perturbations. Cysts are usually surrounded by a fibrotic tissue 
especially at late stage of the disease. Cystic cells have been shown to proliferate more, and to secrete more 
fluid into the lumen. In some cystic models, the formation of cysts is associated with loss of primary cilia. 
Cyst formation may be associated with primary cilia loss 
Primary cilia are organelles that mediate the activity of multiple signaling pathways, in addition to other 
functions such as mechanical stress sensing (reviewed in Gerdes et al., 2009).  
Murine mutants for ciliary proteins develop kidney cysts, as seen in pcy/pcy mice, where NPHP3 is 
inactivated, cpk/cpk mice, in which CYS is disrupted, orpk/orpk mice which lost IFT88 or Kif3a conditional 
KOs. However, the onset and the progression of the disease vary with an end-stage renal failure ranging from 
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a month to nearly a year (Takahashi et al., 1991; Moyer et al., 1994; Gattone et al., 1996; Pazour et al., 2000; 
Hou et al., 2002; Fangming et al., 2003; Olbrich et al., 2003). The number of cilia is also drastically reduced 
in other cystic mutants, such as Glis3 KOs and conditional Pkd2 KOs (Kang et al., 2009a; Kim et al., 2009). 
However, inactivation of Inv, the gene causing Nephronophthisis II that is localized at the cilia, does not 
affect cilia number (Otto et al., 2003). Nevertheless, it does not exclude that their function may be impaired 
(Watanabe et al., 2003). The exact role of cilia in cyst formation is still unclear. 
Aberrant proliferation causes cyst expansion 
Proliferation is a generally admitted mechanism for cyst growth. It is usually associated with increased 
apoptosis. Cystic kidney cells from patient with ADPKD proliferate more than normal epithelial cells 
(Hanaoka and Guggino, 2000). Overproliferation associated with increased cell death is also found in mouse 
mutants such as the Pkd2 or Kif3a conditional KOs (Fangming et al., 2003; Kim et al., 2009).  
However, it is difficult to assess if overproliferation is the cause of cyst formation or just expansion. Indeed, 
only cysts lining cells are overproliferating in bpk/bpk mouse model which have lost BICC1, while a global 
overproliferative phenotype is observed in a Pkd2 haploinsufficiency model, both in cystic and non-cystic 
areas (Nauta et al., 1993; Cogswell et al., 2003; Chang et al., 2006). The latter is surprising, as it would 
suggest that proliferation does not always result in cyst formation, since kidneys at 9 months and upwards 
still have numerous non-cystic nephrons. It is supported by a report from Sharma and colleagues showing 
that proliferation alone is not sufficient to induce cyst formation in adults after cilia disruption (Sharma et al., 
2013). 
Moreover, proliferation is not increased upon Pkd1 kidney-specific deletion in mice, either before or after the 
developmental switch (Piontek et al., 2007). It has been proposed that cysts may emerge only if the angle of 
division is affected (Fischer et al., 2006). Indeed, if cells divide in the longitudinal axis of the tubule it leads 
to tubule extension. On the contrary, if they divide perpendicularly, the tubule diameter expands and may 
lead to cyst formation (Fischer et al., 2006). Further experiments will be necessary to unravel the role of cell 
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division in cyst induction and expansion, and to determine if the major contributor of cyst expansion is the 
loss of oriented cell division. 
Increase fluid secretion is associated with renal cyst formation 
The other major contributor to cyst growth is the secretion of fluid into the lumen, which was mainly studied 
on ADPKD cystic cells in vitro (reviewed in Sullivan et al., 1998). Baso-lateral Na+K+ATPase and K+ 
channels create an inward gradient of cations promoting the transepithelial flow of chloride via the NaKCl2 
transporter on the basal side and CFTR on the apical side. It is followed by a paracellular flow of Na+ and 
water (reviewed in Sullivan et al., 1998). This mechanism is supported by the observation of less severe 
cysts harbored by patients with cystic fibrosis and ADPKD. Furthermore, cyst growth is decreased when 
CFTR is inhibited (O'Sullivan et al., 1998; Montesano et al., 2009). The aquaporin AQP2 is increased in 
different models of PKD, and is translocated to the apical membrane facilitating water exit into the lumen 
(Gresh et al., 2004; Jiang et al., 2006; Starremans et al., 2008). However, the contribution of CFTR-mediated 
fluid secretion to cyst formation does not appear to be necessary in all cystic models. For example, bpk/bpk 
mice show no reduction in cyst formation on a cftr null background, suggesting that other Cl- channels or 
other mechanisms cause massive fluid secretion and implying different cysts may be caused by different 
mechanisms (Nakanishi et al., 2001). 
Fibrosis and inflammation promote cyst expansion 
Defects in the ductal cells that line the cysts are not the sole contributors to cyst formation. Interstitial 
fibrosis is observed in different models of cystic kidney diseases. Nevertheless fibrosis does not cause cyst 
formation as it is observed after cysts started to grow (Okada et al., 2000; Fangming et al., 2003; Chang et 
al., 2006; Jiang et al., 2006; Happé et al., 2013; Wallace et al., 2014). The TGFB signaling pathway may be 
involved in the fibrotic reaction. Indeed, phospho-SMAD2, a TGFB receptor intracellular target, is 
upregulated both in the cystic epithelium and in the mesenchyme surrounding the cysts (Hassane et al., 
2010). Infiltration of inflammatory cells such as macrophages is also observed in cystic areas. These 
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inflammatory cells promote but do not initiate cyst growth and their inhibition slows down cyst growth 
(Karihaloo et al., 2011; Swenson-Fields et al., 2013; Ta et al., 2013). 
Molecular pathways involved in cyst formation 
Several pathways are altered during renal cyst formation. There are either strong evidence that they are 
downstream of the genetic cause of ADPKD, such as Ca2+ intracellular flow, cAMP signaling pathway, and 
MTOR pathway or they are associated to cyst formation, although but their role in the pathogenicity of the 
human disease is less clear, e. g. WNT signaling. 
PKD1, PKD2 and Ca2+ intracellular flow defects in PKD 
As discussed above, PKD1 and PKD2 mutations can cause cysts in the kidney. The complex formed by 
PKD1 and PKD2 acts as a mechanosensor at the cilia and translates mechanical stress into a Ca2+ influx 
(Hanaoka et al., 2000; Nauli et al., 2003). PKD1 is an integral protein with 11 transmembrane domains and a 
large extracellular domain (Hughes et al., 1995). PKD2 is a 6 transmembrane domain protein with both its C 
and N terminal domains in the cytoplasm (Mochizuki et al., 1996). PKD2 is mainly expressed in the 
endoplasmic reticulum. In the presence of PKD1, PKD2 is transported to the plasma membrane and the cilia. 
PKD2 is a nonselective cation channel with a higher permeability for Ca2+ than monovalent cations. Its Ca2+ 
channel permeability is stabilized by its interaction with PKD1 via its coiled-coiled intracellular domain (Cai 
et al., 1999; Foggensteiner et al., 2000; Hanaoka et al., 2000; González-Perrett et al., 2001; Vassilev et al., 
2001; Koulen et al., 2002; Yoder et al., 2002; Grimm et al., 2003; Xu et al., 2003). Thus shear stress at the 
cilia leads to Ca2+ inward flow via PKD1-PKD2 complex (Fig. 9) (Hanaoka et al., 2000). 
Elevated Ca2+ concentrations in the cilia are amplified by the release of Ca2+ from the endoplasmic reticulum 
through PKD2 and ITPR1, thus increasing the intracellular concentration of Ca2+ (Sammels et al., 2010). In 
the absence of functional PKD2 or PKD1, the intracellular concentration of Ca2+ is low (Koulen et al., 2002; 
Nauli et al., 2003). There are multiple consequences, but notably in the kidney low amount of Ca2+ leads to 
an increase of cAMP in the cells due to the loss of inhibition by Ca2+ of ADCY6 or ADCY5, the major Ca2+-
regulated adenylate cyclases in the renal epithelium. Ca2+ also activates PDE1, the main Ca2+-regulated 
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phosphodiesterases in the renal epithelium. Therefore, in low concentration of Ca2+, cAMP synthesis is 
increased while its degradation is reduced (Chabardès et al., 1999; Kakkar et al., 1999; Wang, X. et al., 2009; 
Rees et al., 2014). ADCY are also activated by the vasopressin receptor (Star et al., 1988), and are inhibited 
by somatostatin repressor, two potential drug targets in the treatment of ADPKD (Fig. 9) (reviewed in Riella 
et al., 2015). 
Increase of cAMP signaling in cyst formation 
cAMP stimulates both fluid secretion and proliferation (Mangoo-Karim et al., 1989; Hanaoka and Guggino, 
2000). The activation of CFTR by cAMP contributes to the fluid secretion control (Morales et al., 1996; 
Wallace et al., 2001). Moreover it increases the transcellular Cl- flow by activating basolateral K+ channels 
(Albaqumi et al., 2008). Finally, it also promotes the translocation at the apical membrane of AQP2. The 
mechanism is unclear but most probably does not require PKA activity (Fig. 9) (Klussmann et al., 2001; 
Tamma et al., 2003; Umenishi et al., 2006; Kortenoeven et al., 2012). 
Legend of Fig. 9  
(A) In normal kidney cells, mechanical stress is sensed at the cilia by PKD1 and PKD2 and translated into an inward 
Ca2+ flux. It triggers the release of intracellular Ca2+ stock. Ca2+ inhibits the activity of ADCY6 and actives PDE1, 
leading to a low concentration of cAMP. Moreover the inhibition of BRAF by Ca2+ prevents proliferation. 
(B) In ADPKD, PKD2 or PKD1 is mutated, leading to an impaired inward Ca2+ flux. ADCY6 is active while PDE1 is 
inhibited. The increase of cAMP concentration promotes a transepithelium Cl- and water flux due to the activation of 
CFTR, to the translocation of AQP2 to the apical membrane and to the enhancement of K+ channel. It also promotes 
proliferation via the MAPK pathway and the MTOR pathway that also promote aerobic glycolysis. 
(C) Legend of the different proteins used in cartoons. 
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Fig. 9: Molecular defects causing ADPKD  
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Stimulation of proliferation requires both low concentration of Ca2+ and increase amount of cAMP. Ca2+ 
inhibits BRAF. In its absence, cAMP activated PKA activates BRAF triggering a cascade of activation of 
MAP2K7 and MAPK1, also called MEK and ERK respectively, which stimulates proliferation (Fig. 9) 
(Yamaguchi et al., 2000; Yamaguchi et al., 2003; Belibi et al., 2004; Yamaguchi et al., 2004). 
Increased MTOR signaling pathway activity and aerobic glycolysis in renal cysts  
The activity of the MTOR pathway in the cystic renal epithelial, but not in the non-cystic area, is elevated in 
different cystic mouse models and in ADPKD patients. The overactivation of the pathway may be direct as 
PKD1 interacts with TSC2, an activator of the MTOR pathway, or indirect, via an increase of MAPK1 
activity (Shillingford et al., 2006; Gattone et al., 2009; Rowe et al., 2013). MTOR pathway inhibition slows 
down the progression of the disease in an ADKPD mouse model, and in bpk/bpk mice used as an ARPKD 
model, suggesting that it plays a role in cyst progression (Shillingford et al., 2006; Gattone et al., 2009). 
MTOR pathway activation also promotes aerobic glycolysis, which is used as the main source of energy in 
Pkd1 conditional KO cells in contrast to WT cells. The increase of ATP promotes MAPK1 activity via the 
inhibition of PRKAA1, also called AMPK. MTOR and MAPK1 form thus a feedforward loop. The Pkd1 
conditional KO transcriptome also reflects its metabolic state by the upregulation of glycolytic enzymes. 
Cyst progression in murine models of ARPKD and ADPKD is thus inhibited by the inhibition of glycolysis 
(Rowe et al., 2013). 
Aberrant canonical WNT signaling activity associated with renal cysts 
Overactivation of canonical WNT signaling causes cyst formation in the kidneys (Saadi-Kheddouci et al., 
2001; Chao-Nan et al., 2005). The epithelium lining the cysts is over-proliferative and often multilayered. In 
this model, only the dysplastic epithelium loses cilia. However no decrease of PKD1 or PKD2 was observed 
in these experiments, suggesting that PKD1/2 and the WNT pathway act either in parallel or that the WNT 
pathway acts downstream of these proteins (Chao-Nan et al., 2005). In agreement with the second 
hypothesis, overactive canonical Wnt signaling is also observed in the Pkd2 and Kif3a conditional KOs, both 
models of ARPKD (Fangming et al., 2003; Kim et al., 2009). Moreover, two other proteins whose 
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inactivation causes renal cysts, INV and NPHP3, inhibit canonical Wnt signaling (Simons et al., 2005; 
Bergmann et al., 2008). However, it is unclear if changes in endogenous WNT signaling contribute to cyst 
formation or are a side effect of it. 
6.3.3 Human pancreatic cyst and pancreatic dysplasia 
Cysts can also be found in the pancreas. Cysts can be mistaken for pseudocysts that are not lined by an 
epithelium. Pseudocysts are the most frequent and are observed for example, in pancreatitis when fluid 
accumulation is surrounded by fibrotic tissue (reviewed in Demos et al., 2002). Cysts might be asymptomatic 
or without pathognomonic signs, and escape detection until they are incidentally discovered (Fernandez-del 
Castillo et al., 2003; Laffan et al., 2008; Lee et al., 2010).  
Pancreatic cysts are divided into cystic neoplasms and congenital cysts. Cystic neoplasms are promoted by 
the accumulation of mucin, as seen in mucinous adenocarcinoma, mucinous cystic tumor and intraductal 
papillary tumor. Accumulation of glycogen is found in benign microcystic adenomas observed in patients 
with von Hippel Lindau disease (see below). Endocrine tumors in rare instances might also form cysts 
(reviewed in Demos et al., 2002).  
Congenital pancreatic cysts are usually part of a multi-organ syndrome. The pancreas of cystic fibrosis 
patients is progressively replaced by a fibrotic and adipose tissue with microscopic cysts due to the 
obstruction of the ducts (reviewed in Agrons et al., 1996). Pancreatic cystosis, i. e. the presence of 
macroscopic cysts of more than 1 cm of diameter, is less common as it occurs only in 10% of the cystic 
fibrosis patients (Berrocal et al., 2005).  
Von Hippel-Lindau syndrome is caused by a heterozygote mutation in VHL. The mutation predisposes to 
benign and malignant tumours and is associated with cysts in multiple organs such as kidneys and the 
pancreas (Lamiell et al., 1989).  
Autosomal dominant polycystic kidney disease patients also develop pancreatic cysts. The frequency 
estimation turns around 5% (Nicolau et al., 2000). Pancreatic dysplasia, i. e. fibrosis associated or not with 
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cysts, may also be observed in ARPKD patients (Lundin and Olow, 1961). Other syndromes associate renal 
and pancreatic dysplasia such as renal-hepatic-pancreatic dysplasia and situs inversus totalis with cystic 
dysplasia of kidneys and pancreas. Loss of function of NEK8 or NPHP3, two ciliary proteins, has been 
identified in some cases of the former syndrome but the etiology of the latter is unknown (Ivemark et al., 
1959; Balci et al., 1999; Bergmann et al., 2008; Frank et al., 2013).  
6.3.3.1 The impairment of primary cilia causes cysts in murine pancreas 
Pancreatic cysts have been found in murine mutants in which primary cilia are impaired. In the pancreas, 
primary cilia have been reported on bipotent progenitors lining the ducts, mature ductal cells, and endocrine 
cells (Munger, 1958; Boquist, 1968; Cano et al., 2004). 
Two mutants show the importance of primary cilia in duct homeostasis. orpk/orpk mice have a mutation in 
Ift88 precluding cilia formation (Pazour et al., 2000). Primary cilia are much smaller in orpk/orpk mice and 
their frequency in ductal cells is drastically reduced. Mutants develop ductal cysts after birth combined to 
fibrosis and a progressive loss of acinar tissue. These defects are associated with increased PKD2 expression 
and WNT signaling activity. The second mutants, in which Kif3a was deleted in the pancreatic epithelium, 
have no cilia. Cyst formation starts slightly before birth. They are also associated with fibrosis and 
conversion of acinar cells into adipose tissue. It is noteworthy that these mutants do not have any reported 
endocrine cell defects in spite of the presence of cilia on the cells (Cano et al., 2004; Cano et al., 2006). 
Mutants developing pancreatic cysts such as Sox9 KOs, Hnf6 KOs, Glis3 KOs and Hnf1b KOs, also have 
cilia defects. However it is difficult to establish if it is the initiating cause of cyst formation or a consequence 
(Pierreux et al., 2006; Kang et al., 2009b; Shih et al., 2013; De Vas et al., 2015). 
6.4 Bicaudal C1 
Bicaudal C1 (Bicc1) is mutated in bpk/bpk mice and jcpk/jcpk mice, two models of ARPKD. BICC1 is an 
RNA binding protein found in several species, however, its mechanisms of action are poorly understood 
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(Gamberi and Lasko, 2012). The majority of BICC1 homologs possesses one SAM domain, are able to 
interact with proteins, and have several KH domains that bind RNA molecules (Mahone et al., 1995; 
Bouvrette et al., 2008; Jones et al., 2012). On the contrary, GLD-3, one of the poorly conserved homologs  of 
Bicc1 in Caenorhabditis elegans, that lacks the SAM domain interacts with proteins via its KH domains 
(Eckmann et al., 2002; Nakel et al., 2010). 
6.4.1 Role of GLD-3 and BCC-1 in Caenorhabditis elegans  
GLD-3 and BCC-1 are the homologs of BICC1 in Caenorhabditis elegans (Eckmann et al., 2002). GLD-3 
controls sex determination and mitosis vs meiosis decision. It binds the polyA polymerase, GLD-2, and 
stimulates its activity to stabilize specific mRNAs. Thereby, it promotes their translation by polyA tail 
elongation (Wang et al., 2002). GLD-3 thus causes the cell to enter meiosis instead of mitosis (Eckmann et 
al., 2004). Through a distinct domain, GLD-3 can also sequester the fem3-binding factor (FBF-1) of the 
pumilio family of RNA-binding proteins, inhibiting its interaction with fem mRNA and, thereby promoting 
spermatogenesis at the expense of oogenesis (Eckmann et al., 2002; Eckmann et al., 2004). These 
observations suggest that GLD-3 can regulate mRNA polyA tail elongation and stability by associating with 
a variety of interacting partners. By comparison, little is known about the role of the Bicc1 ortholog BCC-1, 
except that its loss can suppress the loss-of-function phenotype of the receptor tyrosine kinase ROL-3 (Jones 
et al., 2012). 
6.4.2 Role of BicC in Drosophila Melanogaster 
BicC, the first homolog of Bicc1 identified, was isolated during mutagenic screens. Its haploinsufficiency 
causes patterning defects, such as double abdomen embryos or headless embryos (Mohler and Wieschaus, 
1986). They are associated with the mislocalization of osk mRNA, normally present at the posterior side of 
the oocyte, and its premature translation (Mahone et al., 1995; Saffman et al., 1998). The precise relationship 
between BicC and osk mRNA is unknown. BicC interacts with the CCR4-NOT complex, a deadenylase 
complex, and targets it to specific mRNAs such as its own mRNA, leading to a shortening of its polyA tail 
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(Chicoine et al., 2007). No such effect has been reported on osk mRNA, but BicC can instead inhibit osk 
mRNA polyadenylation and translation by sequestering the polyA polymerase orb (Castagnetti and Ephrussi, 
2003; Chicoine et al., 2007).  
BicC KO females are sterile due to an interruption of oogenesis. The follicle cells fail to migrate posteriorly 
and continue to cover nurse cells. The nurse cells then invade the space occupied by the oocyte. Oocyte and 
nurse cells degenerate resulting in an empty eggshell (Mohler and Wieschaus, 1986; Schüpbach and 
Wieschaus, 1991). Although the mechanism underlying the phenotype is unclear, it may be associated with 
cytoskeleton and trafficking defects. For instance, Grk, a protein that is normally secreted at the anteriodorsal 
side of the oocyte, accumulates in vesicles imbedded into actin cages in BicC KOs. BicC interacts with the 
Tral mRNP complex found on the endoplasmic reticulum membrane, and is important to maintain COPII 
coated vesicle exit sites. The cytoskeleton of the nurse cells is also affected in BicC KO females (Wilhelm et 
al., 2005; Kugler et al., 2009; Snee and Macdonald, 2009).  
Beyond these defects, no other functions of BicC have been reported in flies. However, BicC mRNA is also 
expressed in males and at different stages in the embryos (Mahone et al., 1995).  
6.4.3 Role of BICC1 in vertebrates 
Bicc1 is able to induce endoderm formation when overexpressed in Xenopus embryo (Wessely and De 
Robertis, 2000). This ectopic capacity is maybe related to its ability to repress, in vegetal cells, mRNA 
translation, such as tdgf1.3, also called cripto, an important factor for neural development. This repression 
requires its N-terminal region containing its KH domains that bind tdgf1.3 mRNA, and a region upstream of 
its SAM domain that inhibits the translation initiation machinery (Yabe et al., 2003; Zhang et al., 2013). 
Bicc1 is also involved in the establishment of left-right asymmetry. While no defects have been reported in 
cilia formation in Bicc1 KOs or knockdowns, motile cilia are dysfunctional (Tran et al., 2007; Maisonneuve 
et al., 2009; Bouvrette et al., 2010; Ryan et al., 2010; Piazzon et al., 2012). They are not oriented properly on 
node cells, and they are not able to generate the leftward fluid flow. In the node of Bicc1 KOs, hyperactive 
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canonical Wnt signaling was also observed due to the ability of BICC1 to sequester DVL2 in P-bodies 
precluding the activation of canonical Wnt signaling (Maisonneuve et al., 2009). 
6.4.3.1 BICC1 regulates epithelium homeostasis in kidneys 
Bicc1 is expressed in the Xenopus and zebrafish pronephros as well as in the murine metanephros that give 
rise to the kidneys (Wessely and De Robertis, 2000; Wessely et al., 2001; Bouvrette et al., 2010). Its absence 
or its downregulation causes cyst formation in the three species (Nauta et al., 1993; Flaherty et al., 1995; 
Cogswell et al., 2003; Tran et al., 2007; Bouvrette et al., 2010; Tran et al., 2010; Piazzon et al., 2012). In 
humans, mutations of BICC1 have been associated with kidney dysplasia (Kraus et al., 2012). In mice, duct 
enlargement appears around E15.5 (Tran et al., 2010; Piazzon et al., 2012). Cysts are also observed in the 
pancreas as well as in the liver and extra-hepatic ducts (Nauta et al., 1993; Flaherty et al., 1995; Tran et al., 
2010). Moreover kidney cysts have been observed in some aged jcpk heterozygote mice harboring a 
mutation in one of the Bicc1 alleles (Flaherty et al., 1995; Cogswell et al., 2003). 
The mechanism of cyst formation and initiation is still unclear. As in other polycystic kidney disease models, 
cysts are not caused by specification or early differentiation defects (Tran et al., 2007). As already 
mentioned, bpk/bpk cystic cells proliferate more, but overproliferation is not yet observed at early stages 
when cysts start to form (Nauta et al., 1993; Tran et al., 2010). Immotile cilia in kidneys and other organs are 
not affected by Bicc1 deletion (Tran et al., 2007; Maisonneuve et al., 2009; Bouvrette et al., 2010; Ryan et 
al., 2010; Piazzon et al., 2012). However, studies with bpk/bpk mice show that EGFR is mislocalized on the 
apical membrane due to vesicle trafficking defects. The bpk mutation also leads to hyperactivation of the 
MAPK pathway (MacRae Dell et al., 2004; Ryan et al., 2010). The MTOR pathway may also be deregulated 
as its inhibition precludes cyst growth (Shillingford et al., 2006). Eventually, the major role of BICC1 in 
kidney homeostasis may be to promote PKD2 expression, and to regulate cAMP production via microRNA 
regulation (Tran et al., 2010; Piazzon et al., 2012). 
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6.4.3.2 Molecular mechanisms involving BICC1 in kidney homeostasis 
Contrary to the ability of BICC1 to directly repress tdgf1.3 translation in early Xenopus development, 
translation repression by BICC1 in kidneys requires specific microRNAs (Tran et al., 2010; Piazzon et al., 
2012; Zhang et al., 2013). miRNA genes are transcribed into pri-miRNA, which are composed of a stem-
loop structure with unpaired ends. In animal cells, unpaired ends are cleaved by the microprocessor 
containing DROSHA and DGCR8. Alternatively, pri-miRNA may be spliced by the spliceosome when they 
are part of an intron. The stem-loop structure is called pre-miRNA, and is exported to the cytoplasm where 
the loop is cleaved by DICER1. The double stranded miRNA is then unwound and one strand loaded onto 
the RISC complex formed by TNRC6A and AGO1 or AGO2. miRNAs are then able to repress translation by 
inhibiting translation initiation or elongation. They can also destabilize mRNA by inhibiting mRNA capping, 
or by promoting their degradation (Fig. 10) (reviewed in Carthew and Sontheimer, 2009).  
BICC1 is able to target Mir125a to Adcy6 mRNA and MiR27a to Pkia mRNA enabling translation 
repression without affecting mRNA stability or polyA tail length. ADCY6 and PKIA levels are thereby 
elevated in absence of Bicc1. The net impact is an excessive level of cAMP thought to cause cyst formation. 
However it should be mentioned that increased cAMP levels are observed when the cysts are already formed. 
One can therefore not rule out that this mechanism promotes cyst growth and not cyst initiation (Piazzon et 
al., 2012). 
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Fig. 10: Maturation of pri-miRNA into miRNA.  
Pri-miRNA is processed into pre-miRNA by microprocessor containing Drosha and DGCR8 or by the spliceosome. 
Pre-miRNA is exported into the cytoplasm where it is further cleaved by Dicer1, and loaded onto the RISC complex. 
Then, it represses targeted mRNA (from the review of Carthew and Sontheimer, 2009). 
BICC1 has also been involved in the regulation of PKD2 levels by inhibiting Mir17 repression, although no 
direct binding between Mir17 or Pkd2 and BICC1 has been established (Tran et al., 2010). A role of the 
MiR17 or Mir17-92 cluster in kidney cyst formation has been confirmed by two other studies (Sun et al., 
2010; Patel et al., 2013), although this likely involves multiple Bicc1-independent target mRNAs. In 
ARPKD mouse models, Mir17-92 is upregulated and correlated with the severity of the disease. Its 
overexpression alone causes overproliferation while its deletion in ARPKD background limits cyst growth. 
Mir17 is able to downregulate Pkd2 and Pkd1 translation (Patel et al., 2013). Mir17 can also repress PKD2 in 
human cells (Sun et al., 2010). However, elucidating the precise roles of individual miRNAs and their 
potential as therapeutic targets in cyst formation will require further studies. 
Not much is now know about the mechanism of action of BICC1 in different species and organs. Therefore, 
the lack of cohesion between the reported functions precludes a precise overview of its molecular nature. It 
requires miRNA in some but not others and, its functions may depend on its binding partners. Moreover few 
of its targets have been uncovered, and they do not seem conserved across species or systems, except Pkd2 
as it has been shown to also play a role downstream of BICC1 in osteoblastogenesis in mice (Mesner et al., 
2014). Furthermore only one RNA sequence has been described as a binding site for BICC1 in Xenopus, and 
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none in mammals or invertebrates (Zhang et al., 2014). Finally BICC1 should have functions in other tissues 
as it is expressed broadly during development and in the adult (Wessely et al., 2001).  
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7 RESULTS 
7.1 BICC1 is expressed in the pancreas progenitors and ducts during 
pancreas development 
To investigate a possible role for BICC1 during embryonic pancreas formation, its expression was analyzed 
at different stages. Bicc1 mRNA was already detected by Q-PCR at E10.5, whereas the protein was first 
detected at low levels at E11.5 in the whole PDX1+ pancreatic epithelium. The expression level increased 
over time. It was still detected at E18.5 and after birth in ductal cells recognized by their positivity for 
Dolichos Biflorus Agglutinin (DBA), but not in beta cells (Fig. 11). As previously described in cell lines 
(Maisonneuve et al., 2009; Tran et al., 2010), BICC1 protein was present in the cytoplasm (Fig. 12A-C). 
BICC1 is expressed in pancreatic bipotent progenitors 
During the secondary transition, its expression was restricted to the pancreatic progenitors lining ducts and to 
a subset of NEUROG3+ endocrine progenitors, mostly in those that had not yet delaminated to form 
endocrine clusters. It was excluded from the endocrine cells and acini (Fig. 12).  
BICC1 is expressed in the extrahepatic duct 
Contrary to what has been previously published in (Lian et al., 2014), BICC1 was expressed at E11.5 in 
hepatic ducts but not in the hepatoblasts (Fig. 13). However, the nature of the ducts have not been 
investigated. 
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Fig. 11: BICC1 is expressed from E10.5 onward.  
(A) Q-PCR analysis for Bicc1 in E10.5, E11.5 and E12.5 dorsal pancreatic buds indicates that Bicc1 mRNA is already 
present in E10.5 pancreas and its global expression level increases (n=3 for each stage; E10.5-E11.5 p=0.20; E11.5-
E12.5 p=0.0003; E10.5-E12.5 p=0.0008). Bicc1 mRNA level is normalized to Hprt1 level. Results are represented as a 
percentage of Bicc1 expression level at E12.5.  
(B-G) Immunostaining for BICC1 (cyan) and PDX1 (magenta) is performed on E11.5 Bicc1 KO and WT and E14.5 
pancreatic sections. Bicc1 KO is used to evaluate the specificity of the antibody. BICC1 is present in the whole 
pancreatic epithelium positive for PDX1 at E11.5 and in a subset of cells at E14.5.  
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Continuation of the legend of the Fig. 11 
(H-M) E18.5, 2 weeks old WT and Bicc1 KO pancreatic sections are immunostained for BICC1 (cyan), DBA 
lectin (magenta) and INS (orange). The specificity of the antibody is evaluated with sections of 2 weeks old KO. 
BICC1 is present in DBA lectin+ ducts but not in INS+ cells.  
Sections are counterstained with DAPI (white). Scale bars B-G and G-M 25 µm, H-I 20 µm and insets in G-K 10 
µm. See Table 12 in Appendix for further data 
 
Fig. 12: BICC1 expression is restricted to progenitors during the secondary transition. 
E14.5 and E15.5 pancreatic sections are immunostained and counterstained with DAPI (white).  
(A-C) The BICC1 expression domain (cyan) co-localizes with the HNF1B expression domain (magenta) at E14.5, (D-
F) but is excluded from the acinar cells stained by CPA1 (orange) at E15.5.  
(G-I) It is also excluded from the beta cells expressing INS (orange) and from the alpha cells expressing GCG 
(magenta) at E15.5.  
(J-L) A subset of NEUROG3+ cells (magenta) are positive for BICC1 (yellow arrowheads), while the others are 
negative (white arrowheads).  
Scale bars A-L 20 µm. 
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Fig. 13: BICC1 is expressed in hepatic ducts but not hepatocytes. 
(A, B) Immunofluorescence staining performed on E11.5 Bicc1 KO and WT liver sections indicates BICC1 expression 
(cyan) in the hepatic duct (magenta asterisk) but not in the hepatoblasts (yellow asterisk) as this staining is also present 
in Bicc1 KO. Sections are counterstained with DAPI (white). Scale bars 10 µm 
7.2 Bicc1 KO progenitor-lined ducts expand and form cysts 
To further analyze the function of BICC1 during pancreas development, the pancreas from Bicc1 KO mice 
was analyzed at different stages of development.. 
 
Fig. 14: Bicc1 KOs display cysts 
(A, B) Haematoxylin eosin staining of E18.5 WT and Bicc1 KO pancreatic sections shows cysts delineated by ductal 
cells in KO pancreata (asterisks).  
(C) Quantification of pancreatic DBA lectin+ ductal cell numbers detected on immunofluorescence-stained sections at 
P0 shows that there are twice more ductal cells in Bicc1 KO (n=4) than in WT (n=4, p= 0.0003).  
Scale bars A-B 100 µm. See Table 12 in Appendix for further data. 
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Progressively expanding cysts lined by pancreatic progenitors were detected from E14.5 (Fig. 14A-B, 32A-
B), confirming previous observations made at P1 in another Bicc1 KO line and in jcpk/jcpk mouse model 
(Flaherty et al., 1995; Tran et al., 2010) 
 
Fig. 15: Ductal proliferation at late developmental stages is increased in Bicc1 KO. 
(A, B) Immunofluorescence staining is performed on E14.5 WT and Bicc1 KO pancreatic sections for PDX1 (magenta) 
and PHH3 (yellow) 
(C) Percentage of PDX1+ pancreatic progenitors expressing PHH3 among the E14.5 pancreatic progenitors detected on 
the immunostaining exemplified in (A, B). The proliferation is not affected in Bicc1 KO (WT, n=4; Bicc1 KO, n=3, 
p=0.9). The results are expressed as percentage of WT mean.  
(D, E) Immunofluorescence staining for MKI67 (yellow), also known as Ki67, and DBA rhodamin (magenta), marking 
ductal cells, is performed on E18.5 Bicc1 KO and WT pancreatic sections. 
 (F) Percentage of MKI67+ cells among ductal cells detected on the sections exemplified in (D, E). The proliferation in 
Bicc1 KO is increased 1.47-fold compared to WT. KO data are normalized to WT pancreas from the same background 
(WT, n=4; Bicc1 KO, n=4, p=0.016).  
Sections are counterstained with DAPI (white). Scale bars 10 µm. See Table 12 in Appendix for further data. 
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The cysts were not a consequence of the left/right asymmetry defects seen in Bicc1 KO, since they occurred 
both in left- and right-turned pancreata. The cystic web arose in the main duct and interlobular ducts, while 
the intercalated ducts were not enlarged. Quantification of ductal cells expressing DBA at P0 revealed twice 
more cells in Bicc1 KO pancreata than in wild type (WT) pancreata (Fig. 14C).  
Proliferating ductal cell quantification at E18.5 revealed a 1.5-fold increase in proliferation index in Bicc1 
KO pancreata. However, it was not the primary cause of cyst formation as proliferation of pancreatic 
progenitors at E14.5 was not affected by Bicc1 deletion (Fig. 15). Although rare, apoptotic cells were 
detected by terminal deoxynucleotidyl transferase-dUTP nick end labeling assay (TUNEL) in Bicc1 KO 
ducts but not in WT ducts (Fig. 18).  
Although sporadic cells positive for acinar markers and negative for ductal markers were found lining the 
cysts, we did not detect acinar to ductal metaplasia. The boundary between acinar and ductal compartments 
thus appears to be generally conserved (Fig. 16).  
 
 
Fig. 16: No acinar to ductal or ductal to acinar metaplasia is observed in Bicc1 KO 
 (A-D) Immunofluorescence staining on E18.5 WT and Bicc1 KO pancreatic sections for amylase (AMY1, magenta) 
and DBA lectin (yellow) shows that there are few AMY1+ cells in the ducts of Bicc1 KO pancreas but their identity is 
not affected as they do not express DBA lectin (n = 4 for both genotype). C and D show a magnification of the dashed 
boxes in B. 
Scale bars A-B 25 µm C-D 10 µm 
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7.2.1 The Bicc1 KO does not exhibit a decrease in the number of cilia  
Cilia mutants form ductal cysts in the pancreas (Cano et al., 2004; Cano et al., 2006), and other cystic 
mutants have cilia defects (Pierreux et al., 2006; Kang et al., 2009b), thus, propounding that cilia defects may 
contribute to cyst formation in Bicc1 KOs. However, at the beginning of cyst formation, cilia were present at 
E14.5 in Bicc1 KOs and did not show any obvious defects. Moreover, the number of cilia, in both Bicc1 KO 
cystic and non-cystic ducts at E18.5, was not affected (Fig. 17).  
Taken together, these results show that BICC1 deficiency leads to cyst formation during development, and it 
is associated with increased ductal proliferation at later stages. 
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Fig. 17: Cilia are not decreased by Bicc1 deletion either at E18.5 or E14.5 
 (A-L) Cilia on ductal cells are detected by immunofluorescence for acetylated tubulin (Ac TUB) (cyan) and DBA 
lectin (yellow) on E18.5 pancreatic sections. Insets show high magnification view of the dashed boxes in two separate 
channels. Cilia are present in both WT and Bicc1 KO pancreata in intercalated ducts and main/interlobular ducts as 
shown on optical section.  
(M) Percentage of DBA lectin+ Ac TUB+ cells among DBA lectin+ ductal cells in intercalated and main/interlobular 
ducts in Bicc1 KO and WT E18.5 pancreas quantified on 3D reconstructed images. Cilia are not affected by Bicc1 
deletion (n=4 for both genotypes: intercalated ducts, p=0.75; main/interlobular ducts vs cystic ducts, p=0.12).  
(O, P) Cilia (yellow arrows) detected by immunofluorescence for Ac TUB (cyan) on E14.5 WT and Bicc1 KO 
pancreatic sections are not obviously affected by Bicc1 deletion as shown on an optical section. SOX9 antibody 
(magenta) is used to identify the ducts (n = 4 for both genotype).  
Sections are counterstained with DAPI (white). Scale bars A-B, D-E, G-H, and J-K 1 µm; C, F, I and L 5 µm and O-P 
10 µm. See Table 12 in Appendix for further data. 
79 
 
7.3 Endocrine cells are decreased in Bicc1 KO pancreata 
To further explore the role of BICC1 in the pancreas, we investigated the differentiation of the endocrine cell 
types. In Bicc1 KO, islet architecture was disturbed at P0. The islets, detected by their immmunoreactivity 
for INS, GCG, and SST, were visibly smaller. Many endocrine cells were scattered rather than clustered into 
islets. A higher number of endocrine cells had not delaminated from the duct (Fig. 18). 
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Fig. 18: The islet architecture is disturbed and endocrine cells are present in the ducts in Bicc1 KOs 
(A-F) Immunofluorescence staining on P0 WT and Bicc1 KO pancreatic sections for GCG, INS, SST (hormones, 
orange) and DBA lectin (cyan) shows that endocrine cells are rather scattered and form smaller islets in Bicc1KO.  
(G-J) A magnification of a Bicc1 KO pancreatic section shows that some endocrine cells (orange) are in the ducts 
(cyan).  
(K) Quantification of the endocrine cells present in the ducts identified by immunostaining. While there are only a few 
ductal endocrine cells in P0 WT pancreata, there are 14 times more in P0 Bicc1 KO pancreata (n=4 for both genotype; 
n=4, p=0.0086).  
Sections are counterstained with DAPI (white). Scale bars A-F 100 µm and G- J 10 µm. See Table 12 in Appendix for 
further data 
81 
 
  
82 
 
 
Fig. 19: Endocrine cells are reduced at E18.5 but not earlier in Bicc1 KO. 
(A, B) Immunofluorescence staining for GCG (magenta) performed on E12.5 WT and Bicc1 KO pancreatic sections. 
(C) Quantification of GCG+ cells detected on the previous immunostaining shows no differences between WT and 
Bicc1 KO pancreata (n=4 for both genotype, p=0.72) 
(D, E) Immunofluorescence staining highlighting GCG+ alpha cells (magenta) and INS+ beta cells (orange) in E14.5 
Bicc1 KO and WT pancreatic sections.  
(F) Quantification of INS+ and GCG+ cell number on the previous immunostainings shows no difference between Bicc1 
KO (INS+ cells, n=4; GCG+ cells, n=3) and WT (INS+ cells, n=4, p=0.74; GCG+ cells, n=4, p=0.62).  
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Continuation of the legend of Fig. 19 
(G, H) Immunofluorescence staining for INS (orange) on E18.5 Bicc1 KO and WT pancreatic sections reveals a marked 
decrease in KOs. White asterisks indicate cysts.  
(I) Quantification of INS+ beta cells, SST+ delta cells, PPY+ PP cells and GHRL+ epsilon cells on E18.5 WT and Bicc1 
KO pancreatic sections reveals about 50% decrease (beta cells: n=4 for both genotype, p=0.0008; delta cells: WT, n=3; 
Bicc1 KO, n=4, p=0.0029; PP cells: WT, n=3; Bicc1 KO, n=4, p=0.012; epsilon cells: WT, n=3; Bicc1 KO, n=4, 
p=0.011), while the GCG+ alpha cell number is reduced by 20% (WT, n=3; Bicc1 KO, n =4, p=0.0024).  
Sections are counterstained with DAPI ((A-B) blue or (D-E) and (G-H) white). Scale bars 25 µm. See Table 12 in 
Appendix for further data 
At E12.5, the number of cells expressing GCG, the first endocrine cells differentiating in the pancreas was 
not affected by Bicc1 deletion (Fig. 19A-C). At E14.5, the number of both alpha and beta cells, identified by 
their secreted hormones GCG and INS, respectively, was not changed (Fig. 19D-F). As the other endocrine 
cell types form a rare population, they were only analyzed at a later stage. At the end of gestation, the 
number of beta cells was reduced by 50%. The number of ghrelin+ (GHRL+) cells (epsilon cells), SST+ cells 
(delta cells) and PPY+ cells (PP cells) were all significantly decreased in Bicc1 KO pancreata, to the same 
extent as the beta cells. Finally, the alpha cell number was reduced by 20% (Fig. 19G-I). Bicc1 deletion thus 
leads to a global but late endocrine cell decrease during pancreas development. 
7.4 Cellular cause of the endocrine cell decrease in Bicc1 KOs 
The endocrine cell decrease might have different causes such as reduced proliferation, dying cells, global 
decrease of pancreatic progenitor pool or defective differentiation. 
7.4.1 Endocrine cell proliferation and survival are not affected by Bicc1 deletion  
Beta cell proliferation was quantified at E18.5 as endocrine proliferation was too low to be reliably 
quantified earlier. The percentage of beta cells expressing MKI67 was not changed in Bicc1 KO pancreata as 
compared to WTs. Moreover, TUNEL assay, performed at E18.5, showed no apoptosis in both WT and 
Bicc1 KO beta cells (Fig. 20).  
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Fig. 20: Beta cell death and proliferation at E18.5 is not affected by Bicc1 deletion 
(A-C) TUNEL assay (orange) followed by immunofluorescence staining for INS (cyan) and aPKC, an apical marker 
(magenta), on E18.5 WT and Bicc1 KO pancreatic sections shows no apoptotic death in INS+ beta cells (n=4 for both 
genotypes). By contrast, TUNEL+ nuclei are seen in the ducts delimited by aPKC (yellow arrowhead) in Bicc1 KO 
pancreata. An E11.5 paw is used as a positive control for the TUNEL assay.  
 (D) Percentage of MKI67+ INS+ beta cell number among beta cells quantified on INS and MKI67 immunostained 
E18.5 Bicc1 KO and WT pancreatic sections, shows no difference between E18.5 WT and Bicc1 KO pancreata 
(p=0.95). 
Sections are counterstained with DAPI (white). (n=4 for both genotypes) Scale bars A-C 25 µm and insets 10 µm. See 
Table 12 in Appendix for further data. 
7.4.2 Endocrine mass reduction in Bicc1 KOs is not due to pancreatic 
hypoplasia  
The endocrine cell decrease may be explained by a reduction of their progenitor pool, which was thus 
quantified at different stages. At E12.5, contrary to what might be expected based on the endocrine cell mass 
reduction, the number of PDX1+ pancreatic was increased (Fig. 21A-C). However, at E14.5, the number of 
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pancreatic progenitors marked with PDX1 was back to normal (Fig. 21D). Finally at birth, there was again 
no difference between Bicc1 KO and WT pancreata, as quantified by the number of nuclei present in 
pancreata (Fig. 21E). It thus suggests that there is a transient hyperplasia in Bicc1 KO pancreata at early 
stages. At later stages, the size of the pancreas size is normal and cannot cause the observed endocrine cell 
reduction.  
 
Fig. 21: Pancreatic size is increased at E12.5 but not at E14.5 or at P0 in Bicc1 KOs 
(A, B) Immunostaining for PDX1 (magenta) and NEUROG3 (Orange) was performed on E12.5 Bicc1 KO and WT 
pancreatic sections. 
(C) Quantification of the previous immunostaining shows an increase of 1.7-fold of PDX1 positive cells (n=4 for each 
genotype, p=0.0058).  
(D) Quantification of the number of pancreatic progenitors immunoreactive for PDX1 on E14.5 pancreatic sections 
shows no difference between WT and Bicc1 KO pancreata (n=4 for each genotype, p=0.95) 
(E) Quantification of the number of nuclei stained by DAPI at P0 shows no difference between Bicc1 KO and WT 
pancreata. (n=4 for each genotype, p=0.24). 
Sections are counterstained with DAPI (white), scale bar 25 µm. See Table 12 in Appendix for further data. 
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Fig. 22: Endocrine progenitor cells are decreased at E14.5 but not at E12.5 in Bicc1 KOs 
(A) Quantification of NEUROG3+ cells detected on immunostained E12.5 Bicc1 KO and WT pancreatic sections shows 
a 2.2-fold increase in Bicc1 KO (n=4 for both genotypes, p=0.015). 
(B) The quantification in (A) is normalized to the number of PDX1+ pancreatic progenitors immunostained at the same 
time and indicated in percent (Fig. 21A, B). The proportion of NEUROG3+ cells compared to PDX1+ cells is increased 
1.4-fold in Bicc1 KO (n=4, for each genotype, p=0.043) 
(C) Q-PCR analysis for Neurog3 in E12.5 WT and Bicc1 KO dorsal bud pancreata shows no difference and a very high 
variability (WT, n=6; Bicc1 KO, n=5, p=0.27).  
(D) Quantification of NEUROG3+ cells detected on immunostained E14.5 Bicc1 KO and WT pancreatic sections shows 
a decrease by 34% in Bicc1 KO (n=4 for both genotype, p=0.0043). 
(E) The quantification in (D) is normalized on the number of PDX1+ pancreatic progenitors immunostained on adjacent 
sections (Fig. 21D), and indicated in percent. The proportion of NEUROG3+ cells compared to PDX1+ cells is still 
decreased to the same degree as in (D), by 32%,  in Bicc1 KOs (n=4, for each genotype, p=0.011) 
(F) Q-PCR analysis for Neurog3 in E14.5 WT and Bicc1 KO dorsal bud pancreata shows a decrease by 27% in the KO 
(WT, n=4; Bicc1 KO, n=5, p=0.012). 
For Q-PCR analysis, expression levels are normalized to Hprt1 mRNA level. Results are represented as a percentage of 
Neurog3 level in WT. See Table 12 in Appendix for further data. 
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7.4.3 NEUROG3+ cells are reduced upon Bicc1 deletion 
To explore the possibility of a defect in the differentiation pathway from pancreatic progenitors toward 
endocrine progenitors, we quantified the NEUROG3+ endocrine progenitor cells. At E12.5 the endocrine 
progenitors were also increased a little more than the multipotent progenitors (Compare Fig. 21C and Fig. 
22A-B), suggestive of a slightly increased differentiation flux. However, it was not confirmed by Q-PCR 
arguing for a transient hyperplasia of the pancreas and no a specific increase of the endocrine progenitor pool 
(Fig. 22C). 
At E14.5, the endocrine progenitor number was significantly decreased by 34% in Bicc1 KOs. The same 
decrease was also observed if the endocrine progenitors were normalized to the PDX1+ pancreatic 
epithelium. It was consistent with a 30% decrease of Neurog3 mRNA observed by Q-PCR at the same stage 
(Fig. 22D-F). Together, these results suggest that the endocrine progenitor deficiency observed at E14.5 
causes the observed endocrine cell decrease. 
7.4.3.1 NEUROG3+ cells do not undergo apoptosis 
 
Fig. 23: Endocrine progenitor cells do not undergo apoptosis at E14.5 in Bicc1 KO 
(A-B) Immunofluorescence staining for active caspase3 (CASP3) (orange) and NEUROG3 (magenta) was performed 
on E14.5 WT and Bicc1 KO pancreatic sections (n=4 for both genotypes). Insets show a magnified view of the dashed 
boxes. No apoptosis is observed in endocrine progenitor cells. An E13.5 paw is used as a positive control for active 
CASP3. 
Sections are counterstained with DAPI (white). Scale bar 25 µm, insets 10 µm. 
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The decrease in NEUROG3+ endocrine progenitors may be explained by a proliferation rate decrease, cell 
death or a generation rate reduction. It has already been shown that they hardly divide (Desgraz and Herrera, 
2009). Moreover, no NEUROG3+ cells were positive for active caspase3 (active CASP3+) or TUNEL in 
Bicc1 KO E14.5 pancreas arguing that there was no cell death (Fig. 23; data not shown). These results 
suggest that the production of NEUROG3+ endocrine progenitors is affected by Bicc1 deletion. 
7.4.3.2 NEUROG3+ progeny is not further affected by Bicc1 deletion 
To investigate possible additional differentiation defects after endocrine progenitors had been produced, a 
short-term lineage tracing experiment was performed using the Neurog3-RFP reporter line (Kim et al., 2015) 
that marks NEUROG3 expression for about 48h after their emergence. It enabled us to follow the 
differentiation path from endocrine progenitors toward endocrine cells. Indeed, cells started to express 
NEUROG3 before expressing RFP. They then switched off NEUROG3, while RFP expression was switched 
off only after they became hormone-positive (Fig. 24).  
To quantitatively follow this differentiation pipeline, different cell populations were quantified: 
NEUROG3+RFP-, NEUROG3+RFP+, NEUROG3-INS-GCG-RFP+ and INS+ or GCG+RFP+. All of these 
populations were decreased in Bicc1 KO pancreata at E14.5 (Fig. 24I). The similar ratio of the different 
populations in the Bicc1 KO compared to control argues that the decrease of endocrine cells is mainly due to 
a decreased conversion of bipotent progenitors into endocrine progenitors that normally differentiate 
thereafter (Fig. 24J). 
Continuation of the legend of Fig. 24 
(J) Proportion of the different cell populations among RFP+ cells identified in (A-H). There is no global ratio 
difference, indicating no slow-down in the differentiation path toward endocrine cells (NEUROG3+RFP+, p= 0.07; 
Hormones+ RFP+, p=0.80). However, the proportion of NEUROG3-Hormone- RFP+ in RFP+ cells is slightly higher in 
Bicc1 KO pancreas (p= 0.0078) 
Sections are counterstained with DAPI (white). N=4 for both genotypes. Scale bars A-H 25 µm. See Table 12 in 
Appendix for further data. 
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Fig. 24: The endocrine progenitor short-term progeny is decreased to the same extent as endocrine progenitors 
in Bicc1 KO 
(A-H) An RFP reporter under Neurog3 promoter, Neurog3-RFP, was used to characterize the differentiation flux from 
NEUROG3+ endocrine progenitors toward hormone+ endocrine cells. Cells are first NEUROG3+ (green) before 
becoming double positive for NEUROG3 and RFP (red). They switch off NEUROG3 and thereafter start to express 
hormones, INS or GCG (cyan), before switching off RFP, as exemplified in the immunofluorescence staining on 
sections at E14.5 in WT and Bicc1 KO pancreas.  
(I) Quantification of the different cell populations on sections reveals a similar decrease in both RFP- and RFP+ 
fractions (NEUROG3+RFP-: p=0.029; NEUROG3+RFP+: p=0.0021). The two last populations, NEUROG3-Hormone-
RFP+ cells and Neurog3-Hormone+RFP+ cells, have a tendency to decrease that does not reach significance (Neurog3-
Hormones-RFP+ cells: p=0.08; Neurog3-Hormones+RFP+ cells: p=0.16).  
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Fig. 25: Characterization of the Neurog3-RFP mouse line 
(A-D) Optical section of E14.5 Neurog3-RFP pancreas, immunostained for NEUROG3 (cyan), RFP (Orange; 
immunostained for Myc), and INS and GCG (Magenta) shows that some RFP+ cells co-express NEUROG3 (white 
arrowhead) but not all (yellow arrowhead).  
(E) Proportion of RFP+ (green) and RFP- (black) in NEUROG3+ cells, and proportion of NEUROG3+, Hormones+ 
(identified by INS and GCG) (blue) and NEUROG3-/Hormones- (gray) in RFP+ cells.   
Scale bars, 20 µm. See Table 12 in Appendix for further data. 
The WT data obtained during these experiments were used to characterize the Neurog3-RFP mouse line 
(Kim et al., 2015). Only 40% of the NEUROG3+ cells coexpressed RFP+. The majority of the RFP+ cells are 
not NEUROG3+ and nearly 20% expressed either GCG or INS (Fig. 25). 
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7.4.3.3 The NEUROG3+ endocrine production defect is sustained after E14.5 
Moreover, long-term lineage tracing using a Neurog3-Cre line crossed with Rosa26-YFP addressed whether 
NEUROG3+ cell differentiation was steadily defective until the end of gestation. The total number of 
recombined cells harboring the reporter was reduced in the same measure as the endocrine cells thus 
showing that the defect in endocrine progenitor cell production is sustained over the developmental period. 
No increase of NEUROG3 progeny in the acinar and ductal exocrine compartment was observed in Bicc1 
KOs, indicating that the cells expressing Neurog3 are not diverted to a different developmental path (Fig. 
26). 
Together these data support that the endocrine cell defect observed in Bicc1 KOs is due to an endocrine 
progenitor generation defect. 
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Fig. 26: The Endocrine progenitor long-term progeny is reduced similarly to the endocrine cells in Bicc1 KO. 
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Legend of the  Fig. 26 
(A-L) Lineage tracing using the Neurog3-Cre mouse line crossed with the Rosa26 YFP mouse line. 
Immunofluorescence stainings for INS, GCG, SST (Hormones, red), DBA lectin (white) and YFP (green) or CPA1 
(red) and YFP were done on P0 WT and Bicc1 KO pancreatic sections.  
 (M) The total number of YFP+ cells as well as YFP+ cells among endocrine cells (Hormones+) is decreased by half 
(Total cells, p=0.0046 and Endocrine cells, p=0.0003). YFP+ cell numbers in acini is not significantly changed (p=0.49), 
and the number of YFP+DBA lectin+ cells in the ducts is unchanged either (p=0.78), reflecting the increased duct size in 
Bicc1 KOs.  
Sections were counterstained with Draq5 (blue). N=4 for each genotype Scale bars 25 µm. See Table 12 in Appendix 
for further data 
7.5 Molecular causes of endocrine cell decrease in Bicc1 KOs  
The mechanism by which BICC1 controls NEUROG3+ endocrine progenitors was further investigated. 
BICC1 binds to mRNAs and regulates positively or negatively their translation in mouse (Tran et al., 2010; 
Piazzon et al., 2012). A direct regulation of Neurog3 mRNA by BICC1 is unlikely since Neurog3 
transcriptional reporters were affected by Bicc1 deletion to the same degree as NEUROG3 protein. Instead, 
BICC1 may target activators or repressors of Neurog3.  
7.5.1 BICC1 does not regulate NOTCH signaling pathway 
NEUROG3+ cell production is negatively regulated by the NOTCH pathway. HES1, expressed upon 
NOTCH pathway activation, is a repressor of Neurog3. Its deletion leads to massive NEUROG3+ cell 
production and endocrine differentiation (Jensen et al., 2000b; Lee et al., 2001). However, HES1 protein 
levels were not changed in Bicc1 KO pancreata at E15.5 (Fig. 27A, B). Its mRNA level was also unchanged 
one day earlier, as was the mRNA level of Dll1 that activates the NOTCH pathway (Apelqvist et al., 1999) 
(Fig. 27C). In conclusion, the NOTCH pathway does not appear to be affected by Bicc1 deletion in the 
pancreas. 
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7.5.2 BICC1 does not control SOX9, ONECUT1, FOXA2, PDX1, or HNF1B 
We therefore asked whether the loss of Bicc1 affects transcription factors that activate Neurog3 such as 
SOX9, FOXA2, PDX1, HNF1B or ONECUT1 (Jacquemin et al., 2000; Lynn et al., 2007). The SOX9 
expression pattern was indistinguishable between Bicc1 KO and WT pancreata at E14.5 (Fig. 27D, E). 
Moreover, the protein levels of SOX9, FOXA2, PDX1, and HNF1B were not changed at E15.5 upon Bicc1 
deletion (Fig. 27A, B). Although Onecut1 mRNA was increased by 34% in Bicc1 KO compared to WT 
pancreas (Fig. 27F), its protein level was not changed one day later (Fig. 27A, B), and the localization of the 
protein was normal (Fig. 27H, I). In conclusion, NEUROG3+ cell reduction is not due to a decrease of its 
activators SOX9, FOXA2, PDX1, HNF1B and ONECUT1. 
Legend of the  Fig. 27 
(A) Western blot performed for SOX9, HES1, HNF1B, FOXA2, PDX1, and ONECUT1 on E15.5 WT and Bicc1 
KO pancreata, and alpha tubulin (TUB) as a loading control.  
(B) Quantification of the western blot shown in (A) is performed by normalizing band intensity to TUB intensity. 
Results are relative to WT mean. None of them are affected by Bicc1 deletion (SOX9: WT, n=4; Bicc1 KO, n=4, p= 
0.30; HES1: WT, n=4; Bicc1 KO, n=4, p=0.06; HNF1B: WT, n=4; Bicc1 KO, n=4, p= 0.10; FOXA2: WT, n=4; 
Bicc1 KO, n=4, p= 0.48; PDX1: WT, n=4; Bicc1 KO, n=4, p= 0.37; ONECUT1: WT, n=7; Bicc1 KO, n=8, p= 
0.13).  
(C) Q-PCR analysis for Hes1 and Dll1 performed on E14.5 WT and Bicc1 KO dorsal pancreata does not show any 
differences (Hes1: WT, n=4; Bicc1 KO, n=5, p=0.45; Dll1: WT, n=4; Bicc1 KO, n=5, p=0.55).  
(D-E) Immunofluorescence staining performed on E14.5 WT (n=4) and Bicc1 KO (n=4) pancreatic sections do not 
show SOX9 (orange) expression pattern differences between both genotypes.  
(F) Q-PCR analysis of Onecut1 in WT versus Bicc1 KO E14.5 dorsal buds reveals a 34% increase in Onecut1 
transcript in the KO (WT, n=4; Bicc1 KO, n=5, p=0.042). 
(G) Q-PCR analysis of Bicc1 in WT versus Onecut1 KO E14.5 dorsal buds shows a decrease by 40% of Bicc1 
transcript in the Onecut1 KO (WT, n=4; Onecut1, n=3, p=0.027).  
(H-I) Immunofluorescence staining for ONECUT1 on E14.5 WT (n=2) and Bicc1 KO (n=2) pancreatic sections 
shows no expression pattern difference. Q-PCR results are normalized to the housekeeping gene Hprt1. Results are 
represented in percent of WT mean.  
Sections are counterstained with DAPI (white). Scale bars 25 µm. See Table 10 in Appendix for further data. 
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Fig. 27: BICC1 does not regulate the NOTCH pathway or known Neurog3 transcriptional activators and 
functions downstream of ONECUT1. 
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7.5.3 Bicc1 acts downstream of ONECUT1 
Onecut1 KO embryos also develop pancreatic cysts combined with a decrease in endocrine cells due to 
defective endocrine progenitor differentiation (Lynn et al., 2007). Since the experiments above showed that 
BICC1 does not promote ONECUT1 expression, we investigated whether BICC1 functions downstream of 
Onecut1. Indeed, we found that Bicc1 mRNA was decreased by 40% in Onecut1 KO pancreata (Fig. 27G), 
suggesting that ONECUT1 promotes Bicc1 expression. 
7.5.4 WNT signaling is not affected by Bicc1 deletion 
Although BICC1 was previously shown to control WNT signaling in the node and in a cell line reporter 
assay (Maisonneuve et al., 2009), we did not detect any change in Axin2 and Tcf7, two WNT targets, nor any 
alterations in the expression of the Axin2-LacZ reporter in the pancreata of Bicc1 KOs at E14.5 (Fig. 28). 
Taken together, these results show that Neurog3 is transcriptionally regulated by BICC1 but this effect is 
likely to be indirect and we have not identified a direct target. 
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Fig. 28: Canonical WNT signaling is not affected by Bicc1 deletion in the pancreas 
(A-F) LacZ staining followed by fluorescence immunostaining on sections of the pancreas of WT; Axin2 LacZ/+ and 
Bicc1 KO; Axin2 LacZ/+ embryos at E14.5. LacZ staining (black dots) is detected in GCG+ cells (red, red dashed lines) 
and in some mesenchymal cells (yellow arrowheads) but not in the pancreatic progenitor epithelium, stained by CDH1 
(green, green dashed lines) both in WT (n=3) and in Bicc1 KO (n=3).  
(G) Q-PCR analysis for Tcf7 and Axin2 in E14.5 WT and Bicc1 KO dorsal bud pancreata shows no alteration in KOs 
(WT, n=4; Bicc1 KO, n=5: Tcf7, p=0.22; Axin2, p=16). Expression levels are normalized to Hprt1 mRNA level. Results 
are represented as a percentage of mRNA level of WT mean.  
Sections were counterstained with DAPI (blue). Scale bar 25 µm. See Table 12 in Appendix for further data. 
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7.6 Molecular mechanisms behind pancreatic cyst formation 
7.6.1 Uncovering BICC1 targets by RNA sequencing 
To decipher the molecular mechanisms underlying cyst formation in Bicc1 KO pancreata, E13.5 Bicc1 KO 
and WT pancreas transcriptomes were compared by RNA sequencing. At this stage, duct enlargement was 
not yet observed allowing us to detect expression changes prior to cyst formation rather than as a 
consequence of it. Moreover, the RNA sequencing data gave a clear idea of the genes expressed as well as 
their global expression level at E13.5 in dorsal pancreatic buds (Fig. 29). 
 
Fig. 29: Histogram of the number of genes in function of their expression level in E13.5 dorsal pancreatic buds. 
Expressed genes in E13.5 WT pancreatic dorsal buds are classified in function of their expression level in read per 
kilobase per million (rpkm). For clarity, genes which have an rpkm below 0.01 are not represented. Expression level of 
relevant landmark genes is indicated with an arrow. 
The RNA sequencing data where first analyzed using the DESeq method (Anders and Huber, 2010). 
However, this method only gives p-value and no FDR rendering the analysis less stringent. With this 
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approach, the majority of genes significantly changed between Bicc1 KO and WT pancreatic buds, were 
lowly expressed (Tables 13, 14 in Appendix). Fold Changes were important but may have little biological 
significance. 
 
Fig. 30: E13.5 Bicc1 KO and WT dorsal pancreatic bud transcriptome comparison using ANOVA 
(A) Transcriptome analysis comparing E13.5 Bicc1 KO and WT dorsal buds shows high amounts of lowly expressed 
genes. Only 8 and 18 genes were respectively significantly upregulated (green) and downregulated (red). 
(B) The same analysis was performed without genes having an average rpkm below 0.01. 12 and 19 genes were 
respectively significantly upregulated (green) and downregulated (red).  
Both plots represent the fold change in function of WT expression level mean in rpkm. Both axes have a logarithmic 
scale. Each dot represents a gene. 
The analysis was repeated with a more stringent method based on ANOVA and calculating FDR (Sharov et 
al., 2005). For example, Neurog3 was found downregulated in Bicc1 KOs with a p value of 0.0027 while its 
FDR was more than 0.5 (Table 13). This example shows that some genes in this low-confidence category 
may be significant or may just begin to change and may become significant the day after.  
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Table 4: Upregulated mRNA in E13.5 Bicc1 KO pancreas 
Gene symbol WT mean 
(rpkm) 
Bicc1 KO mean 
(rpkm) 
fold change FDR 
Slc16a3 0.89 2.02 2.27 0.0049 
Description Proton-linked pyruvate and lactate transporter (reviewed in Halestrap, 
2013) 
Gm15745 0.16 6.51 41.82 0.0006 
Description Predicted protein with a putative RNA binding domain10,11 
RP23-281E24.2 0.49 1.87 3.85 <  0.0001 
Description Predicted protein without predicted domain10,11 
Cma1 0.38 2.23 5.84 0.0009 
Description Secretory granule protease, expressed by mast cells (Reynolds et al., 
1990) 
Six2 0.18 2.67 15.06 0.0004 
Description Transcription factor involved among other in kidney development 
(Oliver et al., 1995; Self et al., 2006) 
Fam162b 0.22 1.05 4.77 <  0.0001 
Description Predicted protein with a transmembrane domain10,11 
Hdc 0.10 0.32 3.12 0.0446 
Description Enzyme synthetizing histamine from histidine (Werle, 1936; first KO 
description in Ohtsu et al., 2001) 
Rpl30-ps5 0.09 0.28 3.24 0.0473 
Description Pseudogene10 
Myod1 0.09 0.67 7.14 <  0.0001 
Description Transcription factor involved among other in muscle differentiation 
(Davis et al., 1987; Lassar et al., 1989) 
Nkx2.5 0.06 0.46 7.83 0.0321 
Description Transcription factor involved among other in heart development 
(Komuro and Izumo, 1993; Lyons, I. et al., 1995) 
Mcpt4 0.01 0.22 16.23 <  0.0001 
Description Secretory granule protease, expressed by mast cells (Reynolds et al., 
1990) 
1700023F06Rik 0.01 0.50 50.43 <  0.0001 
Description Predicted protein with 2 EF-hand motifs (calcium binding motif)10,11 
mRNAs found upregulated in Bicc1 KO compared to WT pancreata are ordered according to NIA array analysis tool 
and after filtering of the data. The ordering is based on a combination of their expression level in rpkm, their fold 
change, and their FDR. 
  
                                                     
10
 Based on Ensembl genome browser 
11
 Based on SMART tool 
101 
 
Table 5: Downregulated mRNA in E13.5 Bicc1 KO pancreas 
Gene symbol WT mean 
(rpkm) 
Bicc1 KO mean 
(rpkm) 
fold change FDR 
Bicc1 19.12 4.43 4.31 <  0.0001 
S100a9 11.63 2.10 5.54 0.0083 
Description Calcium binding protein, it form a dimer with S100A8. They have 
different roles in inflammation (reviewed in Kerkhoff et al., 2012) 
Pah 16.42 4.78 3.43 0.0118 
Description Catabolizes phenylalanine into tyrosine (Mitoma, 1956) 
S100a8 7.10 1.26 5.62 0.0111 
Description Calcium binding protein, it form a dimer with S100A9. They have 
different roles in inflammation (reviewed in Kerkhoff et al., 2012) 
Calcr 16.85 8.74 1.93 <  0.0001 
Description Receptor for calcitonin, lowering blood calcium (Copp and Cheney, 
1962; Yamin et al., 1994) 
2010107G23Rik 30.82 20.19 1.53 0.0321 
Description Predicted protein with one transmembrane domain12,13 
Pkd2 10.57 5.63 1.88 0.0001 
Description Calcium channel, see introduction p 59 
Crp 23.85 15.71 1.52 0.0092 
Description Activator of the immune acute phase (Bodmer and Siboo, 1977)  
4930533K18Rik 4.95 1.48 3.34 <  0.0001 
Description Predicted protein without predicted domain12, 13 
BC100530 3.07 0.50 6.10 0.0118 
Description Predicted protein with a cystatin-like domain12, 13 
Slc5a9 2.30 1.22 1.88 0.0481 
Description Sodium-dependent glucose transporter (Tazawa et al., 2005) 
Cer1 2.19 1.03 2.13 0.009 
Description BMP and Nodal antagonist (Belo et al., 2000) 
Ngp 2.69 0.39 6.88 0.0027 
Description Secreted protein, expressed during myeloid differentiation (Moscinski 
and Hill, 1995) 
Anxa9 1.13 0.41 2.77 0.0006 
Description Interacts with periplakin in the epidermis (Boczonadi and Määttä, 2012) 
Gm5483 1.31 0.23 5.77 0.0004 
Description Predicted protein with a cystatin-like domain12, 13 
Gm13305 0.84 0.23 3.66 <  0.0001 
Description Predicted protein coding from Il11ra212 
Olfm4 1.48 0.19 7.83 0.0001 
Description Extracellular glycoprotein involved in innate cell immunity 
(Rosenbauer et al., 2004) 
                                                     
12
 Based on Ensembl genome browser 
13
 Based on SMART tool 
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Il11ra2 0.41 0.06 7.22 <  0.0001 
Description Alpha chain receptor for interleukin11, present in testis, lymph node 
and thymus (Robb et al., 1997) 
Gm2002 0.49 0.02 26.95 <  0.0001 
Description Predicted protein coding from Il11ra214 
mRNAs found downregulated in Bicc1 compared to WT pancreata are ordered according to NIA array analysis tool and 
after filtering of the data. The ordering is based on a combination of their expression level in rpkm, their fold change, 
and their FDR. 
The RNA sequencing data were also filtered to remove the noise, i. e. genes with less than 0.01 rpkm 
representing more than 2000 genes (Fig. 29 and 30). Even so, only few genes were significantly upregulated 
or downregulated with a FDR below 0.05 (Tables 4, 5). All upregulated genes were expressed at low levels, 
with an rpkm below 1 in WT pancreata. These results suggest little changes at the mRNA levels in Bicc1 KO 
pancreata compared to WTs prior cyst and endocrine progenitor defect onset. 
7.6.2 MicroRNA sequencing 
BICC1 regulates translation via miRNAs in vertebrates (Tran et al., 2010; Piazzon et al., 2012). To gain 
insight into the miRNAs expressed in the pancreas at E13.5the miRNA content of E13.5 WT and Bicc1 KO 
dorsal pancreatic buds were sequenced. We could not collect enough material for multiple independent 
sequences and the data presented in (Fig. 31) thus represent the outcome of one WT sample, all consisting of 
several pancreatic buds. More than 800 microRNAs were uncovered. The range of microRNA expression 
level was very broad. The majority of them had high rpkm due to the small length of microRNAs and the 
high depth of the sequencing (Fig. 31). 
                                                     
14
 Based on Ensembl genome browser 
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Fig. 31: Distribution of mircoRNAs found in E13.5 dorsal pancreatic buds by RNA sequencing 
Expressed microRNAs in E13.5 WT pancreatic dorsal buds are classified in function of their expression level in rpkm. 
The expression level of microRNAs known to interact directly or not with BICC1 is indicated with an arrow. 
Even though BICC1 was never shown to regulate miRNA half-life, miRNA content in WT and Bicc1 KO 
pancreatic dorsal buds were compared using DESeq method. As no replicates were sequenced, miRNA fold 
changes were considered significant when their p-value was below 0.01. 10 miRNA were upregulated in 
Bicc1 KO pancreatic buds and 1 was downregulated (Table 6). 
Table 6: miRNA changed in E13.5 Bicc1 KO pancreatic dorsal bud compared to WT  
Gene symbol WT (rpkm) KO (rpkm) fold change p-value 
Mir29b-1 299 812 2.72 <  0.0001 
Mir875 821 1657 2.02 0.0001 
Mir6243 4319 11616 2.69 0.0002 
Mir6366 1650 3797 2.30 0.0003 
Mir2183 1216 2306 1.90 0.0014 
Mir494 1546 2989 1.93 0.0023 
Mir5127 1074 1864 1.74 0.0038 
Mir344c 8033 3941 0.49 0.0038 
Mir804 346 599 1.73 0.0048 
Mir3471-2 648 1058 1.63 0.0064 
Mir23b 1586 2832 1.79 0.0068 
Changed miRNAs in Bicc1 KO dorsal pancreatic buds are ranked by p-value obtained with DESeq. n=1 per genotype 
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Targets for these miRNAs were then searched among the mRNAs down- or up-regulated upon BICC1 
inactivation, using the DESeq analysis (Tables 13, 14 in Appendix). Based on seed discovery, only four 
upregulated genes were targeted by one of the differentially expressed miRNAs (Table 7).  
Table 7: Putative mRNA targets of differentially expressed miRNA in Bicc1 KOs at E13.5 
Gene symbol mean WT (rpkm) Fold change p-value Targeted by 
Slc2a1 10.71 1.57 0.0241 Mir374 
Stard9 0.56 1.63 0.0304 Mir804 
Robo2 2.59 2.75 <  0.0001 Mir494 
Tnfrsf9 0.10 2.94 0.0176 Mir494 
Putative targets, based on seed discovery by TargetScan, are ranked in function of their fold change.  
As the genes uncovered were not present in the ANOVA analysis, this research line was not pursued. 
Moreover, if BICC1 behaves as previously reported (Dorey and Hill, 2006; Piazzon et al., 2012; Zhang et al., 
2013), only the protein level of BICC1 pancreatic targets may change in absence of BICC1 without mRNA 
level modification. Changes in the levels of miRNAs and their putative targets could be secondary effects of 
Bicc1 deletion and may not necessarily reflect direct interactions with BICC1.  
7.6.3 Bicc1 deletion is associated with PKD2 downregulation 
Among the downregulated genes in the RNA sequencing, Pkd2 was decreased by 1.9 fold in Bicc1 KO 
compared to WT pancreata (Table 5). Since PKD2 deficiency results in pancreas and kidney cyst formation 
(Wu et al., 2000; Chang et al., 2006), we decided to validate whether its expression in Bicc1 KO pancreata is 
also reduced at the protein level.  
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Fig. 32: PKD2 expression level is downregulated in Bicc1 KO. 
(A-B) E14.5 WT and Bicc1 KO pancreatic sections were stained by immunofluorescence for PKD2 (cyan) and PDX1 
(yellow) highlighting pancreatic epithelium. E14.5 Bicc1 KO pancreata (n=4) have a marked PKD2 decrease in the 
epithelium compared to WT littermate pancreata (n=4).  
(C) Example of western Blot for PKD2 in E15.5 WT and Bicc1 KO pancreata and TUB as a loading control.  
(D) Quantification of the Western blot shown in (C). PKD2 intensity is normalized to TUB intensity, and results are 
relative to WT mean. PKD2 in Bicc1 KO pancreata is decreased 2.1-fold (WT, n=8; Bicc1 KO, n=8, p<0.0001) 
Sections are counterstained with DAPI (white). Scale bars A-B 10 µm. See Table 12 in Appendix for further data. 
Immunostaining detected PKD2 protein in pancreatic ducts, and this signal was significantly diminished in 
Bicc1 KOs. Moreover, Western blot confirmed a 2.1-fold decrease in PKD2 protein levels in Bicc1 KO 
pancreata at E15.5. Since this decrease is similar in magnitude to the one detected by RNA sequencing at the 
mRNA levels (1.9-fold), we conclude that BICC1 regulates PKD2 expression primarily before mRNA 
translation (Fig. 32). 
7.6.4 Bicc1 KO pancreata are characterized by an immune response and a 
stromal reaction 
Due to the small number of differentially regulated genes uncovered by the ANOVA analysis, it was not 
possible to perform gene ontology analysis. Nevertheless an important proportion of both up and 
downregulated genes were related to the immune system such as S100a8, S100a9, Crp, Cma1 arguing for an 
immune status change (Tables 4, 5). 
106 
 
 
Fig. 33: Immune cell infiltration and stromal reaction are observed in Bicc1 KO. 
(A-B) Immunofluorescence staining for PTPRC (cyan), a pan-immune marker also called CD45 (yellow arrowheads), is 
performed on E14.5 WT and Bicc1 KO pancreatic sections. The inset in (A) shows a high magnification of the dashed 
box.  
(C) Quantification of the immunostaining shows a 2.1-fold increase of PTPRC+ cells in Bicc1 KOs (WT, n=4; Bicc1 
KO, n=4, p=0.017).  
(D-G) Immunofluorescence staining performed on E14.5 WT (n=5) and Bicc1 KO (n=6) pancreata for EMR1 (cyan), a 
macrophage marker, and ACTA2 (magenta). E14.5 WT intestinal wall is used as a positive control for ACTA2. Both 
genotypes show EMR1+ macrophages in the pancreas. While ACTA2+ cells are not observed in E14.5 WT pancreata, 
they were present in a subset of Bicc1 KO pancreata. Inset represents high magnifications of the dashed box.  
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Legend of the Fig. 33. 
 (H-K) Immunofluorescence staining for ACTA2 (magenta), EMR1 (cyan) and DBA lectin (orange) performed on 
E18.5 WT and Bicc1 KO pancreatic sections. ACTA2+ cells surround cysts (n=4), but not WT ducts (n=4). 
Macrophages (yellow arrowheads) are present around cystic ducts in E18.5 Bicc1 KO pancreata (n=2), while there are 
only a few, scattered macrophages in WT pancreata (n= 4). Insets represent high magnifications of the dashed boxes.  
Sections are counterstained with DAPI (white). Scale bars, A-B, and insets 10 µm, and D-K, 20µm. See Table 12 in 
Appendix for further data. 
To further investigate this observation, the number of cells stained for PTPRC, also called CD45, a pan-
immune cell marker, was quantified in Bicc1 KO and WT E14.5 pancreata. It revealed a 2-fold increase in 
the Bicc1 KO (Fig. 33A-C). Moreover, the higher was the increase; larger was the dilation of the pancreatic 
ducts. Many of these cells were macrophages expressing EMR1, also called F4/80 (Fig. 33D-G). In addition, 
the tissue surrounding the cysts at E18.5 also exhibited numerous PTPRC+ cells and EMR1+ cells. The cysts 
at this stage were also surrounded by smooth muscle actin+ (ACTA2+) cells, suggestive of fibroblast 
activation (Apte et al., 1999; Haber et al., 1999) (Fig. 33H-K). ACTA2+ cells were only present at E14.5 in a 
subset of Bicc1 KO pancreata (Fig. 33D-G), which suggests a secondary effect of cyst formation and/or of 
immune cell recruitment. In conclusion, cysts arose in a context of PKD2 decrease and immune cell 
infiltration with stromal reaction. 
7.6.5 Cyst formation is not associated with an increased ADCY6 or PKIA level 
To start investigating direct targets, a candidate approach was initially used. In kidneys, BICC1 is able to 
repress the translation of ADCY6 and PKIA by respectively targeting Mir125a and Mir27a to their mRNA 
(Piazzon et al., 2012). Both ADCY6 and PKIA are expressed in E13.5 dorsal pancreatic buds based on the 
RNA sequencing. Their expression level is similar to PDX1, BICC1 or PKD2 (Adcy6: 10.71 rpkm and Pkia: 
11.22 rpkm) (Fig. 29). Moreover both Mir125a and MiR27a are expressed in E13.5 dorsal pancreatic buds 
(Mir125a: 66793 rpkm and Mir27a: 2809) (Fig. 31). In the kidneys, neither these mRNAs nor their 
respective miRNAs are affected by Bicc1 deletion. However, their protein level is. Therefore, the protein 
level of ADCY6 and PKIA was investigated in E15.5 Bicc1 KO pancreata, and compared to WT littermates. 
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Contrary to kidneys, neither ADCY6 nor PKIA were affected by Bicc1 deletion (Fig. 34). This thus suggests 
that ADCY6 and PKIA do not play a role in early cyst formation Bicc1 KO pancreata.  
 
Fig. 34: ADCY6 and PKIA are not affected by Bicc1 deletion in the pancreas  
(A) Example of Western blot performed for ADCY6 and PKIA on E15.5 WT and Bicc1 KO pancreata, and alpha 
tubulin (TUB) as a loading control.  
(B) Quantification of the Western blot shown in (A) is performed by normalizing band intensity to TUB intensity. 
Results are relative to WT mean. ADCY6 and PKIA are not affected by Bicc1 deletion (ADCY6: WT, n=8; Bicc1 KO, 
n=8, p= 0.33; PKIA: WT, n=7; Bicc1 KO, n=8, p=0.35).  
See Table 12 in Appendix for further data. 
7.7 WNT signaling inhibition is not affected by new BICC1 human 
variants associated with cystic kidney diseases  
In collaboration with the group of Dr. Bellané-Chantelot in Paris, BICC1 mutations associated with kidney 
dysplasia were previously uncovered. They affect BICC1 ability to inhibit canonical WNT signaling (Kraus 
et al., 2012). Although the role of BICC1 in WNT signaling does not appear to be conserved in the pancreas, 
it appears to be relevant in the kidney for the former mutations. 5 new variants in BICC1 were identified by 
the groups of Pr. Bingham, Pr. Ellard and Pr Hattersley in a cohort of 149 patients. They were associated 
with cystic kidneys and both oldest patients were also diabetic (Table 8 and Fig. 35A). 
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Table 8: BICC1 variants with kidney phenotype and diabetes onset time 
Mutation Age Renal cyst diagnosis age Diabetes Family history 
of diabetes 
D45G 55 42 years Yes Yes 
V206M 4 Large echogenic kidneys  Yes 
R800Q 32 21 years Yes Yes 
G821K 4 8 months  Yes 
T845K 22 3 years   
 
Since BICC1 is able to inhibit WNT signaling, the functionality of new BICC1 variants were evaluated with 
a TopFlash assay as previously performed (Maisonneuve et al., 2009; Kraus et al., 2012). Contrary to what 
had been observed with BICC1 Q87Stop and BICC1 E932G, the new variants do not inhibit canonical WNT 
signaling less effectively than WT BICC1 (Fig. 35B). This result suggests that kidney cysts observed in 
patients with new BICC1 variants are unlikely due to canonical WNT signaling up-regulation. 
110 
 
 
Fig. 35: New human BICC1variants inhibit canonical WNT signaling as strongly as WT BICC1. 
(A) Cystic patient associated variations (arrow) are indicated below a schematic representation of human BICC1 mRNA 
with its translated sequence shown in green, its KH domains in red and its SAM domain in blue (domain identification 
is based on SMART tool). The previously identified BICC1 mutations are indicated on top of BICC1 mRNA drawing. 
(B) TopFlash assays were performed to assess canonical WNT signaling. HEK293T cells were transfected with 
TopFlash, DVL2 to induce firefly luciferase expression, except for the negative control, and Renilla luciferase to 
normalize firefly luciferase activity. They were co-transfected with either BICC1 or one of the BICC1 variants. BICC1 
Q87Stop was used as a positive control. The different transfection mix components are indicated by black crosses. 
Canonical WNT signaling was inhibited as effectively by BICC1 variants as BICC1 (n=10 for each assay, except 
negative control n=6: BICC1 vs DVL1, p<0.0001; BICC1 vs BICC1 Q87Stop, p<0.0001; BICC1 vs BICC1 D54G, 
p=0.74; BICC1 vs BICC1 V206M, p=0.27; BICC1 vs BICC1 R800Q, p=0.28; BICC1 vs BICC1 G821E, p=0.92; 
BICC1 vs BICC1 T845K, p=0.58). Results are represented as percentage of DVL2 induced relative luciferase activity. 
See Table 12 in Appendix for further data. 
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8 DISCUSSION 
8.1 BICC1 integrates epithelial morphogenesis and differentiation 
BICC1 is able to integrate appropriate pancreatic ductal tree morphogenesis and differentiation of endocrine 
cells originating from the progenitor-lined ducts. The absence of BICC1 causes cysts in both pancreatic and 
liver ducts, in addition to kidney dysplasia (Maisonneuve et al., 2009; Tran et al., 2010). Moreover, this work 
showed that BICC1 normally potentiates NEUROG3+ endocrine progenitor production leading to endocrine 
cell reduction in Bicc1 KO pancreata (Fig. 36).  
 
Fig 36: Proposed model of BICC1 function during pancreas development. 
During the secondary transition, bipotent ductal progenitors (yellow) can differentiate into NEUROG3+ endocrine 
progenitors (green). These progenitors leave the ducts (grey cells) while differentiating into endocrine cells (red). After 
the onset of the secondary transition, BICC1 is present in bipotent ductal progenitors (yellow). It regulates PKD2 and 
thereby inhibits ductal overproliferation maintaining ductal homeostasis. BICC1 may also directly inhibit proliferation. 
It also promotes Neurog3 expression via an unknown factor enabling the differentiation toward endocrine progenitor 
(green). While ONECUT1 directly activates Neurog3 (Jacquemin et al., 2000), it also promotes Bicc1 expression. 
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During pancreas development, three distinct, stage dependent expression patterns of BICC1 were uncovered. 
Before E12.5, BICC1 was first expressed at low level in all PDX1 positive pancreatic progenitors. Then, its 
level increased, and BICC1 was restricted to the bipotent progenitors. Thereafter, BICC1 expressed in the 
ducts. The expression patterns highlighted different functions of BICC1: at early stages, BICC1 transiently 
controls pancreatic size and later, it promotes endocrine progenitor production and ductal homeostasis. 
8.2 Transient hyperplasia at early stages 
In the absence of BICC1, both the multipotent progenitors and the endocrine progenitors were hyperplastic at 
E12.5 (Fig. 21, 22). However, this effect was transient, as at E14.5 the pancreatic epithelium size was 
unaffected by Bicc1 deletion. This suggests that the size control function is restricted to earlier stages of 
development, and compensatory mechanisms may restore the size later on. Two different mechanisms may 
cause hyperplasia: either more cells are specified, or proliferation is increased. Even though pancreatic size 
has not been assessed before E12.5, it is unlikely that BICC1 has a role during pancreas specification. 
Indeed, the absolute number of GCG+ cells at E12.5 was not affected by Bicc1 deletion. Endocrine cells 
come from endocrine progenitors and, therefore, pancreatic progenitors produced earlier. This argues 
strongly against an increase in endocrine progenitors and multipotent progenitors at earlier stages. In order to 
get more insight into the hyperplasia mechanism and the compensatory mechanism restoring pancreatic size 
later on, it would be interesting to estimate the mitotic index at E11.5 and at E13.5, but also the apoptotic 
index. 
8.3 Endocrine progenitor production defect during the secondary 
transition 
At E12.5, it was not clear if Bicc1 deletion affected NEUROG3+ cell production. Indeed, while the cell 
counting revealed a relative increase of NEUROG3+ cells, Q-PCR data tended to indicate no changes in 
Neurog3 transcript (Fig. 21A, B, 22A-C). The latter results had a great variability mainly due to the low 
113 
 
number of NEUROG3+ cells representing only one percent of the total pancreatic epithelium. It should be 
noted that at this stage, the epithelium represents around half of the total pancreas (Landsman et al., 2011; 
and data not shown). Hence, NEUROG3+ cells represent less than a percent of the total pancreas. Therefore 
if the cell number only slightly changes, a large variation in proportion is detected. Moreover the Cleaver 
laboratory has shown that Neurog3 transcription is transiently inhibited at E11.25, and re-expressed at E12 
(Villasenor et al., 2008). Delays between littermates may lead to relatively large variations around the time 
when Neurog3 transcription is reinitiated. In Bicc1 KO pancreata Neurog3 was not yet significantly 
decreased at E13.5 based on RNA sequencing data. At E14.5, NEUROG3 was decreased (RNA and cell 
number). Therefore, the defect occurred after the secondary transition has started, i. .e. when the 
differentiation of bipotent progenitors toward endocrine cells, via NEUROG3+ cells, is strongly enhanced 
(Mori and Haga, 1960; Rutter et al., 1968; Gradwohl et al., 2000). In Bicc1 KOs the endocrine cell decrease 
followed the endocrine progenitor reduction, being detected at E18.5 but not yet at E14.5.  
The analysis of the fate of NEUROG3+ cell progeny, at E14.5 and E18.5, revealed a sustained decrease of 
30-50% of endocrine cell production from E14.5 onwards (Fig. 24, 26). Since GCG+ cells are produced in 
large numbers before E14.5 (Johansson et al., 2007), they were consequently less affected than the other 
endocrine cells in Bicc1 KOs. Although most of NEUROG3-expressing cells become endocrine, a subset 
adopts an acinar or ductal fate (Schonhoff, S. et al., 2004; Wang et al., 2010; Beucher et al., 2012). Due to 
the general decrease in NEUROG3+ cells, it might be expected that their small acinar and ductal progeny 
would also be decreased in Bicc1 KOs (Fig. 26). However, acinar progenitors are segregated from bipotent 
progenitors before the regulation of endocrine progenitor production by BICC1, accounting for a normal size 
of the acinar progeny in Bicc1 KOs. On the contrary, there is no time window restriction to NEUROG3+ cell 
ability to adopt a ductal cell fate (Zhou et al., 2007; Beucher et al., 2012; Pan et al., 2013). Ductal Neurog3+ 
progeny should thus be decreased in the Bicc1 mutant, but duct expansion, due to increased proliferation, 
compensated for this defect. As Neurog3+ progeny and endocrine cells were similarly reduced in Bicc1 KOs, 
and BICC1 was absent of the differentiating endocrine cells, I conclude that BICC1 does not control 
endocrine cell production downstream of Neurog3. 
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8.4 Target(s) of BICC1 regulating endocrine progenitor production 
In vertebrates, BICC1 is able to repress translation of target mRNAs either by facilitating miRNA binding 
(Piazzon et al., 2012) or by directly inhibiting the translation initiation machinery (Zhang et al., 2013). It is 
also able to enhance translation by inhibiting miRNA activity thus stabilizing protein levels of the targets 
even though no direct interaction between miRNA and BICC1 have been uncovered in this case  
(Tran et al., 2010; Gamberi and Lasko, 2012).  The role of BICC1 in targeting mRNAs implies that its action 
may not be seen at the mRNA level (Dorey and Hill, 2006; Piazzon et al., 2012; Zhang et al., 2013) 
It has not been reported that BICC1 regulates transcription. However, the transcription of Neurog3 was 
affected by Bicc1 deletion since we observed a similar reduction of the number of cells expressing 
transcriptional reporters, Neurog3-Cre and Neurog3-RFP, and of the number of cells expressing NEUROG3 
protein (Fig. 22, 24, 26). Hence the direct regulation of Neurog3 by BICC1 can be ruled out. 
8.4.1 Known transcriptional regulators of Neurog3 are not affected by Bicc1 
deletion 
Since BICC1 do not control directly Neurog3 transcription, BICC1 might either enhance a transcriptional 
activator of Neurog3 or inhibit one of its transcriptional repressors. It has already been shown that expression 
level of transcriptional activator of Neurog3 is important to produce the adequate number of endocrine 
progenitor cells. For instance, Sox9 haploinsufficiency causes a decrease by 50% of endocrine progenitors 
(Seymour et al., 2008). 
Nevertheless, the protein level of the different transcriptional regulators of Neurog3 tested in this study was 
unaffected by Bicc1 deletion. HES1, a transcriptional repressor of Neurog3, was not changed in Bicc1 KO 
pancreas, neither were SOX9, FOXA2, PDX1 and HNF1B, some of its transcriptional activators (Lee et al., 
2001; Shih et al., 2012; Ejarque et al., 2013). ONECUT1 also activates Neurog3 expression (Jacquemin et 
al., 2000), but, although Onecut1 was upregulated at the mRNA level, its protein level was not changed, 
arguing against its being targeted by BICC1 (Fig. 27).  
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However, the ductal cell number has not been estimated at E15.5. If this cell population is expanded due to 
duct dilatation, the expansion may hide a decrease of the expression level of a given transcription factor. 
Indeed if the level of a transcription factor per cell is decreased in the same degree as the ductal population is 
increased, the global expression level detected by Western blot will be similar between WT and Bicc1 KO 
pancreata. Nevertheless, such expansion is unlikely. For example, a 50% decrease of SOX9, corresponding 
to a 50% reduction of endocrine progenitors, would require a 50% increase of the bipotent progenitor cell 
population in order to get a similar expression level. Moreover, HES1 is not upregulated in Bicc1 KO 
pancreata, contrary to what would be expected with an increased number of ductal cells (Fig. 27). In order to 
circumvent the potential ductal population increase, the expression of these transcription factors would have 
to be quantified in individual cells, e.g. using flow cytometry. 
8.4.2 Putative BICC1 targets affecting endocrine progenitor cell production 
ONECUT2, HNF1A and GLIS3 are able to activate Neurog3 promoter (Lee et al., 2001; Vanhorenbeeck et 
al., 2007; Yang et al., 2011). As for the other transcription activators of Neurog3, their protein level would 
have to be assessed in order to evaluate if they are regulated by BICC1. However, there is little evidence that 
ONECUT1 and HNF1A have, in vivo, an important role in the generation of NEUROG3+ cells. ONECUT2 
acts redundantly with ONECUT1, and its deletion does not cause an endocrine progenitor decrease 
(Vanhorenbeeck et al., 2007). In addition, HNF1A expression is excluded from the bipotent expression 
domain at E15.5 (Maestro et al., 2003). Hnf1a deletion causes neither a decrease of endocrine progenitor cell 
number nor the formation of cysts, although cyst formation and endocrine progenitor decrease may be 
uncoupled as discussed from p 116. The Hnf1a KO mice become glucose intolerant over time (Pontoglio et 
al., 1996; Pontoglio et al., 1998). Compared to ONECUT2 and HNF1A, GLIS3 is a more likely BICC1 
target due to the phenotypic overlap between knockouts. A drastic decrease in pancreatic endocrine 
progenitors together with cyst formation is observed in Glis3 KOs. Glis3 KOs also develop cyst in the 
kidneys. Finally, based on seed prediction tool (TargetScan), seeds for Mir17 involved in kidney cyst 
formation in Bicc1 KOs (Tran et al., 2010) and for Mir29b-1 found downregulated in the pancreas are 
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present in its 3’UTR. Unfortunately GLIS3 levels in Bicc1 KO could not be tested due to poor antibody 
quality. 
NEUROG3+ cell production is also inhibited by GDF11, a member of the TGFB family. The action of 
GDF11 is independent of the NOTCH signaling pathway (Nakashima et al., 1999; Harmon et al., 2004). 
More endocrine progenitors are observed in Gdf11 KOs. However, it has additional effects on beta cell 
maturation which do not match Bicc1 KO phenotype. SMAD2 haploinsufficiency causes the same phenotype 
as Gdf11 KOs arguing that SMAD2 is the downstream effector of GDF11 (Harmon et al., 2004). It would be 
interesting to test the SMAD2 expression and activity levels in Bicc1 KO pancreata.  
Finally BICC1 may also target an unknown modulator of Neurog3 promoter and therefore a more unbiased 
approach to identify BICC1 targets may be advisable, but rendered difficult by the heterogeneity and small 
size of the cell populations present in the developing pancreas. 
A study to which I contributed is presented in the annex on page 151 and may be relevant to the mode of 
action of BICC1.  We showed that bipotent progenitors have different modes of division. They can divide 
symmetrically, and generate either two bipotent progenitors or two endocrine progenitors. They also divide 
asymmetrically, and generate one bipotent progenitor and one endocrine progenitor. The choice to produce 
endocrine progenitors by symmetric or asymmetric cell division is hypothesized to be associated with the 
cell cycle. If the bipotent progenitor is primed for an endocrine progenitor fate before a certain time in the 
cell cycle, the cell exits the cell cycle and differentiates into endocrine progenitor. If the priming occurs after 
this restriction point, the bipotent progenitor continues the cell cycle and generates two endocrine progenitors 
after mitosis (Kim et al., 2015). It would be interesting to see if the deletion of Bicc1 causes an imbalance 
between the asymmetric and symmetric cell division generating endocrine progenitor as it would indicate the 
involvement of different factors before and after the restriction point, or give insight on its molecular nature. 
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8.5 BICC1 controls pancreatic epithelial morphogenesis after the 
secondary transition as started 
In Bicc1 KO pancreata, ducts were dilated after the secondary transition has started. Cysts developed in the 
dilated ducts and formed a connected web rather than isolated foci (as shown by the movies in Lemaire et al., 
in press). In ARPKD patients, tube dilation also precedes cyst formation, reminiscent of what was observed 
in Bicc1 KO pancreata (Ockenden and Blyth, 1971). 
8.5.1 Endocrine cell defects are unlikely caused by cyst formation and vice versa 
In addition to a complete loss of endocrine cells, Neurog3 KOs harbor cysts smaller than those seen in Bicc1 
KOs (Gradwohl et al., 2000; Magenheim et al., 2011a). However, these cysts are thought to originate from 
an accumulation of progenitors failing to further differentiate into endocrine cells. This is not the case in 
Bicc1 KOs where NEUROG3 progeny instead were reduced to the same extent as endocrine cells, arguing 
that the endocrine cell decrease observed in Bicc1 KOs is not the cause of cyst formation (Fig. 27). On the 
contrary, it is also unlikely that the presence of cysts causes the endocrine defect since no pancreatic 
endocrine alterations have been reported in pancreatic cystic mutants, such as Pkd2 KOs, Pkd1 KOs, Pkhd1 
hypomorphs, or cilia defective mutants (Lu et al., 1997; Wu et al., 2000; Cano et al., 2004; Cano et al., 2006; 
Gallagher et al., 2008) 
8.5.2 Aberrant proliferation vs cell shape defect as cause of cyst formation  
In kidneys, proliferation is one of the major mechanisms of cyst expansion, although it is not sufficient to 
induce cyst formation (Hanaoka and Guggino, 2000; Fangming et al., 2003; Chang et al., 2006; Piontek et 
al., 2007; Kim et al., 2009; Sharma et al., 2013). In Bicc1 KO pancreata, ductal proliferation was only 
increased at late stages, while at E14.5 it was unaffected (Fig. 15). A similar picture emerges from other 
pancreatic cystic mutants. The E15.5 Hnf6 KO pancreatic epithelium does not over-proliferate, and neither 
do the pancreatic ducts of ciliary mutants (Cano et al., 2004; Cano et al., 2006; Pierreux et al., 2006). 
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Moreover, when cystic and non-cystic proliferation in Bicc1 KO pancreata were considered separately, only 
the cystic cell mitotic index was increased compared to WT animals (data not shown). This result is in line 
with observations in kidneys where the mitotic index is increased in cysts but not in non-cystic areas (Nauta 
et al., 1993). In addition, uncontrolled proliferation is not observed in early renal cysts of Bicc1 KOs (Tran et 
al., 2010). Overall, we conclude that while over-proliferation may contribute to late cyst expansion, it does 
not account for early duct dilation or cyst initiation in Bicc1 KO pancreata. 
It has been shown in several rodent models that kidney cyst formation is preceded by an impairment of 
oriented cell divisions parallel to the longitudinal axis of the nephron (Fischer et al., 2006). Pancreatic 
bipotent progenitors similarly divide mainly within the plane of the progenitor-lined duct at E14.5 (YH Kim, 
unpublished data). Ductal dilation observed in Bicc1 KO pancreata may be caused by a loss of oriented cell 
division promoting more longitudinal and less circumferential divisions, especially if the number of bipotent 
progenitors is not increased. Although little is known about the shape of cyst-lining cells, a deformed shape 
with an increased width-over-height ratio may also be another mechanism causing duct dilation. It may also 
result in the misorientation of the cells in the ducts as observed in kidney of Wnt9b KOs (Karner et al., 
2009). Therefore, the study of the shape of cells lining dilated ducts or cysts in Bicc1 KO pancreata would 
give insight into the mechanisms of cyst initiation and expansion. 
8.5.3 Cilia defects are not observed in the absence of Bicc1 
Cyst formation is a shared feature of several mutants affecting pancreas development. Cilia mutants have 
cysts in the pancreas, although cysts also arise in intercalated duct and dilation is only observed at late 
gestational stages, contrary to what was observed in Bicc1 KO pancreata. Onecut1 KOs lack cilia at early 
stages while Glis3 KOs and Sox9 conditional KOs have less cilia in cyst-lining cells indicating an association 
between cilia and cysts formation (Cano et al., 2004; Cano et al., 2006; Pierreux et al., 2006; Kang et al., 
2009b; Shih et al., 2012).  
However, the presence of cilia has been reported in the cochlea and node of Bicc1 KOs (Maisonneuve et al., 
2009; Piazzon et al., 2012) and we also observed them in their pancreata (Fig. 17). Nevertheless, BICC1 
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affects cilia position on the cells and their ability to synergistically rotate in the node. These cilia normally 
generate a flow of extracellular signals creating left-right asymmetry in embryos. In Bicc1 KOs the fluid 
flow randomization thus leads to left-right randomization (Maisonneuve et al., 2009). They might therefore 
also be altered in pancreatic ducts however, their position and function is difficult to assess in the tortuous 
pancreatic ductal network. 
8.5.4 BICC1 acts downstream of ONECUT1 
The Bicc1 KO pancreatic phenotype partially recapitulates the Onecut1 KO phenotype. Indeed in both cases 
there are ductal cysts and less endocrine cells due to a failure to produce endocrine progenitors (Jacquemin et 
al., 2000). I found that ONECUT1 regulated Bicc1 transcript levels. ONECUT1 may activate Bicc1 
expression directly, but an indirect control via HNF1B is plausible. Indeed, ONECUT1 enhances Hnf1b 
expression and the latter is able to induce Bicc1 expression in the kidney, although a direct binding as not 
been confirmed in E12.5 pancreata (Maestro et al., 2003; Verdeguer et al., 2010; De Vas et al., 2015). 
8.5.5 BICC1 acts upstream of PKD2 
PKD2 was downregulated at E13.5 (mRNA level, RNA sequencing) and at E15.5 (protein level) in Bicc1 
KO pancreata (Table 5, Fig. 32). Pkd2 KOs embryos and adult heterozygotes acquiring a spontaneous 
mutation of the second allele exhibit cysts in the pancreas and in kidneys (Wu et al., 1998; Wu et al., 2000; 
Chang et al., 2006). Moreover, if the expression level of PKD2 is as important as that of PKD1, a more than 
2-fold decrease might lead to cyst formation (Lantinga-van Leeuwen et al., 2004; Jiang et al., 2006). In 
kidneys, BICC1 inhibits targeting of Pkd2 by Mir17, thus stabilizing PKD2 (Tran et al., 2010). BICC1 does 
not affect Mir17 expression level (Piazzon et al., 2012). In the pancreas, BICC1 may also repress Mir17 
without altering its stability since Mir17 is present in E13.5 pancreata (Fig. 31). PKD2 also functions 
downstream of BICC1 in osteoblasts, and knock-down of Bicc1 is rescued by overexpressing Pkd2 (Mesner 
et al., 2014). Together, this argues that PKD2 is a major mediator of BICC1 activity in multiple organs.  
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PKD2 is also a major player of cyst formation in pancreata since its expression level is altered in several 
mutants. Pkd2 is increased in Hnf1b conditional mutants, while Bicc1 and several cyst associated genes are 
decreased, arguing that the inhibition of Pkd2 expression by HNF1B is upstream or independent of BICC1, 
rather than downstream (De Vas et al., 2015). Late Sox9 deletion in the pancreas also causes cyst formation. 
It is associated with Pkd2 downregulation without affecting Bicc1 expression (Shih et al., 2012). SOX9 is not 
affected in Bicc1 KOs. Therefore, SOX9 and BICC1 appear to prevent cyst formation independently of each 
other by controlling Pkd2 expression.  
PKD2 is a Ca2+ channel allowing Ca2+ inward flow in response to shear stress at the primary cilia. Ca2+ 
intracellular level is decreased in cystic kidneys (Hanaoka et al., 2000; González-Perrett et al., 2001; 
Vassilev et al., 2001; Koulen et al., 2002). The role of Ca2+ associated signaling is relatively unknown in 
pancreas development. It would therefore be interesting to see if the Ca2+ concentration is reduced in Bicc1 
KO pancreata suggesting that initial mechanisms of cyst formation are conserved between kidney and 
pancreas and uncovering the importance of Ca2+ in ductal homeostasis.  
8.5.6 BICC1 does not regulate ADCY6 or PKIA during pancreas development 
Contrary to what has been described in the kidneys (Piazzon et al., 2012), ADCY6 and PKIA were not 
upregulated by BICC1 in E15.5 pancreata. It may be argued that the analyzed stages do not correspond to the 
same cyst enlargement in both organs. Indeed, ADCY6 and PKIA protein level are upregulated from E17.5 
in the kidneys, when cysts are already clearly present (Piazzon et al., 2012), whereas the ducts of E15.5 
Bicc1 KO pancreata were normal to slightly cystic (Fig. 34).  
In addition, BICC1 might target other genes involved in cAMP production regulation in the developing 
pancreas. Other Ca2+-regulated proteins controlling cAMP level were expressed, but at low level, in the 
E13.5 pancreas, such as Adcy5 (expression level < 1 rpkm by RNA sequencing), Pde1a, Pde1b, and Pde1c 
(around 1 rpkm by RNA sequencing) (Kakiuchi et al., 1973; Chabardès et al., 1999; Wang, X. et al., 2009). 
It might thus first be important to assess cAMP levels at different stages in Bicc1 KO and WT pancreata to 
evaluate if pancreatic cyst formation is associated with cAMP dysregulation.  
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Increased levels of cAMP are known to both promote proliferation and fluid secretion, causing mainly cyst 
expansion (Hanaoka and Guggino, 2000; Tamma et al., 2003; Yamaguchi et al., 2003; Montesano et al., 
2009). However, proliferation is not yet increased at cyst initiation stage in Bicc1 KO pancreata. 
Furthermore, in E13.5 dorsal pancreatic buds, two major actors of cystic fluid secretion, CFTR and AQP2, 
are absent or only expressed at low level, respectively (Cftr mRNA < 1 rpkm by RNA sequencing). These 
data argue that cyst initiation and expansion mechanisms are not shared. Conversely, cyst formation 
mechanisms might be different in the pancreas and in kidneys. Alternatively, cyst formation in different 
models may rely on distinct mechanism. Indeed, patients with cystic fibrosis and ADPKD develop less 
severe cysts (O'Sullivan et al., 1998), while the absence of CFTR in bpk/bpk mice does not prevent cyst 
growth (Nakanishi et al., 2001).  
8.5.7 Canonical WNT signaling is not altered in Bicc1 KO pancreatic cysts 
Several pieces of evidence argue for a role of canonical WNT signaling in cyst formation both in kidneys 
and in the pancreas. Forced hyperactivation of canonical WNT signaling causes kidney cysts (Saadi-
Kheddouci et al., 2001; Chao-Nan et al., 2005). Constitutively active WNT signaling also induces cysts in 
pancreata, but only if the activation starts before E12.5 (Heiser et al., 2006). Increased canonical WNT 
signaling combined with cysts in kidneys and the pancreas has also been reported in inv/inv mutants (Cano et 
al., 2004; Simons et al., 2005). Other cystic kidney mutants also have an increased WNT activity (Fangming 
et al., 2003; Kim et al., 2009). Finally, WNT signaling is more active in the pancreas of orpk/orpk mutants 
(Cano et al., 2004). As BICC1 has been shown to inhibit canonical WNT signaling in the node 
(Maisonneuve et al., 2009), it could be expected that its deletion increases WNT signaling. However 
canonical WNT signaling is detected in the mesenchyme in E14.5 pancreata (Dessimoz et al., 2005), 
implying that a direct effect of BICC1 on canonical WNT signaling is unlikely. More importantly overactive 
WNT signaling was not detected with reporter mouse lines or gene readout (Fig. 28) suggesting that 
canonical WNT signaling is neither involved in cyst formation nor in endocrine cell decrease observed in 
Bicc1 KO pancreata. 
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8.5.8 Role of apico-basal polarity defects in Bicc1 KO cysts 
Apico-basal polarity is globally unaffected in bpk/bpk kidneys (Ryan et al., 2010). Normal apico-basal 
polarity was also observed in Bicc1 KO pancreata. Apical markers, such as aPKC and MUC1, were facing 
the lumens and not the basal side (Fig. 20, data not shown for MUC1). However, DBA and MUC1 had a 
tendency to be weaker in Bicc1 KO pancreata (data not shown). Although the general apico-basal polarity 
machinery is conserved in the kidney of jcpk/jcpk mice and bpk/bpk mice, the EGFR receptor is not localized 
properly. The mislocalization causes an over-activation of the MAPK signaling pathway that may induce 
proliferation. EGFR mislocalization may be caused by a dysregulation of the endosome sorting pathway. 
Moreover, bpk/bpk renal cystic cells also secrete more EGF related ligands in the lumen, thereby, inducing 
proliferation (Sweeney and Avner, 1998; MacRae Dell et al., 2004; Ryan et al., 2010). Lastly pancreatic 
cysts of Kif3a conditional KOs also harbored increased phospho-MAPK1 without indication of EGFR 
mislocalization (Cano et al., 2006). The role of EGF/MAPK pathway may thus deserve further 
investigations. 
EGFR localization and its contribution to cyst formation have not been assessed in Bicc1 KO pancreata. It 
was expressed in E13.5 WT pancreata at relatively low level (around 1 rpkm, based on RNA sequencing 
data), while Erbb2, Erbb3, and Erbb4 were expressed at higher level (around 10 rpkm, based on RNA 
sequencing data). Indeed, ERBB4 has been detected by immunostaining in duct at E12.5 (Huotari et al., 
2002). Inactivation of EGFR causes slight hypoplasia with a higher relative reduction of beta cells, and BTC, 
an EGF ligand, promotes beta cell mass (Miettinen et al., 2000; Huotari et al., 2002). It should be noted that 
overexpression of TGFA causes ductal dilatation with interstitial fibrosis (Jhappan et al., 1990; Sandgren et 
al., 1990). TGFA, secreted by  bpk/bpk renal cells, is also able to promote cyst expansion (MacRae Dell et 
al., 2004). This information may be valuable as EGFR receptor inhibition may reduce cyst growth. 
8.5.9 Role of MTOR signaling pathway alterations in Bicc1 KO cysts  
MTOR inhibition in bpk/bpk mice represses kidney cyst growth (Shillingford et al., 2006). Moreover, in 
Pkd1 KO cells, a upregulation of MTOR signaling has been associated to an increase of aerobic glycolysis, 
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the main source of energy of Pkd1 KO cells (Rowe et al., 2013). The glycolytic enzymes, Aldoa, Pfkl, and 
Eno1, were upregulated in Bicc1 KOs using the DESeq analysis even though the analysis is not stringent 
enough to reliably assess gene changes (Table 14). In the case of Neurog3, the downregulation observed at 
E13.5 was confirmed at later time points. Glycolytic enzymes may follow the same pattern and become 
reproducibly upregulated at a later time point. It would therefore be interesting to assess both MTOR 
pathway and aerobic glycolysis in Bicc1 KO pancreata, and whether their inhibition may slow down cyst 
expansion. 
8.6 An indirect and early mesenchymal contribution to cyst formation 
A conserved feature of cyst formation in kidneys is its association with fibrosis and infiltrating macrophages 
(Okada et al., 2000; Fangming et al., 2003; Chang et al., 2006; Jiang et al., 2006; Happé et al., 2013). 
Activated macrophages have been shown to promote cyst formation in polycystic kidney disease models 
(Karihaloo et al., 2011; Swenson-Fields et al., 2013; Ta et al., 2013). However, macrophages are not 
sufficient to induce cyst formation in the fetal pancreas, and instead promote beta cell mass (Banaei-
Bouchareb et al., 2004; Geutskens et al., 2005). Conversely, in adults, macrophages as well as other cell 
types are able to activate pancreatic stellate cells, a subset of fibroblasts present in the pancreas (Watari et al., 
1982; Schmid-Kotsas et al., 1999). Once activated, stellate cells start to express ACTA2. They increase their 
production of extracellular matrix components and secrete cytokines that recruit inflammatory cells and 
sustain active pancreatic stellate cell state. If this positive feedback loop is not turned off, it leads to fibrosis 
(Apte et al., 1999; Masamune et al., 2009; Shi et al., 2014).  
Although collagen accumulation, and therefore actual fibrosis, were not detected in E18.5 Bicc1 KO 
pancreata, resident or infiltrating immune cells, such as macrophages, were increased in Bicc1 KOs. The 
expansion occurred early, as immune associated genes are already affected in E13.5 Bicc1 KOs, and an 
increase of immune cells was observed at E14.5. Immune cell increase was followed by the activation of 
fibroblasts, indicated by their positivity for ACTA2+. Only some E14.5 Bicc1 KO pancreata had ACTA2+ 
fibroblasts, whereas at E18.5, all Bicc1 KO pancreata had ACTA2+ cells surrounding the largest cysts (Table 
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4, 5 Fig. 33). As for the kidneys, macrophages together with active fibroblasts, may thus promote cyst 
growth. Ongoing experiments using the organoid system developed in our laboratory are being performed to 
assess the role of the stroma and immune cells in cyst initiation. In this system, growth and branching of the 
pancreatic epithelium without its surrounding mesenchyme is observed (Greggio et al., 2013). 
TGFB is able to activate pancreatic stellate cells and promote fibrosis (Apte et al., 1999). It is also associated 
with kidney cysts (Hassane et al., 2010). Moreover, in the RNA sequencing analysis using DESeq analysis 
several TGFB signaling pathway components were upregulated (Table 14), arguing that TGFB signaling 
could be altered at least at later stages. It would thus be interesting to inhibit TGFB signaling in explants or 
organoid cultures and see if the inhibition slower the stromal reaction or cyst growth. 
8.7 Human cystic syndromes, diabetes, and BICC1  
Heterozygous BICC1 mutations in human have been identified and associated with kidney dysplasia (Kraus 
et al., 2012). The groups of Pr. Bingham, Pr. Ellard, and Pr Hattersley, identified 5 new heterozygote variants 
of BICC1 in another cohort of patients having cystic kidneys and, for the oldest patients, diabetes. Our 
investigation suggests that pancreatic defects may be expected in these patients. Although these mutations 
are rare, it cannot be excluded that mutations occur in BICC1 introns or in its promoter changing its 
expression level. However, it suggests that these mutations act in a dominant manner. 
8.7.1 Impact of the BICC1 variation on its protein 
One of the previously characterized mutations disrupts the SAM domain of BICC1 while the other leads to a 
truncated form which includes the N-terminal part until the middle of the first KH domain (Fig. 35A) (Kraus 
et al., 2012). The effect of the new BICC1 variations on the protein structure is less clear. Only one of them 
(D54G) mutates a known BICC1 domain, its first KH domain. The others lie before or after the SAM 
domain (Fig. 35A). Therefore, if the new variations affect the functionality of BICC1, they may be useful in 
probing its molecular mechanisms. 
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8.7.2 Functionality assay of the new BICC1 variants 
The precedent mutations affect the ability of BICC1 to inhibit canonical WNT signaling (Kraus et al., 2012). 
However, the new variants did not lose their ability to repress canonical WNT signaling, even partially. Loss 
of WNT signaling inhibition has not been associated to cyst formation in Bicc1 KOs, even though 
constitutionally active WNT signaling causes kidney cysts (Saadi-Kheddouci et al., 2001; Chao-Nan et al., 
2005; Maisonneuve et al., 2009). Other functions of BICC1 may be affected in the variants. They might 
affect BICC1 ability to localize to P bodies, as shown for human BICC1 E932G mutation (Kraus et al., 
2012). Moreover, the Constam lab is investigating if the variants are still able to regulate ADCY6 and PKIA 
translation. Finally, variants might lose the ability to promote PKD2 expression. Addressing this would be 
interesting since PKD2 is a common target in the pancreas and the kidneys. Therefore, the mutation might 
associate kidney and pancreatic defects. 
8.7.3 Association between BICC1 and diabetes 
Kidney defects may be associated with diabetes in several human syndromes. For example, MODY5 
syndrome, where HNF1B is mutated, is characterized by kidney cysts and diabetes (Bellanné-Chantelot et 
al., 2005). Both HNF1B and BICC1 prevent kidney cysts and control pancreas development. This might 
reflect a role of HFN1B in the transcriptional activation of Bicc1 in the kidney (Haumaitre et al., 2006; 
Verdeguer et al., 2010). In the pancreas HNF1B also activates Bicc1, but the activation might be indirect (De 
Vas et al., 2015). It will be important to investigate whether BICC1 mutations contribute to diseases 
combining kidney cysts and diabetes or to link BICC1 with already identified genes in such pathologies. 
Other monogenic forms of diabetes may also be associated with kidney dysplasia. For example, GLIS3 
mutations can cause neonatal diabetes associated with cystic kidneys (Senée et al., 2006).  
It might be argue that BICC1 is not expressed in beta cells and, therefore, its mutation could not cause 
diabetes. Indeed, BICC1 was neither expressed in beta cells at E18.5 nor in 2 weeks old animals (Fig. 11). 
However we cannot rule out that BICC1 is expressed in beta cells at later stages. BICC1 mRNA was also 
detected in low amounts in the beta cell-derived bTC cell line (not shown). Defects in endocrine progenitor 
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production in the long term may cause glucose intolerance, as observed in Sox9 haploinsufficiency (Seymour 
et al., 2008; Dubois et al., 2011). It would also be interesting to evaluate if Bicc1 KO pups, which have half 
less beta cells, are hyperglycemic or glucose intolerant, even though this remains difficult to determine due 
to embryonic and early postnatal lethality. Conditional deletion of Bicc1 in the developing pancreas or in the 
endoderm, using e. g. Sox17CreGFP, a tool I contributed to characterize (see Annex p150) , would address 
these issues as it circumvents the kidney lethality (Choi et al., 2012). Moreover, we could not identify stable 
glucose intolerance in Bicc1 heterozygotes (data not show). 
8.8 Putative role of BICC1 in endocrine cell differentiation 
The analysis of the expression pattern of BICC1 might give cues on the possible roles of BICC1 in the 
production of endocrine cells in different organs (Wessely et al., 2001). Enteroendocrine cells are present in 
both the stomach and the intestines. While enteroendocrine cells in the stomach do not require NEUROG3, 
they are generated from NEUROG3+ cells in the intestines (reviewed in May and Kaestner, 2010). BICC1 
might thus be important for their production. Nevertheless BICC1 does not seem to be present in the 
intestines around E13.5-E14.5 as it does not in the stomach (Wessely et al., 2001; data not shown). 
Endocrine organs such as the pituitary gland, the pineal gland, the hypothalamus, the thyroid, parathyroids, 
and adrenal glands might also rely on BICC1 function for their development. However, the expression 
pattern of BICC1 in these organs and during their ontogeny is too poorly characterized to hypothesize any 
role (Wessely et al., 2001). Moreover, the early lethality of Bicc1 KO precludes any physiological studies 
(Maisonneuve et al., 2009). On the contrary, both female and male gonads express Bicc1 at high level. Bicc1 
is present in the stroma of the ovary as well as in the theca cells secreting androgen. It is also expressed at 
low level in the primary follicle giving rise to the granulosa secretin estrogen and later the corpus luteum 
secreting progestogen (Wessely et al., 2001; Norris and Carr, The Endocrinology of Mammalian 
Reproduction, in Vertebrate Endocrinology, 2013). The expression pattern in the developing and adult testes 
was not characterized by Wessely and colleagues (Wessely et al., 2001). However, the data in the ovaries 
suggest a role for BICC1 in the generation of the gonadal sex-hormones producing cells. The use of Bicc1 
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conditional deletion circumventing the early lethality will be necessary to assess the function of BICC1 in 
the different endocrine organs. 
8.9 Conservation of BICC1 functions 
The actions of BICC1, in different species, are still too poorly understood to establish the conservation of 
BICC1 functions. Until now, they are rather contracdictory. For example, BICC1 is able to regulate the 
length of polyA tail either positively in Caenorhabditis elegans or negatively in Drosophila, while BICC1 
does not affect the polyA tail of PKD2, ADCY6 or PKIA in mice (Eckmann et al., 2004; Chicoine et al., 
2007; Tran et al., 2010; Piazzon et al., 2012). Moreover only few mRNA targets have been identifed and 
validated (Chicoine et al., 2007; Piazzon et al., 2012; Zhang et al., 2013). Two screens have been performed 
to identified mRNA targets using RNA co-immunoprecipitation in stage 7 Xenopus embryos and in 
Drosophila ovarian extracts. However, the targets do not overlap. It could be mainly due to used of unrelated 
systems (Chicoine et al., 2007; Zhang et al., 2013). Thus, BICC1 functions may mainly rely on its binding 
partners and mRNA targets. 
8.10 Concluding remarks 
This study showed that BICC1 was important to produce adequate numbers of endocrine cells, and to 
promote ductal homeostasis during pancreas development. In its absence, endocrine progenitor cells were 
reduced due to a production defect. The ducts dilated, and became progressively cystic. A stromal reaction 
was then observed around the largest cysts. PKD2 is downregulated even before ducts start to enlarge. 
However, no target of BICC1 promoting endocrine progenitor production has been identified. Therefore, 
acquiring more knowledge on BICC1 binding partners and targets will be fundamental to understand its 
function in endocrine progenitor production. These studies may be relevant for the pathogeneicty of 
monogeneic diabetes as much as that of multifactorial type II diabetes. As BICC1 muations are implicated in 
kidney dysplasia, it might be an important gene to screen in cystic kidney patients with unknown genetic 
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defects, both for genetic counselling and for the diagnosis as well as early managment of possible diabetes or 
impaired glucose tolerance. 
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9 MATERIALS AND METHODS 
9.1.1 Association between BICC1 and pancreatic and/or renal dysplasia 
We have also observed a stromal reaction in Bicc1 KOs, which leads us to think that some patients with 
pancreatic dysplasia may bear Bicc1 mutations. One of this syndromes is the renal-hepatic-pancreatic 
dysplasia in which kidneys are cystic and the pancreas fibrotic (Vankalakunti et al., 2007). In a subset of 
cases, the genetic cause has been identified. Mutations have been found in NEK8 and, for the Ivemark 
syndrome, a subtype of the renal-hepatic-pancreatic dysplasia, in NPHP3 (Bergmann et al., 2008; 
Fiskerstrand et al., 2010; Frank et al., 2013). Situs inversus totalis with cystic dysplasia of kidneys and 
pancreas, another autosomal recessive disease, is even more similar to Bicc1 KO mice (Balci et al., 1999). 
Since no genetic cause has been identified for this rare syndrome, it would be interesting to look for BICC1 
mutations. These studies will be important for genetic counseling and patient management.  
9.2 Mice and genotyping 
Mice (Mus Musculus) were either housed at École Polytecnique Fédrérale de Lausanne, Switzerland, at the 
University of Copenhagen, Denmark or at Université Catholique de Louvain, Belgium. The Service de la 
consommation et des affaires vétérinaires, Vaud in Switzerland, the Commission d'Ethique 
d'Expérimentation Animale of the Université Catholique de Louvain in Belgium or the Dyreforsøgstilsynet 
in Denmark approved the mouse housing and experiments in the respective countries. The following mouse 
lines were used for this study: Bicc1tm1Bdc (Bicc1) (Maisonneuve et al., 2009), Tg(Ngn3-tRFP)AGB 
(Neurog3-RFP) (Kim et al, submitted), Gt(ROSA)26Sortm1(EYFP)Cos (Rosa26 YFP) (Srinivas et al., 
2001), Tg(Neurog3-cre)C1Able Ngn3-Cre (Neurog3-Cre) (Schonhoff, S. et al., 2004) and Onecut1 
(Jacquemin et al., 2000) B6.129P2-Axin2tm1Wbm/J ( Axin2-LacZ) (Lustig et al., 2002). Genotyping primers 
and conditions are listed in Table 9. 
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Table 9: Primer sequences and their annealing temperature. 
Target Forward primer Reverse primer Annealing temperature 
Reference 
Bicc1 locus WT allele CCCAACACGGCATCTTTAGTC 
GCACGGAAGCAGGGTTAT
GTC 58 
(Maisonne
uve et al., 
2009) Bicc1 locus KO allele CAGGGTCGCTCGGTGTTC 
GCACGGAAGCAGGGTTAT
GTC 
Neurog3-RFP locus AAGCCTTCATCAACCACACC 
GCGGGTTTCTTGGATCTGT
A 60 
 
Rosa26 YFP locus AAAGTCGCTCTGAGTTGTTAT 
GCGAAGAGTTTGTCCTCAA
CC 
50 (Soriano, 1999) Rosa26 YFP locus 
recombined 
AAAGTCGCTCTGAGTTG
TTAT 
GGAGCGGGAGAAATGGAT
ATG 
Neurog3 Cre locus TGCCACGACCAAGTGACAGC 
CCAGGTTACGGATATAGTT
CATG 58 
 
Axin2 locus WT allele AGTCCATCTTCATTCCGCCTAGC 
TGGTAATGCTGCAGTGGCT
TG 
60 
(Yu et al., 
2005) 
Axin2 locus LacZ 
allele 
AGTCCATCTTCATTCCG
CCTAGC 
AAGCTGCGTCGGATACTTG
AGA 
Hprt1mRNA GGCCAGACTTTGTTGGATTTG 
TGCGCTCATCTTAGGCTTT
GT 59.5 
 
Bicc1 mRNA CCTAGGCAAATACACGGATGTCT 
TGTGAGGGTGAGGAATGT
CTGA 60 
 
Neurog3 mRNA TGGCCCATAGATGATGTTCG 
AGAAGGCAGATCACCTTC
GTG 60 
 
Hes1 mRNA ATAGCTCCCGGCATTCCAAG 
TGTTGGGGAAATACCCGC
C 59 
 
Dll1 mRNA TCAATGGAGGACGATGTTCA 
ACCGGCACAGGTAAGAGT
TG 60 
 
Onecut1 mRNA ACCCTTCACCAATGACTCCTATG 
ATGATGACTGCAGCAAAT
CGC 60 
 
Tcf7 mRNA GCTGCCATCAACCAGATCCT 
GCTGCCATCAACCAGATCC
T 59 
 
Axin2 mRNA GGCAGTGATGGAGGAAAATG 
TGGGTGAGAGTTTGCACTT
G 60 
 
 
9.3 Specimen preparation 
Guts, pancreas or dorsal pancreatic buds were dissected from mouse embryos at different stages or 
postnatally in phosphate buffer saline (PBS) ( 1.8 mM KH2PO4, 10 mM Na2HPO4, 137 mM NaCl, 2.7 mM 
KCl pH7.4). For embryonic tissue, midday after a vaginal plug was seen was considered as E0.5. Organs 
were either snap frozen or fixed. In the latter case, organs were fixed in 4% paraformaldehyde in PBS (4% 
PFA) for 30 minutes at room temperature or overnight at 4°C. Specimens were then washed in PBS, 
equilibrated in 0.12M phosphate buffer 15% sucrose overnight at 4°C. They were then soaked in 0.12M 
phosphate buffer 15% sucrose 7.5% gelatin warmed at 37°C. Afterward, organs were included in a gelatin 
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bloc and solidified at 4 degrees. Blocs were frozen in isopentane cooled down at -65°C by an ethanol-dry ice 
mix. Blocs were kept at -80°C. 7 µm thick cryostat sections were generally collected. If guts were stained 
with 3-12-beta-galactosidase staining (X-Gal staining), 10 µm thick cryostat sections were collected. In the 
case of cilia quantification on E18.5 pancreas, 15 µm thick sections were collected. For cell number 
quantification, systematic uniform random sampled sections (SUR sections) were collected every 5, 6, 10 
sections for E12.5, E14.5, and E18.5/P0 respectively.  
9.4 LacZ staining 
Guts were dissected and fixed with 4% PFA for 10 minutes at room temperature. They were washed 3 times 
5 minutes with X-Gal buffer (5 mM EGTA, 2 mM MgCl2, 0.02% NP40, 0.01% Deoxycholate in PBS). They 
were then stained with X-Gal staining solution (5 mM C6FeK3N6, 5 mM C6FeK4N63H2O, 0.05% X-Gal) for 5 
hours 45 minutes at 37°C. Afterward they were washed 3 times 5 minutes in PBS, post-fixed 30 minutes at 
room temperature or overnight at 4 degrees and, processed normally for bloc embedding. 
9.5 Histology, immunofluorescence, and TUNEL assay 
Haematoxylin eosin staining was performed on cryosections. In case of immunofluorescence staining, 
cryosections were dried, rehydrated in 0.1% triton X-100 in tris buffer (50 mM Tris pH 7.5, 150 mM NaCl, 
0.1% triton X-100) (TBST), permeabilized with 0.25% triton X-100 in tris buffer, blocked with 10% donkey 
serum (Sigma D9663) in TBST (blocking buffer) for 30 minutes to 4 hours and incubated overnight at 4°C 
with primary antibodies diluted in blocking buffer. The next day, sections were washed in TBST and 
incubated with secondary antibodies with DAPI or Draq5 as a nuclear counterstaining diluted in blocking 
buffer for 45 minutes at room temperature. They were subsequently washed in TBST and slides were 
mounted with a glass coverslip and 50% glycerol in PBS. They were sealed with nail polish. In case of 
biotin-streptavidin amplification, sections were incubated with Streptavidin Biotin blocking solution (Vector 
Laboratories, SP-2002) prior to primary antibody incubation following the manufacturer’s protocol. After 
secondary antibody incubation and washes, slides were incubated with streptavidin-conjugated fluorophore 
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and DAPI diluted in blocking buffer. Slides were then washed in TBST and mounted. Antibodies and the 
dilution used in this study are listed in Table 10. TUNEL assay was performed with the ApopTag® 
Fluorescein Direct In Situ Apoptosis Detection Kit (Millipore, S7160). Cryosections were post-fixed 10 
minutes in 1% PFA in PBS and permeabilized with 0.5% triton X-100 in PBS on ice. TUNEL assays were 
then carried out in accordance of the manufacturer’s protocol followed by standard immunofluorescence 
staining, as described above. 
Table 10: Antibodies, nuclear dyes and their dilution 
Antibody Company Catalog 
number Dilution 
anti-Ac TUB Sigma T6793 1/500 
anti-ACTA2 Sigma A5228 1/400 
anti-Active CASP3 Cell Signaling Technology 9664 1/500 
Anti-ADCY6* Protein Tech 14616-1-AP 1/500 
anti-AMY1 Merk Millipore 171534 1/400 
anti-aPKC Santa Cruz sc-216 1/500 
anti-BICC1 Sigma HPA045212 1/50 
anti-chick Al488 InVitrogen A-11039 1/1000 
anti-EMR1 Serotec MCA497 1/500 
anti-FOXA2* Abcam ab40874 1/5000 
anti-GFP Abcam AB13970 1/1000 
anti-Ghrelin Santa Cruz sc-10368 1/800 
anti-goat Al488 Life Technologies A11055 1/1000 
anti-goat Al568 Life Technologies A11057 1/1000 
anti-goat biotin JIRE 705-065-1470 1/400 
anti-goatAl488 Molecular Probes A-11055 1/800 
anti-guinea pig 
Al488 Life Technologies A11073 1/2500 
anti-guinea pig 
Al568 Life Technologies A11075 1/800 
anti-guinea pig 
Al568 Molecular Probes A11075 1/600 
anti-guinea pig biotin JIRE 706-065-1480 1/400 
anti-HES1*  Santa Cruz sc-25392X 1/2000 
anti-HNF1B Santa Cruz sc-7411 1/50 
anti-HNF1B* Santa Cruz sc-22840 1/200 
anti-ONECUT1 Santa Cruz sc-13050 1/250 
anti-ONECUT1* Santa Cruz sc-13050 1/200 
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anti-INS Dako A0564 1/50 or 1/100 
anti-mouse Al568 Life Technologies A10037 1/1000 or 1/2000 
anti-mouse Al647 JIRE 715-605-1500 1/2000 
anti-mouse biotin JIRE 715-065-150 1/800 
anti-myc InVitrogen 13-2500 1/200 
anti-PHH3 Merk Millipore 06-570 1/1000 
anti-PDX1 Beta Cell Biology Consortium ab2027 1/1000 
anti-PDX1* Beta Cell Biology Consortium ab2027 1/2000 
anti-PKD2 Santa Cruz sc-2549 1/500 
anti-PKD2* Santa Cruz sc-2549 1/1000 
Anti-PKIA Santa Cruz sc-1943 1/200 
anti-PP peninsula lab (Bachem) T-4088 1/400 
anti-PTPRC Becton Dickinson 550539 1/200 
anti-rabbit Al488 JIRE 711-545-1520 1/200 
anti-rabbit Al568 Life Technologies A10042 1/500 
anti-rabbit Al647 JIRE 711-605-1520 1/600 
anti-rabbit HRP JIRE 111-035-003 1/200 
anti-Rabbit HRP* Dako P0048 1/2000 
anti-Rat HRP* JIRE 712-035-153 1/10000 
anti-ratAl488 Life Technologies A10042 1/600 
anti-SOX9 Millipore AB5535 1/500 
anti-SOX9* Millipore AB5535 1/2000 
anti-STS Dako A0556 1/800 
anti-TUB Abcam sb6160 1/10000 
DAPI Sigma D9542-1MG 1/10 000 
DBA lectin Vector B1035 1/500 or 1/800 
DBA rhodamin Vector RL-1032 1/500 
draq5 Bionordika 4084 1/500 
goat anti-CPA1 R&D AF2765 1/500 
goat anti-NEUROG3 Beta Cell Biology Consortium AB2774 1/1000 
guinea pig anti-GCG Linco 4031-01F 1/400 or 1/800 
mouse anti-GCG Sigma G2654 1/2000 
mouse anti-MKI67 novocastra laboratories NCL-L-Ki67-MM1 1/500 
rabbit anti-CPA1 ANAWA 1810-006 1/800 
rabbit anti-MKI67 Abcam AB16667 1/100 
rabbit anti-
NEUROG3 
Beta Cell Biology 
Consortium 
AB2011 
(2369B) 1/500 
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Streptavidin Al488 Molecular Probes S-11223 1/800 
Streptavidin Al647 JIRE 016-600-0840 1/1000 
* Antibodies used for western blot 
9.6 Images and image analyses 
A Leica SP8 confocal, a Leica DM5500 upright wide-field microscope, and a 3DHISTECH panoramic MIDI 
slide scanner were used for imaging. 
Cell number quantifications were performed on pictures from a Leica DM5500 upright wide-field 
microscope, and a 3DHISTECH panoramic MIDI slide scanner. Assuming a similar cell size distribution in 
WT and Bicc1 KO, quantification was obtained by counting stained positive-cell profiles harboring a nucleus 
either manually or automatically with home-made Macros in Fiji software (Schindelin et al., 2012) on 
immunofluorescence-stained SUR sections. For E12.5 and E14.5 pancreata, cell profiles were counted on all 
the sampled sections or every 4th section (progenitor proliferation). For E18.5 pancreata, quantifications were 
performed on every section (beta cells, automated quantification), every other section (other endocrine cell 
quantification) or every 8th sections (ductal proliferation). P0 quantification was performed every 4th section 
manually (ductal quantification) or automatically (lineage tracing and number of DAPI nucleus). Numbers 
per samples were then multiplied to get total cell profile numbers for all stained SUR sections except for P0 
data. For cilia quantification, areas of 3801 µm2 of immunostained 15µm-thick OCT sections of E18.5 
pancreata were scanned by confocal microscopy. For WT animals (n=4), 4 main or interlobular ducts and 4 
intercalated ducts were imaged while cystic areas were imaged instead of main or interlobular ducts in the 
case of KO animals (n=4). The number of cilia were quantified on 3D-reconstructed images and normalized 
to the total number of DBA lectin+ cells present in the field. 
9.7 Western blot 
E15.5 pancreata were lysed in Laemmli buffer and sonicated (Bioruptor® Plus, Diagenode; intensity: high, 
[30 seconds ON-30 seconds OFF] x 2). Protein size separation on NuPage gel (Life Technologies, Novex, 
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NP0321) was achieved by voltage constant electrophoresis (Life Technologies, Novex, XCell Surelock™) in 
MES running buffer (Life Technologies, NP0002-02). Proteins were then wet-transferred on a nitrocellulose 
membrane (GE Heathlcare Life sciences, RPN303D; Biorad, Minipotrein tetrasystem) in transfer buffer 
(3.02 g/l Trizma Base, 14.4 g/l Glycine, 20% Methanol) using an intensity constant electric field of 400 mA 
for one hour and a half. Proteins on the gel were visualized by Coomassie Blue staining (Life Technologies, 
LC6065). After washing in Tris buffer saline Tween20 (2.42 g/l Trizma base, 8 g/l NaCl, 0.1% Tween20 
pH7.6) (TBSTw), the membrane was blocked in 10% skimmed milk in TBSTw for 1 hour. It was incubated 
with a primary antibody diluted in 5% BSA in TBSTw overnight at 4°C. After washes with TBSTw, the 
membrane was incubated with HRP-conjugated secondary antibody diluted in 5% skimmed milk in TBSTw 
for 1 hour. It was then washed in TBSTw. ECL kit (GE Healthcare, RPN2232) was used for detection with 
Biorad Gel Doc™ following the manufacturer´s protocol. The antibody on the membrane could be stripped 
with stripping buffer (72.5 mM Tris pH 7.5, 2% SDS, 125 mM β-mercaptoethanol) at 65°C for 20 minutes. 
The membrane was then washed in TBSTw and used for another immunoblot. Antibodies and the dilution 
used in this study are listed in Table 10. For comparison, the protein of interest was normalized to alpha 
tubulin (TUB) level. Results are relative to WT mean. 
9.8 RNA extraction and Q-PCR 
RNA was extracted from E10.5, E11.5, E12.5 and E14.5 dorsal buds using RNeasy Mini Kit (QIAGEN, 
74104) including a DNase treatment with RNase-free DNase (QIAGEN, Set 79254) following the 
manufacturer´s instructions. 100 ng to 500 ng of RNA was then reverse-transcribed into cDNA with 
SuperScript III Reverse Transcriptase (Life Technology, 18080-044) following the manufacturer’s protocol. 
Q-PCRs were performed on 1/5 to 1/50 of the synthetized cDNA on the StepOnePlus™ Real-Time PCR 
system (Life Technology) using Power SYBR® Green as dye (Applied Biosystems, 4368577). 
Quantifications were normalized against standard curves of the respective genes. For comparison, the gene 
of interest was normalized to the housekeeping gene Hprt1. Results are indicated as percentage of WT mean. 
Primer sequences and annealing temperatures are listed in Table 9. 
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9.9 RNA and microRNA sequencing 
RNA was extracted from E13.5 dorsal buds using the RNeasy Plus Micro Kit (QIAGEN, 74034) following 
the manufacturer´s protocol allowing small RNA elution. For RNA sequencing, three samples of the same 
genotype were then pooled together. TruSeq RNA libraries were synthetized from 500 ng of three WT and 
three Bicc1 KO pools. Libraries were sequenced on an Illumina HiSeq 2500 platform (3 replicates per 
condition, 100nt single-end reads) at the genomic facility, University of Lausanne. Reads were mapped to 
the mm9 mouse genome with bowtie v0.12.7 (480M reads mapped in total) (Langmead et al., 2009). The 
data were first analyzed using the DESeq method by Solenne Carat at the Bioinformatics and Biostatistics 
Core Facility at Ecole Polytechnique Fédérale de Lausanne (Anders and Huber, 2010). The data were then 
reanalyzed. They were filtered to eliminate genes which had read per kilobase per million (rpkm) below 0.01 
and analyzed using NIA array analysis tool (http://lgsun.grc.nia.nih.gov/ANOVA/). Differences with FDR 
below 0.05 were considered as statistically significant. RNA sequencing data are available on NCBI Gene 
Expression Omnibus (accession number: GSE58833). 
For the microRNA sequencing, all E13.5 dorsal pancreatic bud RNA samples of the same genotype 
remaining after the synthesis of the TruSeqRNA libraries were pooled. TruSeq Small RNA libraries were 
then synthetized from 2.4 µg of RNA of WT and Bicc1 KO. Libraries were sequenced on an Illumina HiSeq 
2500 platform (1 replicate per condition, 100nt single-end reads) at the genomic facility, University of 
Lausanne. The sequences were mapped to the mm9 mouse genome using Eland_v2e. The data were than 
analyzed using DESeq method by Solenne Carat at Ecole Polytechnique Fédérale de Lausanne (Anders and 
Huber, 2010). 
9.10 Human BICC1 mutation 
The Group of Pr. Bingham, Pr. Ellard and Pr. Hattersley sequenced the exons of BICC1 in 149 patients 
presenting cystic kidney disease with unknown genetic cause. 5 new variants of BICC1 were identified. 
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Yvan Pfister cloned the variants as well as WT BICC1 and BICC1Q87Stop into the pcDNA3.0 plasmid. 
Two HA epitopes were also inserted in BICC1 sequence. 
9.11 Luciferase assay 
HEK293T cells were plated in 48-well plates at a density of 80 000 cells/cm2 and grown in DMEM medium 
with Glutamax (Life technologies, 31966021) supplemented with 10% fetal calf serum (Life Technologies, 
10270-106). After one day, they were transfected using TransfastTM (Promega, E2431) according to the 
manufacturer´s protocol except that the transfection medium was replaced by normal culture medium after 4 
hours. The transfection mixes contained 252.5 ng of DNA: 50ng of pMegaTOPflash (gift of Dr. Fuerer), 2.5 
ng of pGL3::RenillaTK (provided by the luciferase assay kit) combined with 50 ng of DVL2 (gift of Pr. 
Constam) and 150ng of pcDNA3.0 containing WT BICC1 or one of the BICC1 variants. In case of the 
negative control (no induction), 200ng of pcDNA3.0 plasmid were added and in the case of DVL2 alone, 
150ng of pcDNA3.0 replaced the BICC1 plasmid. After two days, luciferase assays were performed using 
the Dual-Luciferase® Reporter Assay System (Promega, E1910) according to the manufacturer´s protocols. 
Every transfection was done in 5 replicates and the experiment was repeated once. 
9.12 Statistical analysis 
Statistical analyses were performed with GraphPad Prim4 and 6 softwares and Excel. Results were indicated 
by the mean ± standard deviation and graphically represented by the mean + standard deviation except in 
Fig. 30, 31, 32 and 34C, Fig. 30 and 32 show histograms. Fig. 31 shows scattered plots and Fig. 34C shows a 
dot plot with the mean. Differences assessed with a t test (assuming normal distribution) were considered as 
statistically significant when the p-value was below 0.05.  
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10 APPENDIX 
10.1 Tables 
Table 11: List of the gene symbol and their official name cited in this work. 
Gene symbol Official name 
1700023F06-
Rik RIKEN cDNA 1700023F06 gene 
2010107G23-
Rik RIKEN cDNA 2010107G23 gene 
4930533K18-
Rik RIKEN cDNA 4930533K18 gene 
Abcc8 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 8 
Acta2 actin, alpha 2, smooth muscle, aorta 
Actb actin beta 
Acvrl1 activin A receptor type II-like 1 
Adcy5 adenylate cyclase 5 
Adcy6 adenylate cyclase6 
Ago1 argonaute RISC catalytic subunit 1 
Ago2 argonaute RISC catalytic subunit 2 
Akt thymoma viral proto-oncogene 1 
Aldoa aldolase A, fructose-bisphosphate 
Alms1 Alstrom syndrome 1 
Amy1 amylase 1, salivary 
Anxa9 annexin A9 
Apc adenomatosis polyposis coli 
Aqp2 aquaporin 2 
Arx aristaless related homeobox 
Avpr2 arginine vasopressin receptor 2 
Axin2 axin2 
Bc100530 cDNA sequence BC100530 
Bcc-1 protein BCC-1 
BicC Bicaudal C 
Bicc1 bicaudal C homolog 1 (Drosophila) 
Blk B lymphoid kinase 
bpk Balb/c Polycystic Kidneys 
Braf Braf transforming gene 
Btc 
betacellulin, epidermal growth factor 
family member 
Calcr calcitonin receptor 
Gene symbol Official name 
Casp3 caspase 3 
Cdh1 cadherin 1 
Cel carboxyl ester lipase 
Celsr1 
cadherin, EGF LAG seven-pass G-type 
receptor 3 (flamingo homolog, 
Drosophila) 
Celsr2 
cadherin, EGF LAG seven-pass G-type 
receptor 2 (flamingo homolog, 
Drosophila) 
Celsr3 
cadherin, EGF LAG seven-pass G-type 
receptor 3 (flamingo homolog, 
Drosophila) 
Cer1 cerberus 1 homolog (Xenopus laevis) 
Cftr 
cystic fibrosis transmembrane 
conductance regulator 
Cma1 chymase 1, mast cell 
Cpa1 carboxypeptidase A1, pancreatic 
cpk congenital polycystic kidney 
Crp C-reactive protein, pentraxin-related 
Csf1 
colony stimulating factor 1 
(macrophage) 
Ctnnb1 
catenin (cadherin associated protein), 
beta 1 
Cys1 cystin 1 
Dgcr8 
DiGeorge syndrome critical region 
gene 8 
Dicer1 dicer 1, ribonuclease type III 
Dll1 delta-like 1 (Drosophila) 
Dll4 delta-like 4 (Drosophila) 
Drosha drosha, ribonuclease type III 
Dvl2 
dishevelled 2, dsh homolog 
(Drosophila) 
Eef1a1 
eukaryotic translation elongation factor 
1 alpha 1 
Egfr epidermal growth factor receptor 
Eif2ak3 
eukaryotic translation initiation factor 2 
alpha kinase 3 
Emr1 
EGF-like module containing, mucin-
like, hormone receptor-like sequence 1 
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Gene symbol Official name 
Eno1 enolase 1, alpha non-neuron 
Erbb2 
v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2, 
neuro/glioblastoma derived oncogene 
homolog (avian) 
Erbb3 
v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 3 (avian) 
Erbb4 
v-erb-a erythroblastic leukemia viral 
oncogene homolog 4 (avian) 
Fam162b 
family with sequence similarity 162, 
member B 
fbf-1 Protein FBF-1 
fem-3 Protein FEM-3 
Fgf10 fibroblast growth factor 10 
Fgf4 fibroblast growth factor 4 
Fgfr2 fibroblast growth factor receptor 2 
Fgfr4 fibroblast growth factor receptor 4 
Foxa1 forkhead box A1 
Foxa2 forkhead box A2 
Foxp3 forkhead box P3 
Fzd2 frizzled homolog 2 (Drosophila) 
Fzd3 frizzled homolog 3 (Drosophila) 
Fzd7 frizzled homolog 7 (Drosophila) 
Fzd8 frizzled homolog 8 (Drosophila) 
Gata4 GATA binding protein 4 
Gata6 GATA binding protein 6 
Gcg glucagon 
Gck glucokinase 
Gdf11 growth differentiation factor 11 
Ghr ghrelin 
Gld2 Protein GLD-2 
Gld3 Protein GLD-3 
Glis3 GLIS family zinc finger 3 
Gm13305 predicted gene 13305 
Gm15745 predicted gene 15745 
Gm2002 predicted gene 2002 
Gm5483 predicted gene 5483 
Grk gurken 
Gsk3b glycogen synthase kinase 3 beta 
H19 
H19, imprinted maternally expressed 
transcript 
Hdc histidine decarboxylase 
Hes1 
hairy and enhancer of split 1 
(Drosophila) 
Gene symbol Official name 
Hnf1a HNF1 homeobox A 
Hnf1b HNF1 homeobox B 
Hnf4a hepatic nuclear factor 4, alpha 
Hprt 
hypoxanthine guanine phosphoribosyl 
transferase 
Ift88 intraflagellar transport 88 
Il11ra2 interleukin 11 receptor, alpha chain 2 
Ins insulin 
Insm1 insulinoma-associated 1 
Inv inversin 
Isl1 
ISL1 transcription factor, 
LIM/homeodomain 
Itpr1 inositol 1,4,5-trisphosphate receptor 1 
Jag1 jagged1 
Jag2 jagged 2 
jcpk 
juvenile congenital polycystic kidney 
disease 
Kcnj11 
potassium inwardly rectifying channel, 
subfamily J, member 11 
Kif3a kinesin family member 3A 
Klf11 Kruppel-like factor 11 
lacZ Beta-D-galactoxidase (E. coli) 
Lef1 lymphoid enhancer binding factor 1 
Lrp5 
low density lipoprotein receptor-related 
protein 5 
Lrp6 
low density lipoprotein receptor-related 
protein 6 
Maml1 mastermind like 1 (Drosophila) 
Map2k7  
mitogen-activated protein kinase kinase 
7 
Mapk1 mitogen-activated protein kinase 1 
Mapk8 mitogen-activated protein kinase 8 
Mapk8 mitogen-activated protein kinase 8 
Mcpt4 mast cell protease 4 
Mib1 mindbomb homolog 1 (Drosophila) 
Mki67 
antigen identified by monoclonal 
antibody Ki 67 
Mnx1 
motor neuron and pancreas homeobox 
1 
mt-Co1 
mitochondrially encoded cytochrome c 
oxidase I 
mt-Cytb mitochondrially encoded cytochrome b 
MtOR 
mechanistic target of rapamycin 
(serine/threonine kinase) 
Muc1 mucin 1, transmembrane 
Myod1 myogenic differentiation 1 
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Gene symbol Official name 
Myt1 myelin transcription factor 1 
Nek8 
NIMA (never in mitosis gene a)-related 
expressed kinase 8 
Neurod1 neurogenic differentiation 1 
Neurog3 neurogenin 3 
Ngp neutrophilic granule protein 
Nkx2.2 NK2 homeobox 2 
Nkx2.5 NK2 homeobox 5 
Nkx6.1 NK6 homeobox 1 
Nkx6.2 NK6 homeobox 2 
Noth1 notch 1 
Noth2 notch 2 
Noth3 notch 3 
Noth4 notch 4 
Nphp3 nephronophthisis 3 (adolescent) 
Olfm4 olfactomedin 4 
Onecut1 one cut domain, family member 1 
Onecut2 one cut domain, family member 2 
orb oo18 RNA-binding protein 
orpk Oak Ridge Polycystic Kidney 
osk oskar 
Pah phenylalanine hydroxylase 
Pax4 paired box 4 
Pax6 paired box 6 
pcy polycystic 
Pde1a 
phosphodiesterase 1A, calmodulin-
dependent 
Pde1b 
phosphodiesterase 1B, Ca2+-
calmodulin dependent 
Pde1c phosphodiesterase 1C 
Pdx1 pancreatic and duodenal homeobox 1 
Pfkl phosphofructokinase, liver, B-type 
Pkd1 polycystic kidney disease 1 homolog 
Pkd2 polycystic kidney disease 2 
Pkhd1 polycystic kidney and hepatic disease 1 
Ppy pancreatic polypeptide 
Prkaa1 
protein kinase, AMP-activated, alpha 1 
catalytic subunit 
Ptf1a 
pancreas specific transcription factor, 
1a 
Ptprc 
protein tyrosine phosphatase, receptor 
type, C 
Rbpj 
recombination signal binding protein 
for immunoglobulin kappa J region 
Gene symbol Official name 
Rbpjl 
recombination signal binding protein 
for immunoglobulin kappa J region-like 
Rfx6 regulatory factor X, 6 
Robo2 roundabout homolog 2 (Drosophila) 
rol-3 Protein ROL-3 
Rpl30-ps5 ribosomal protein L30, pseudogene 5 
Rps3 ribosomal protein S3 
S100a8 
S100 calcium binding protein A8 
(calgranulin A) 
S100a9 
S100 calcium binding protein A9 
(calgranulin A) 
Shh sonic hedgehog 
Six2 sine oculis-related homeobox 2 
Slc16a3 
solute carrier family 16 
(monocarboxylic acid transporters), 
member 3 
Slc19a2 
solute carrier family 19 (thiamine 
transporter), member 2 
Slc2a1 
solute carrier family 2 (facilitated 
glucose transporter), member 1 
Slc5a9 
solute carrier family 5 (sodium/glucose 
cotransporter), member 9 
Smad2  SMAD family member 2 
Sox9 SRY (sex determining region Y)-box 9 
Sst somatostatin 
Sstr2 somatostatin receptor 2 
Stard9 START domain containing 9 
Tcf7 transcription factor 7, T cell specific 
tdgf1.3 
teratocarcinoma-derived growth factor 
1 
Tgfa transforming growth factor alpha 
Tgfb trasnforming growth factor beta 
Tgfbr1 
transforming growth factor, beta 
receptor I 
Tgfbr2 
transforming growth factor, beta 
receptor II 
Tnfrsf9 
tumor necrosis factor receptor 
superfamily, member 9 
Tnrc6a trinucleotide repeat containing 6a 
tral trailer hitch 
Tsc2 tuberous sclerosis 2 
Tub alpha tubulin 
Vhl von Hippel-Lindau tumor suppressor 
Wfs1 Wolfram syndrome 1 (wolframin) 
Wnt1 
wingless-type MMTV integration site 
family, member 1 
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Gene symbol Official name 
Wnt4 
wingless-type MMTV integration site 
family, member 4 
Wnt5a 
wingless-type MMTV integration site 
family, member 5a 
Wnt5b 
wingless-type MMTV integration site 
family, member 5b 
Gene symbol Official name 
Wnt7b 
wingless-type MMTV integration site 
family, member 7B 
Wnt9b 
wingless-type MMTV integration site 
family, member 9b 
Official name corresponds to mouse name with the exception of the genes in blue that are Caenorhabditis elegans genes 
and the red-color genes that are from Drosophila melanoblaster  
Table 12: Average, standard deviation, number of samples (n) and t test p value from the different figures. 
      Average 
Standard 
deviation n 
T test p 
value 
Fig. 9 Q-PCR quantification           
  
Bicc1/Hprt1 (% of E12.5 mean) 
E10.5 55 7 3 
E10.5 vs 
E11.5: 
0.20 
  E11.5 64 5 3 
E11.5 vs 
E12.5: 
0.0003 
  E12.5 100 3 3 
E10.5 vs 
E12.5: 
0.0008 
Fig. 12 Ductal cell number at P0           
  
DBA lectin
+
 cell number 
WT 5151 742 4 0.0003 
  Bicc1 KO 10451 1188 4 
 Fig. 13 
Pancreatic progenitor proliferation at 
E14.5           
  
PHH3
+
PDX1
+
cells/PDX1
+
cells (% of WT 
mean) 
WT 100 15 4 
0.90 
  
Bicc1 KO 101 14 3 
Ductal proliferation at E18.5           
  
MKI67
+
DBA lectin
+ 
cells/DBA lectin
+ 
cells 
(% of WT mean) 
WT 100 23 4 
0.016 
  Bicc1 KO 147 16 4 
  Fig. 15 Cilia at E18.5           
  Intercalated ducts           
  Ac TUB
+
DBAlectin
+
cells / DBAlectin
+
cells 
(%) 
WT 65 14 4 
0.75 
  Bicc1 KO 69 18 4 
  
Main/inter-/intralobular ducts vs cystic 
ducts           
  
Ac TUB
+
DBAlectin
+
cells/DBAlectin
+
cells 
(%) 
WT 64 5 4 
0.12 
  Bicc1 KO 55 8 4 
Fig. 16 Endocrine cells in the duct at P0           
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Hormones
+
DBAlectin
+
 cell number 
WT 8 4 4 
0.0086 
  Bicc1 KO 113 28 4 
Fig. 17 Endocrine cells at E12.5           
  
Alpha GCG
+
 cell number 
WT 136 11 4 
0.72 
  Bicc1 KO 127 48 4 
Endocrine cells at E14.5           
  
Beta INS
+
 cell number 
WT 679 189 4 
0.74 
  Bicc1 KO 725 185 4 
  
Alpha GCG
+
 cell number 
WT 824 228 3 
0.62 
  Bicc1 KO 930 280 4 
  Endocrine cells at E18.5           
  
Beta INS
+
 cell number 
WT 14515 1624 4 
0.0008 
  Bicc1 KO 6964 1833 4 
  
Alpha GCG
+
 cell number 
WT 3807 115 3 
0.0024 
  Bicc1 KO 3047 206 4 
  
Delat STS
+
 cell number 
WT 1567 223 3 
0.0029 
  Bicc1 KO 726 185 4 
  
PP PP
+
 cell number 
WT 1022 221 3 
0.012 
  Bicc1 KO 560 91 4 
  
Epsilon GRH
+
 cell number 
WT 449 102 3 
0.011 
  Bicc1 KO 208 59 4 
Fig. 18 Beta cell proliferation at E18.5           
  
MKI67
+
INS
+ 
cells/INS
+ 
cells (%) 
WT 11.1 3.2 4 
0.95   Bicc1 KO 11 2.8 4 
Fig. 19 Pancreatic progenitor number at E12.5           
 
PDX1
+
 cell number 
WT 2237 341 4 
0.0058  Bicc1 KO 3767 648 4 
  Pancreatic progenitor number at E14.5           
  
PDX1
+
 cell number 
WT 34600 6690 4 
0.95   Bicc1 KO 34271 8532 4 
 Pancreatic size at P0           
 
DAPI nucleus number 
WT 85612 10986 4 
0.24  Bicc1 KO 93573 5126 4 
Fig. 20 Endocrine  progenitor number at E12.5           
NEUROG3
+
 cell number 
WT 26 6 4 
0.015 Bicc1 KO 57 18 4 
Relative endocrine  progenitor number 
at E12.5           
NEUROG3
+
 cell number/PDX1
+
 cell 
number (%) WT 1.1 0.16 4 0.043 
  Bicc1 KO 1.5 0.24 4  
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Q-PCR quantification Neurog3 at E12.5           
Neurog3/Hprt1 (% of WT mean) 
WT 100 66 6 
0.27 
Bicc1 KO 56 57 5 
Endocrine progenitor E14.5           
NEUROG3
+
 cell number 
WT 3032 388 4 0.0043 
Bicc1 KO 1989 262 4  
Relative endocrine  progenitor number 
at E14.5       
NEUROG3
+
 cell number/PDX1
+
 cell 
number (%) 
WT 8.9 0.90 4 
0.011 Bicc1 KO 6.0 1.29 4 
Q-PCR quantification Neurog3 at E14.5           
Neurog3/Hprt1 (% of WT mean) 
WT 100 8 4 0.012 
Bicc1 KO 72 14 5  
 Fig. 22 Lineage tracing with Neurog3-RFP           
  
NEUROG3
+
RFP
-
 cell number 
WT 1820 308 4 
0.029   Bicc1 KO 1281 216 4 
  
NEUROG3
+
RFP
+
 cell number 
WT 1212 174 4 
0.0021   Bicc1 KO 708 88 4 
  
NEUROG3
-
Hormones
-
RFP
+
 cell number 
WT 3136 562 4 
0.08   Bicc1 KO 2482 277 4 
  
NEUROG3
-
Hormones
+
RFP
+
 cell number 
WT 1001 253 4 
0.16   Bicc1 KO 751 188 4 
 
Lineage tracing with Neurog3-RFP: 
proportion to total RFP cells           
 
NEUROG3
+
RFP
+
 cells/RFP
+ 
cells (%) 
WT 23 3 4 0.07 
 Bicc1 KO 18 3 4  
 NEUROG3
-
Hormones
-
RFP
+
 cells/RFP
+
 cells 
(%) 
WT 59 1 4 0.0078 
 Bicc1 KO 63 2 4  
 
Hormones
+
RFP
+
 cells/RFP
+
 cells (%) 
WT 18 2 4 0.80 
 Bicc1 KO 19 3 4  
Fig. 23 Characterization of Neurog3-RFP           
 NEUROG3
+
RFP
-
 cells/NEUROG
+ 
cells (%) WT 60 4.5 4  
 NEUROG3
+
RFP
+
 cells/NEUROG
+ 
cells (%) WT 40 4.5 4  
 NEUROG3
+
RFP
+
 cells/RFP
+ 
cells (%) WT 23 3 4  
 
NEUROG3
-
Hormones
-
RFP
+
 cells/RFP
+
 cells 
(%) WT 59 1 4 
 
 Hormones
+
RFP
+
 cells/RFP
+
 cells (%) WT 18 2 4  
Fig. 24 Lineage tracing with Neurog3-Cre           
 YFP
+
 cell number WT 7539 1022 4 0.0046 
  Bicc1 KO 4364 1024 4  
 
Hormones
+ 
YFP
+
 cell number (endocrine 
cells) WT 3791 344 4 
0.0003 
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  Bicc1 KO 1740 444 4  
 CPA1
+
YFP
+
 cell number (acinar cells) WT 1268 440 4 0.49 
  Bicc1 KO 921 505 4  
 
DBA lectin
+ 
YFP
+
 cell number (ductal 
cells) WT 835 239 4 
0.78 
  Bicc1 KO 886 263 4  
Fig. 25 Western blot quantification           
  
SOX9/TUB (relative to WT mean) 
WT 1 0.31 4 
0.30 
  Bicc1 KO 1.25 0.31 4 
  
HES1/TUB (relative to WT mean) 
WT 1 0.08 4 
0.06 
  Bicc1 KO 0.73 0.23 4 
  
HFN1B/TUB (relative to WT mean) 
WT 1 0.05 4 
0.10 
  Bicc1 KO 1.11 0.10 4 
  
FOXA2/TUB (relative to WT mean) 
WT 1 0.05 4 
0.48 
  Bicc1 KO 0.92 0.20 4 
  
PDX1/TUB (relative to WT mean) 
WT 1 0.14 4 
0.37 
  Bicc1 KO 1.13 0.23 4 
  
ONECUT1/TUB (relative to WT mean) 
WT 1 0.18 7 
0.13 
  Bicc1 KO 0.81 0.27 8 
  Q-PCR quantification           
  
Hes1/Hprt1 (% of WT mean) 
WT 100 15 4 
0.45 
  Bicc1 KO 92 16 5 
  
Dll1/Hprt1 (% of WT mean) 
WT 100 19 4 
0.55 
  Bicc1 KO 92 18 5 
  
Onecut1/Hprt1 (% of WT mean) 
WT 100 8 4 
0.042 
  Bicc1 KO 134 26 5 
  
Bicc1/Hprt1 (% of WT mean) 
WT 100 20 4 
0.027 
  
Onecut1 
KO 61 6 3 
Fig. 26 Q-PCR quantification           
  
Tcf7/Hprt1 (% of WT mean) 
WT 100 22.71 4 
0.22 
  Bicc1 KO 80.97 20.01 5 
  
Axin2/Hprt1 (% of WT mean) 
WT 100 19.25 4 
0.16 
  Bicc1 KO 77.15 23.65 5 
Fig. 28 Western blot quantification           
  
PKD2/TUB (relative to WT mean) 
WT 1 0.13 8 
<0.0001 
  Bicc1 KO 0.45 0.12 8 
 Fig. 29 Immune cells           
  
PTPRC
+
 cells 
WT 84 10 4 
0.017 
  Bicc1 KO 175 55 4 
Fig. 30 Western blot quantification           
  ADCY6/TUB (relative to WT mean) WT 1 0.20 8 0.33 
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  Bicc1 KO 1.11 0.26 8 
  
PKIA/TUB (relative to WT mean) 
WT 1 0.28 7 
0.35 
  Bicc1 KO 1.12 0.21 8 
 Fig. 31 Luciferase assay quantification  
 
TopFlash assay normalized on Renilla 
luciferase chemiluminescence (% of 
DVL1) 
Negative 
control 2 1 6 
 
  DVL1 100 8 10  
  BICC1 73 11 10 
BICC1 vs 
DVL1, 
p<0.0001 
  
BICC1 
Q87Stop 109 11 10 
BICC1 vs 
BICC1 
Q87Stop, 
p<0.0001 
  
BICC1 
D54G 74 6 10 
BICC1 vs 
BICC1 
D54G, 
p=0.74 
  
BICC1 
V206M 78 6 10 
BICC1 vs 
BICC1 
V206M, 
p=0.27 
  
BICC1 
R800Q 78 8 10 
BICC1 vs 
BICC1 
R800Q, 
p=0.28 
  
BICC1 
G821E 73 8 10 
BICC1 vs 
BICC1 
G821E, 
p=0.92 
  T845K 76 11 10 
BICC1 vs 
BICC1 
T845K, 
p=0.58 
Table 13: Downregulated mRNA in E13.5 Bicc1 KO pancreas using DESeq 
Gene Symbol WT 
mean 
(rpkm) 
KO 
mean 
(rpkm) 
Fold 
change 
p value 
Gm2002 0.52 0.02 28.23 3.9E-19 
Gm1082 0.05 0.00 22.46 0.0003 
Fcnb 0.09 0.01 16.52 0.0015 
Stfa2 0.74 0.07 11.29 3.2E-08 
Camp 1.02 0.10 9.71 1.7E-09 
Prap1 0.51 0.06 8.83 0.0003 
Olfm4 1.66 0.20 8.45 2.2E-22 
Stfa3 0.96 0.12 7.96 4.5E-06 
Stfa1 2.39 0.30 7.88 5E-11 
Ngp 3.10 0.40 7.82 1.1E-19 
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Ifitm6 0.32 0.04 7.59 0.0039 
Il11ra2 0.43 0.06 7.51 4.9E-10 
BC100530 3.58 0.51 6.96 2.1E-16 
Xlr5c 0.07 0.01 6.82 0.0402 
Xlr5a 0.19 0.03 6.64 0.0002 
S100a8 8.19 1.28 6.40 1.3E-15 
Gm5483 1.46 0.23 6.30 1.2E-06 
Xlr5b 0.16 0.03 6.19 0.0013 
Stfa2l1 0.65 0.11 6.13 0.0009 
S100a9 13.09 2.16 6.05 8.8E-21 
Ltf 0.52 0.09 5.43 3.5E-09 
Gm15845 0.26 0.06 4.72 0.0437 
Bicc1 19.13 4.45 4.30 9.3E-47 
Lcn2 0.38 0.10 3.88 4.5E-05 
Gm13305 0.86 0.23 3.75 6E-08 
Mmp8 0.13 0.03 3.63 0.0255 
4930533K18-
Rik 
4.97 1.49 3.35 9.9E-08 
Pah 16.63 5.12 3.25 7.4E-21 
Tbx18 0.11 0.04 3.13 0.0208 
Anxa9 1.14 0.42 2.73 0.0004 
Chi3l1 0.29 0.12 2.53 0.0310 
Prodh2 0.77 0.34 2.25 0.0179 
Cer1 2.20 1.05 2.10 0.0092 
Adamts18 0.58 0.28 2.05 0.0215 
Adamts16 5.86 3.03 1.93 1.1E-06 
Calcr 16.85 8.79 1.92 0.0011 
Slc5a9 2.32 1.23 1.89 0.0011 
Ppp1r1b 2.54 1.34 1.89 0.0103 
Pkd2 10.61 5.64 1.88 2.5E-08 
Cmah 2.23 1.23 1.81 0.0004 
Pappa 1.05 0.63 1.68 0.0385 
Serpini2 20.50 13.05 1.57 0.0084 
2010107G23-
Rik 
30.91 20.29 1.52 0.0017 
Serpina6 381.90 251.75 1.52 6E-05 
Crp 23.87 15.79 1.51 0.0158 
Neurog3 60.02 39.99 1.50 0.0027 
Table 14: Upregulated mRNA in E13.5 Bicc1 KO pancreas using DESeq 
Gene Symbol WT 
mean 
(rpkm) 
KO 
mean 
(rpkm) 
Fold 
change 
p value 
Mcpt4 0.01 0.26 25.51 4E-07 
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Mcpt2 0.01 0.30 20.78 1.7E-07 
Six2 0.21 3.00 14.32 7.7E-34 
Gm10055 0.00 0.04 14.27 0.01173 
Myod1 0.10 0.70 7.23 4.3E-10 
Nkx2.5 0.07 0.50 7.02 2.1E-07 
Cma1 0.39 2.45 6.28 2E-12 
Gm12733 0.07 0.42 6.25 0.0039 
Tpsab1 0.02 0.09 5.19 0.0121 
Fam162b 0.22 1.08 4.82 0.0001 
Gm2214 0.16 0.70 4.49 0.0405 
Gm12798 0.15 0.68 4.44 0.0060 
Myh3 0.05 0.19 3.97 9E-05 
Myog 0.23 0.91 3.94 9.6E-05 
RP23-281E24.2 0.49 1.88 3.81 3.2E-10 
Trhde 0.02 0.08 3.43 0.0026 
3110047P20Rik 0.30 1.01 3.32 2.1E-07 
Rpl9-ps3 0.21 0.68 3.27 0.04387 
Hdc 0.11 0.34 3.25 4.2E-05 
3110047P20Rik 0.35 1.10 3.17 7E-08 
Rpl21-ps5 0.42 1.34 3.17 0.0243 
Actc1 0.60 1.90 3.15 5E-05 
Hoxa6 0.18 0.56 3.02 0.0183 
Tnfrsf9 0.10 0.28 2.94 0.0176 
Robo2 2.59 7.11 2.75 4.1E-12 
Lor 0.16 0.44 2.72 0.0366 
Hecw1 0.17 0.46 2.67 0.0004 
Kazald1 1.99 5.13 2.57 2.5E-05 
Cpa3 1.15 2.95 2.57 0.0002 
Gm13239 0.46 1.14 2.47 0.0215 
Frzb 0.83 2.04 2.45 0.0003 
Itga8 3.86 9.44 2.44 7.7E-13 
Bai2 0.23 0.55 2.40 0.0033 
Gm13155 0.52 1.26 2.40 0.0274 
Gm8178 0.52 1.26 2.40 0.0274 
CT030724.1 31.93 74.96 2.35 5.9E-07 
Frmpd4 0.11 0.25 2.34 0.0057 
Nkx3-2 0.98 2.29 2.33 0.0041 
Mme 0.88 2.01 2.27 0.0002 
Oit3 0.42 0.94 2.27 0.0276 
Gm10169 20.41 45.49 2.23 4.7E-05 
Slc16a3 0.91 2.03 2.23 0.0002 
Kcne3 0.94 2.08 2.22 0.0354 
E030013I19Rik 0.47 1.04 2.22 0.0215 
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Hoxa7 0.97 2.13 2.20 0.0023 
Fibin 1.44 3.11 2.16 0.0020 
Cyp26b1 1.57 3.36 2.13 0.0001 
CT025683.1 82.47 172.63 2.09 2.1E-07 
Htr7 0.77 1.60 2.09 0.0056 
Barx1 1.78 3.69 2.08 0.0192 
Gm13611 20.56 42.77 2.08 0.0003 
Rpl36-ps3 7.61 15.71 2.06 0.0215 
RP23-52O21.2 10.36 21.00 2.03 0.0112 
Fabp4 8.56 17.21 2.01 0.0025 
Pfkl 3.54 7.11 2.01 1.4E-05 
Gm16379 14.70 29.13 1.98 0.00155 
Ltbp4 2.43 4.80 1.98 3.3E-05 
AL928940.2 34.51 68.10 1.97 0.0145 
Rps8-ps1 8.61 16.88 1.96 0.0061 
Tlx1 2.43 4.75 1.95 0.0139 
Arhgef4 0.47 0.90 1.92 0.0430 
Tnc 0.81 1.54 1.90 0.0032 
Hoxb8 1.67 3.15 1.89 0.0183 
Xist 1.69 3.20 1.89 0.0002 
Rusc2 0.57 1.07 1.87 0.0221 
Gm5121 14.12 26.35 1.87 0.0062 
Chpf 3.32 6.18 1.86 0.0013 
Emilin1 10.41 19.28 1.85 4E-06 
Gm14303 70.11 127.09 1.81 0.0067 
Slc40a1 19.97 35.86 1.80 9.5E-06 
Ntm 20.34 35.74 1.76 0.0009 
BC005764 2.82 4.81 1.70 0.0417 
Rpl35 45.33 75.95 1.68 0.0009 
Lrp1 3.44 5.75 1.67 0.0001 
Gm12481 47.77 79.77 1.67 0.0154 
Ptms 19.88 33.09 1.66 0.0060 
Gadl1 12.82 21.11 1.65 0.0020 
Igfbp2 16.30 26.70 1.64 0.0048 
Fzr1 3.69 6.00 1.63 0.0304 
Stard9 0.56 0.91 1.63 0.0304 
Dchs1 9.55 15.36 1.61 0.0003 
Hspg2 3.29 5.25 1.60 0.0032 
Mbd3 17.96 28.55 1.59 0.0159 
Ftl1 366.04 580.07 1.58 0.0005 
Btbd2 6.14 9.66 1.57 0.0448 
Gm11539 64.93 102.05 1.57 0.0241 
Slc2a1 10.71 16.82 1.57 0.0241 
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Gm10736 297.16 465.70 1.57 0.0080 
Ak4 5.12 7.94 1.55 0.0241 
Tcf21 16.30 25.15 1.54 0.0435 
Kcnj8 16.16 24.92 1.54 0.0174 
Ptov1 8.15 12.56 1.54 0.0353 
Rpl28-ps3 117.87 181.03 1.54 0.0179 
Rpl8 106.07 162.57 1.53 0.0122 
Gm10116 241.13 368.70 1.53 0.0043 
Pkd1 16.29 24.80 1.52 0.0279 
Gm15501 81.93 124.63 1.52 0.0304 
Gsn 16.67 25.27 1.52 0.0255 
Eno1 60.54 91.66 1.51 0.0016 
Gm13699 309.53 467.28 1.51 0.0024 
Kif26b 4.65 7.01 1.51 0.0327 
Gm15590 512.61 771.19 1.50 0.0074 
Aldoa 84.25 126.18 1.50 0.0040 
Bat2 303.27 453.77 1.50 0.0121 
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10.2 Articles 
10.2.1 Dual lineage-specific expression of Sox17 during mouse embryogenesis. 
Authors: Eunyoung Choi; Marine R Kraus; Laurence A Lemaire; Momoko Yoshimoto; Sasidhar Vemula; 
Leah A Potter; Elisabetta Manduchi; Christian J Stoeckert; Anne Grapin-Botton; Mark A Magnuson 
Contribution: I have performed the characterization of the Sox17 CreGFP mouse line (Supplemental Figure 2). 
Sox17 CreGFP mice were crossed with Rosa26 LacZ reporter mice. The embryos were collected at E12.5. LacZ 
staining was performed as described in the material and method on sections. The sections were 
counterstained with eosin. 
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Supplementary Figures 
Supplemental Figure 1. Expression pattern of Sox17GFPCre/+ at E7.5 
A) 3D reconstruction of an E7.5 Sox17GFPCre/+ embryo. Intense GFP fluorescence was observed in the definitive 
endoderm area (arrow) and weaker expression seen in visceral endoderm area (arrowhead). Anterior (A), posterior (P), 
proximal (Pr), distal (Di). Scale bar = 100 µm. 
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Supplemental Figure 2. Cre recombinase efficiency assessment  
A-D) β -D-Galactosidase staining of E9.5 Sox17GFPCre/+;R26RLacZ/+ embryo sections showed LacZ activity in all 
endoderm-derived cells such as (A) the first branchial pouch (BP1) (B) the second branchial pouch (BP2) (C) the 
foregut (Fg), the hepatic primordium (HP) and (D) in the hindgut (Hg). It was also present in endothelia as illustrated 
for the dorsal aorta endothelium (DA). E-F) β -D-Galactosidase staining was performed on E12.5 
Sox17GFPCre/+;R26RLacZ/+ embryo sections. The recombination of the Rosa26 locus was detected in (E) the 
endocardium (heart, H) as well as in the endothelia, such as in the aorta (A). The enzyme activity was also present in all 
endoderm-derived organs, such as the liver (Li), the stomach (St), the dorsal and ventral pancreas (DP and VP), the 
small intestine (It) (F), as well as the colon and the caecum (G). Scale bar = 100 µ m (A-D, F-G), 200 µ m (E). 
Magnification insert scale bar = 20 µ m 
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Supplemental Figure 3. Fate tracing of Sox17-expressing cells at multiple stages  
A) Immunolabeling of E9.5 R26ReYFP ;Sox17GFPCre embryos revealed YFP and Foxa2 colocalization in the gut tube 
(GT), ventral pancreas (VP), and liver (Li). However, Foxa2 is not detected in YFP-positive endothelial cells (arrows). 
Scale bar = 50 µm. B) Immunolabeling of E11.5 and E15.5 R26ReYFP;Sox17GFPCre pancreata revealed YFP co-
localization with pancreatic markers, such as Ptf1a, Ngn3, Ins, and the ductal stain, Dolichos biflorus agglutinin (DBA). 
Scale bar = 50 µm. 
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Supplemental Figure 4. Fate tracing of Sox17-expressing cells in different organs  
A) Immunolabeling of E15.5 R26ReYFP;Sox17GFPCre embryos revealed YFP and PECAM colocalization in the vein 
(V), liver (Li), pancreas (P), and hepatic vein (HV). B) Immunolabeling of E9.5 R26ReYFP;Sox17GFPCre embryos 
revealed YFP and pre-HSC markers co-localization in the blood island of yolk sac. 
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Supplemental Figure 5. Analysis of the two Sox17-expressing cell populations  
A) EpCAM immunolabeling was used to analyze the number of EpCAM+ and EpCAM- cells present in E9.5 
Sox17GFPCre/+ whole mouse embryos. GFP/EpCAM co-positive cells represent ventral pancreatic cells (EpCAM+), 
and GFP-positive/EpCAM-negative cells represent hemogenic endothelial cells (EpCAM-). Percentages indicate the 
mean percentage of EpCAM+ or EpCAM- cells which are GFP-positive (n=4). B) Quantification of EpCAM+ and 
EpCAM- cells analyzed by FACS from all GFP-positive cells identified in E9.5 Sox17GFPCre/+ whole mouse 
embryos. C) The mid region including ventral pancreas (red box) was dissected from whole embryos to increase 
sorting efficiency. Immunohistochemistry on E9.5 Sox17GFPCre/+ whole mount embryo cryo-sections showed that 
GFPCre was expressed in the ventral pancreatic bud (VP) with weaker expression in the dorsal aorta (DA) in P-Sp 
area. Image was acquired using AZ100 multizoom microscope, Nikon. Zoom = 5.7x. Scale bar = 100 µm 
Choi et al, 2012  25 
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Supplemental Figure 6.  
Comparison of coverage plots on mouse Sox17 gene locus Coverage plot of uniquely mapped sequence reads (red) 
from EpCAM- and EpCAM+ samples following RNA-Seq. Predicted Sox17 transcripts taken from either the UCSC 
database (Sox17 (UCSC)) or RefSeq and EMBL/GenBank databases (Sox17 (TROMER)) are shown below mapped 
reads. Exons 1 – 5 are noted, and a CpG island spanning exons 4 – 5 is indicated. Blue box indicates exon 2 region 
which contains mapped reads for EpCAM- sample. 
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Supplementary Tables 
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Supplementary Table 4 and 5 are available on the Stem Cell website 
http://onlinelibrary.wiley.com/doi/10.1002/stem.1192/suppinfo
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10.2.2 Cell cycle-dependent differentiation dynamics balances growth and   
endocrine differentiation in the pancreas 
Authors: Yung Hae Kim, Hjalte List Larsen, Pau Rué, Laurence A. Lemaire, Jorge Ferrer, Anne Grapin-
Botton 
Contribution: I have characterized the Neurog3-RFP transgenic line mouse (Figure S3C and S3D). Guts 
were collected at E14.5. They were embedded in gelatin. Systematic uniform random sampled sections (SUR 
sections) were collected every 6 sections. Immunostainings for NEUROG3, Myc (recognizing RFP), and 
INS and GCG (Hormones) were performed. The number of RFP+ cells were counted on all the 
immunostained sections as well as the subpopulations: RFP+NEUROG3+ and RFP+Hormones+. The number 
of RFP+NEUROG3-Hormones- cells was deduced from the quantified population. The number of 
NEUROG3+RFP- cells was also quantified.  
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Supporting Information  
Text S1. Supplemental methods 
Text S1.1. Cell cycle analysis 
Pooled pancreata from 1 or 2 litters of E14.5 embryos with different genotypes from Pdx1tTA/+;Neurog3-RFP 
x tetO-H2B-GFP breeding were dissociated mechanically using 0.05% Trypsin containing DNase I (200 
U/ml), and fixed in 4% PFA. After washing with PBS, the dissociated cells were nuclear-stained by DAPI (1 
µg/ml). Then cell cycle analysis was performed by sorting GFP+ and RFP+ single cells by LSRFortessa cell 
analyzer (BD Bioscences). Cell cycle curve fitting and calculation were done using FCS express software 
(De Novo Software). 
 
 
Text S1.2. Time-lapse imaging with Neurog3-EYFP;Neurog3-RFP pancreata 
 
Pancreatic explant culture and live imaging were performed as described in the Materials and Methods, with 
imaging modifications of 10 minute intervals for up to 65 hours using a 20X glycerol-immersion objective. 
 
 
Text S1.3. Quantitative characterization of transient Neurog3-RFP response in differentiating cells 
 
To study the dynamics of cells during fate specification we performed live tracking of single cells using a 
novel Neurog3-RFP reporter. As a first step, we quantitatively characterized the response of the fluorescent 
reporter upon cell differentiation. We extracted fluorescence time traces of individual cells at a high temporal 
resolution (10 frames/hour) and used the average signal intensity over a spherical region of interest of radius 
(5 µm) approximately located around the center of cell nuclei. We selected those cells for which we could 
completely track the response of the signal. Figure S5A shows the RFP fluorescence traces for those cells 
(n=6). All cells displayed a transient rise in fluorescence followed by a rapid descent. Despite the maximum 
signal amplitude varied from cell to cell, the shape of the transient response was fairly conserved amongst 
cells. To confirm this pattern we aligned signals in time and normalized their maximum amplitude to one. 
With this transformation fluorescence signals from all cells collapsed into one stereotypical response curve 
(Figure S5B), a pulse consisting a rapid increase in fluorescence followed by an exponential decay. 
According to this shape, the total persistence of the fluorescence after the onset is of about 20-30 hours. 
Fitting an exponential to the decay we estimated an effective half-life of 5-6 hours for the RFP (Figure S5C). 
Such fast turnover indicates that the perdurance of the RFP signal might be due to constant transcription.   
Another important aspect of the dynamics of the RFP signal in reporting the cell differentiation state is the 
delay between the priming event and the reporter onset. Analysis of cells bearing both EYFP and RFP 
reporters indicates that the latter is delayed by about 2.8 to 6.3 hours with respect to the former (Figure S4D-
E). Because the onset of the EYFP reporter might also be delayed with respect to the priming event, we 
consider the estimated range to be a lower boundary of the true delay between the differentiation priming and 
the onset of the RFP reporter. 
 
 
Text S1.4. Analysis of tissue level coordination of cell differentiation 
 
Live imaging of the RFP reported onset allowed us to detect individual cells undergoing NEUROG3 
differentiation within the expanding tissue. An initial analysis of the RFP onset events pointed towards 
discrete waves of differentiation. This is best illustrated by the undulated profiles of the cell differentiation 
probability. These profiles were obtained by gaussian kernel density estimation (bandwidth: 10 minutes) and 
depicted in Figure 4A (reproduced in Figure S6B). However, because the results of kernel density estimation 
depend on the selected bandwidth, we decided to further analyze the statistics of the time intervals between 
consecutive differentiating cells. To do so, we compared our data to a homogeneous Poisson process. In such 
process each event (i.e., the RFP onset of one cell) is independent of the others, the rate of events is constant 
over time and the time between consecutive events has an exponential distribution. This means that the 
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average time between consecutive events is equal to its standard deviation and hence the coefficient of 
variation (standard deviation normalized to the mean, CV) is equal to one. Using the data of four explant 
locations during the initial 35 hours of time-lapse movies (right panels in Figure S6B), we estimated the CV 
of the time between consecutive RFP onset events to be close to one (1.16±0.08). We also computed the CVs 
using a sliding window of width 10 hours and found that this is maintained around one most of the time 
(Figure S6B, left panels). Hence, with these results we cannot completely rule out the possibility that the 
observed patterns of differentiation are mere instances of a homogeneous process.  
 
 
 
Text S1.5. Estimation of the probability of differentiation and association between cell cycle and 
differentiation priming 
 
In tissues with only two cellular types, namely a proliferating and a differentiated fate, each cell division can 
be classified into either symmetric proliferating (SP) if the two newly formed cells are proliferative (P cells); 
symmetric differentiating (SD) if the two daughters  differentiate (N cells), or asymmetric (AD) divisions if 
there is one daughter of each kind. 
 This classification provides a straightforward way to indirectly estimate the probability of cell 
differentiation, q, given the probabilities (frequencies) of division types:  
q = Pr[SD] + ½ Pr[AD]. 
That is to say, the probability of differentiation can be regarded as the contribution of all cells stemming 
from SD divisions plus half of the cells from asymmetric divisions. 
It is important to note, however, that the relation between the probability of differentiation q and the 
frequency of each division type is not unambiguous, i.e., there are infinitely many combinations of Pr[SP], 
Pr[SD] and Pr[AD] that lead to the same probability of differentiation q. Thus, given only q we cannot infer 
the frequencies of each division type.  
However, with the proportions of each division type we can test whether the fate adopted by pairs of sibling 
cells is statistically independent or tied. In the case where sibling cells decide to differentiate independently 
of each other, the frequencies of the cell division modes follow a binomial relation as in the case of allele 
frequencies of a population in Hardy-Weinberg equilibrium: 
Pr[SD] = q2,    Pr[AD] = 2q(1-q),    and    Pr[SP] = (1-q)2 
Lack of independence (or linkage disequilibrium) can be statistically assessed by means of contingency table 
tests such as Pearson’s χ2 or Fisher’s exact test. 
 
In the case developing pancreatic progenitors, we estimated the proportions of SP (P/P), AD (P/N) and SD 
(N/N) division from the in vivo clonal analysis (Figure 2H). These are 69.9%, 18.6% and 11.5%, 
respectively. From these we estimate the probability of cell differentiation to be q=0.208. That is to say, 
around 20.8% of the newly born cells will eventually differentiate. This probability of differentiation implies 
a net exponential growth of the tissue (q<0.5). If these differentiation events were independent in sibling 
cells, the proportions of each division type would be 62.7% for SP divisions, 33% for AD and only 4.3% for 
SD divisions. These proportions are far from the observed ones thus suggesting that fates of sibling cells are 
statistically linked. This is further confirmed with statistical tests on the absolute numbers of divisions 
recorded (p<10-7 for both Pearson’s χ2 or Fisher’s exact tests). Note that even though the above proportions 
have not been directly computed from the recorded raw numbers of divisions of each type (SP: 146, SD: 34, 
SD: 21), the raw relative amounts of each division mode do not differ from the above estimates 
(146/201=72.6% vs 69.9%,  33/201=17% vs 18.6% and 21/201=10.4% vs 11.5%) and nor does q (3.6% vs 
4.3%).  
 
 
Text S1.6. Mathematical modeling 
 
In order to gain conceptual and quantitative insight into the cell proliferation and differentiation dynamics 
during pancreas development, we conceived a simple model of cell cycle-dependent stochastic priming of 
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progenitors to endocrine fate. The model considers three different cell types: pancreatic progenitors (P), post-
mitotic Neurog3 cells (N), and cells primed for differentiation that will complete the division cycle (L cells). 
Each newly formed cell from a dividing P cell will adopt one of the three fates above with certain 
probabilities: a cell might differentiate with probability q or remain as a P cell with probability 1 - q. 
Furthermore, a differentiating cell might either adopt N or L fate with probabilities θ and 1- θ, respectively 
(Figure 6D). All L cells eventually divide generating two N cells. Note that the cellular state L is transient 
and thus from an experimental point of view L cells might not be distinguishable from P cells. These rules 
lead to seven different division events that can be classified into the three modes generally considered:  
- SP divisions: P → P + P,  P → L + L and P → P + L,  
- AD divisions: P → L + N and P → P + N, and  
- SD divisions: P → N + N and L → N +N. 
We have formally stated and analyzed these events in terms of a model of discrete-time dynamic equations - 
mathematical details can be found elsewhere(Rué et al., 2014). Here we briefly summarize the model results.  
- Given the parameters q and θ, the frequencies of each division mode are:  
Pr[SP] = (1-q)(1-qθ),  Pr[SD] = q(1-θ(1-q)), and Pr[AD] = (1-q)2qθ. 
- Conversely, the parameters q and θ can be inferred from the experimentally observed frequencies of 
each division mode: q = Pr[SD] + ½ Pr[AD]   and    θ =  ½ Pr[AD]/(q(1-q)). Therefore, from the in 
vivo data we estimate q=0.208 and θ=0.565. 
- The long-term composition of the tissue can also be predicted from the model. The fractions of each 
cell type are given by the following equations πP=(1-2q)(1-q)/(1- qθ), πL=(1-2q)(q-qθ)/(1- qθ) and 
πN=2q. For the experimentally estimated values the model predicts that 52.5% of the cells are 
progenitors, 41.5% are post-mitotic cells, and only 6% of the cells are of the type L (i.e., they are 
committed to differentiation but will divide once).   
- The model also discriminates between those SD divisions that are due to an L cell from those that 
occur in P cells when the two daughter cells independently adopt the N fate. The fraction of 
divisions of the former type is given by: 
    Pr[mother cell is L | SD] = (qθ-q2θ2)/(1 – θ + qθ - qθ2), and 
    Pr[mother cell is P | SD] = (1 - θ)/(1 – θ + qθ - qθ2). 
With our data we estimate these proportions to be 90.2% vs 9.8%. That is to say, the vast majority of 
SD divisions are due to cells that are already primed for differentiation before division. 
In addition to these predictions, the model can also prognosticate the dynamics of cell differentiation. For 
that to occur we need to interpret the model in a specific manner by linking the probability θ to the cell cycle 
phase. In particular, we need to assume that progenitor cells are susceptible to be primed for differentiation 
within a window of the cell cycle (which could correspond to the whole cycle or to a specific phase). In 
addition, this priming event might have different outcomes depending on whether it occurs at the beginning 
or the end of this time window. If this time window has a length of one, then θ might represent the time 
when the cell commits to cell cycle completion. Any priming event before θ implies the exit from cell cycle 
and terminal differentiation (N state adoption), and any event after θ involves a cell that will divide into two 
differentiated cells (L state adoption). Therefore, if the probability of being primed is approximately uniform 
throughout the time window, then the model presented above precisely describes this system. This 
interpretation in terms of priming time implies further testable predictions. Hereafter we assume <T> to be 
the average cell cycle and the susceptibility window to span the whole cell cycle duration: 
- Obviously, sibling cells stemming from L cells will be perfectly synchronized, as there is only one 
priming event common to both cells (it occurs in the mother L cell). Hence, according to the model, 
a perfect synchronization is expected in at least 93.8% of all SD divisions (see above). 
- On average, the time between birth and priming in differentiated cells stemming from a P cell is 
<∆tP>=½θ<T>. On the other hand, in differentiated cells stemming from a L cell this time becomes 
<∆tL>=-½(1-θ)<T> (i.e., the priming event occurs before division). Therefore, on average, N cells 
stemming from L cells will anticipate their differentiation programme by about <∆tP>-
<∆tL>=½<T> (i.e., half a cell cycle) the cells from stemming from P cells. 
- On average, lag time between birth and priming in differentiated cells stemming from asymmetric 
divisions is <∆tAD>=<∆tP> (all cells stem from a P cell). In cells stemming from SD divisions, this 
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time becomes <∆tSD>=<∆tP> Pr[mother cell is P | SD]   +  <∆tL> Pr[mother cell is L | SD]≈<∆tL>, 
and therefore cells from SD divisions anticipate those from AD divisions in differentiation by 
approximately ½<T>. 
Despite the simplicity of the model, the generated predictions are approximately fulfilled by the experimental 
data (see Figure 6), thus suggesting that the model might be capturing the dynamics of cell fate adoption 
during pancreas development.  
We decided to include more details in the model in order to generate more 
quantitatively accurate predictions and compare them to the experimental data. We 
proceeded by performing Monte Carlo simulations of the model including the observed 
variability in the cell cycle length and the delay in the onset of the reporter. In 
the simulations each newly born cell n is randomly assigned a cell cycle length Tn 
from a Gamma shifted distribution (shift 17, shape 4, scale 1). This distribution 
(Figure S9A) has a mean time of 21 hours and standard deviation of 2 hours, which 
closely resemble those measured experimentally (Figure 4D). These cells become 
randomly primed with probability q. Once a cell is primed for differentiation, it 
is assigned a delay δrep for the onset of the reporter. In the first set of 
simulations we consider this delay to be fixed to 8 hours, which we consider to be 
a reasonable delay for the RFP (see previous section for an estimate of the lower 
boundary of this delay). For each cell primed for differentiation, a random number 
r between 0 and 1 is drawn, and the priming event is considered to occur at time 
Tnr after cell birth. If r<θ then the cell differentiates into an N cell (i.e., 
becomes post mitotic). Conversely, if r≥θ the cell commits to cell cycle completion 
and divides at time Tn, giving rise to two N cells. It can be shown that the 
average behaviour of this computational model corresponds to the analytic model 
described above.  
Individual clones starting from an individual progenitor cell are simulated for a 
period of 150 hours. Figure S11 shows a graphical representation of 5 simulated 
clones. The results from the simulation of 10,000 clones are displayed in Figure 
S9. Panel B in this figure shows the distribution of times from division (of the 
mother cell) to the priming event for cells stemming from P and L cells. As 
expected, the former cells display positive times, as the decision is made after 
the last division; and the latter show negative times, as the decision is made in 
the mother (L) cell. Now, if cells are classified according to the division type 
they stem from, the results are slightly different (Figure S9C). In this case, the 
distribution of times for AD divisions is basically the same as for P mother cells 
(cf. panels B and C) but the distribution for SD divisions includes a small tail 
upwards. This tail corresponds to the residual fraction of SD divisions that stem 
from a P cell rather than from an L cell. For a constant delay of the fluorescent 
reporter, the distributions of lag times between cell division and the reporter 
onset are basically the same but shifted (cf. panels D, C in Figure S9). Now, if we 
classify differentiated cells into those stemming from AD vs SD divisions, then the 
results are slightly different (Figure S9C). Interestingly, even when the delay 
considered for the reporter is as long as 8 hours, the model predicts a very small 
fraction of cells from SD divisions that will turn on the reporter before dividing. 
We have observed this phenomenon in a few cells (Figure 5 and Table S6). The model 
simulations also anticipate a high degree of synchronization in the lag time of 
reporter onset between sibling cells (Figure S9E and 6G).  
We have also considered the effect of introducing variability in the delay of the 
RFP onset. We assumed that the delay in the RFP onset is normally distributed 
around 8 hours with a standard deviation of 0.25 (i.e, that 99.99% of cells turn on 
the RFP between 7 and 9 hours after being primed, see Figure S9F). This level of 
variability had little impact in the distribution of lag times in ACD and SCD 
originated cells (Figure S9G) and also in the synchronization of sibling cells 
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(Figure S9H). As we increased the variability in the delay, we observed that 
synchronization progressively deteriorated.  
Finally, we included the 11.6% false negative rate in the reporter (Figure S4C) of 
the model. We did that by relabeling 11.6% of the SCD originated cells as being 
originated by ACD. This re-assignation of cells introduced a tail in the lower 
range of the distribution of lag times in ACD cells (Figure S10) but overall the 
results were not significantly affected. 
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Supplementary Figure  and Supplementary Figure Legends 
 
 
Figure S1. 3-D live imaging of dividing cells in pancreatic explants. 
(A-E) Still images of 24-hour live imaging in 3-D maximum intensity projection from Movie 1, showing an 
overall growth of explant and cell divisions. Numbering denotes elapsed time in hr:min. (F-I) Images in 3-D 
projection of fixed explant with native GFP (G) and immunostained for NEUROG3 (H) and SOX9 (I). Insert 
shows NEUROG3+ cells (H, nuclear signal; arrowheads) in high magnification. Channels in (H) and (I) are 
masked by native GFP channel (G) to exclude non-specific background in mesenchymal regions. (J-O) 
Images in 3-D maximum intensity projection of immunostained control explant without imaging and laser 
exposure. The overall morphology after 48 hours of culture, equivalent to 24-hour live imaging, reveals that 
the epithelium branches (J). The white square is an area zoomed in (K-O). Cells in the trunk region are 
differentiating into NEUROG3+ endocrine progenitors (M, nuclear signal). The epithelium is intact as shown 
by E-CADHERIN staining (M), and branching ducts and acini are apically polarized as revealed by aPKC 
staining (O). Arrowheads in (K) indicate endocrine cell clusters. The blue channel (M) is masked by the 
native GFP channel (L) to exclude non-specific background in mesenchymal regions. A Z-stack is shown in 
Movie 2 (J-O). Scale bars, 50 µm. 
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Figure S2. NEUROG3+ endocrine progenitor generation is more efficient in vivo than in vitro. 
Comparison of 2-cell clone frequency distribution from in vivo clonal analysis (left column, n = 244), and in 
vitro clonal analysis (right column, n = 96) using E13.5 Hnf1bCreER;mTmG explants cultured on filters. 
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Figure S3. Neurog3-RFP transgenic line. 
(A) Construct. A 7.6 kb Neurog3 promoter region is linked to an intron, open reading frame of turboRFP, 
which contains a nuclear localization signal (NLS) and a Myc-tagC (Myc), and a bGH-PolyA signal (PolyA). 
The transgenic construct injection resulted in 2 transgenic mouse lines. (B) Optical section of a pancreatic 
explant from a Pdx1tTA;tetO-H2B-GFP;Neurog3-RFP embryo, immunostained for NEUROG3 (blue), SOX9 
(white) and aPKC (white). The RFP (red) and GFP (green) channels are native signals from each fluorescent 
protein. (C) Characterization of Neurog3-RFP in the E14.5 pancreas: Proportion of RFP+ (immunostained for 
Myc) (red) and RFP- (white) in NEUROG3+ cells, and proportion of NEUROG3+, Hormones+ (identified by 
INSULIN (INS) and GLUCAGON(GCG)) and NEUROG3-/Hormones- in RFP+ cells. (D) Optical section of 
E14.5 Neurog3-RFP pancreas, immunostained for NEUROG3 (cyan), RFP (Orange; immnostained for 
Myc), and INS and GCG (Magenta). White arrowheads indicate RFP+/NEUROG3+ cells, and yellow 
arrowheads indicate RFP+/NEUROG3- cells. Scale bars, 20 µm. Histograms and error bars represent the 
mean and standard deviation (n = 4). 
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Figure S4. Comparison of Neurog3-RFP transgenic line to Neurog3-EYFP knock-add-on line. 
(A) Scheme summarizing the genetic strategy to evaluate Neurog3-RFP fidelity compared to Neurog3-
EYFP. (B) Scheme of imaging and analysis. Pancreatic explants from E12.5 Neurog3-EYFP; Neurog3-RFP 
embryos are cultured, and 3-D time-lapse imaging is done for over 48 hours. Then, EYFP- and RFP-
expressing cells are tracked. (C) Quantification of EYFP and RFP cells at time 0 of time-lapse movies.  Note 
that EYFP+/RFP+ bar (orange) includes cells that are initially RFP- but acquire RFP over time, whereas 
EYFP+/RFP- bar indicates cells express EYFP only throughout the movie. All RFP+ cells are EYFP+ (brown 
bar). Histograms and error bars represent the mean and standard deviation (n = 3). (D) Lag time of RFP onset 
after EYFP onset. RFP expression is delayed by 4.7 (±1.1) hours in EYFP+ cells. (E) Fluorescence intensity 
of EYFP and RFP in 4 cells in time-lapse movies. The green and red lines indicate EYFP and RFP signals, 
respectively. Note RFP signal is delayed by several hours, and both EYFP and RFP signals have similar 
trend of increase and decrease over time. See Table S5 for further data. 
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Figure S5. Dynamics of Neurog3-RFP during 48-hour time-lapse. 
(A) Fluorescence intensity of individual Neurog3-RFP cells over time. Different colored lines indicate 
individual RFP cells. (B) Normalized fluorescence of all the RFP signals from (A) and aligned by 25% 
intensity to time 0. Black line indicates average intensity of all RFP signals. (C) Estimation of RFP half-life. 
Red line indicates the trend of exponential decay. RFP half-life is estimated as 5.3 hours. 
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Figure S6. Analysis of Neurog3-RFP onset from time-lapse movies. 
(A) RFP onset time distribution from 4 time-lapse movie positions (n = 56, 89, 54 and 125). Each circle 
indicates onset time of RFP cell. Red, blue, and yellow circles indicate RFP cells arising from asymmetric, 
symmetric, and RFP divisions, respectively. (B) Analyses of RFP onset Coefficient of Variance and sliding 
window for oscillatory patterns. The Coefficient of Variance of each time-lapse onset distribution is 
equivalent to a homogeneous process, which is equal to 1. 
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Figure S7. Cell cycle analysis of e14.5 Pdx1tTA/+;tetO-H2B-GFP;Neurog3-RFP pancreata. 
(A) Flow cytometry of dissociated pancreatic cells from pooled pancreata from a litter (10 embryos: 2 
GFP+/RFP+, 1 GFP+, 1 RFP+, and 6 negative pancreata) for DNA content by DAPI staining. (B) Cell cycle 
analysis of pancreatic progenitors (Pdx1tTA/+;tetO-H2B-GFP) by DAPI-stained DNA content. This panel 
shows 66.3% of cells in G1/G0 phase, 29.2% in S phase, and 4.5% in G2/M phase. (C) Cell cycle analysis of 
endocrine progenitors (Neurog3-RFP) by DAPI-stained DNA content. Note 97.2% of cells in G1/G0 phase, 
1.6% in S phase and 1.2 in G2/M phase, as endocrine progenitors are mostly post-mitotic. (D) Average cell 
cycle of pancreatic progenitors (n = 3). 68.7 (± 2.1)% of cells are in G0/G1, 26.6 (± 2.4)% in S phase, and 
4.7 (± 1.2)% in G2/M phase. 
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Figure S8. Distance between two daughters relative to time after division.  
The X axis represents the time between division and NEUROG3 end-point immunostaining. White triangles 
show the distance between 2 progenitor daughters originating from symmetric divisions (P/P), pink triangles, 
distance between 1 progenitor and 1 NEUROG3 cell from asymmetric divisions (P/N), and blue triangles, 
distance between 2 NEUROG3 cells from symmetric divisions (N/N). Distance from P/P divisions was 
measured one frame prior to daughter divisions, which time indicates doubling time between mother and 
daughter divisions. There is therefore no data point before 18 hours. Regardless of the cell division mode, the 
distance between daughters increased, as time after division increased (Pearson’s r, 0.81 (P/P), 0.33 (P/N), 
and 0.27 (N/N)). All 3 different modes of division showed statistically significant correlations between 
daughter distance and time: P/P division, p=0.0025, P/N division, p=0.0012, and N/N division, p=0.016. The 
gray line indicates 30 µm threshold used for in vivo clonal analysis for 2-cell clone boundaries. 90.2% of all 
data are under this threshold. 
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Figure S9. A model of cell cycle-dependent stochastic priming of progenitors to endocrine fate 
accounts for the observed RFP onset dynamics. 
Monte Carlo simulations of clone expansion according to the model. Each newly born cell is randomly 
assigned a cell cycle length from a Gamma shifted (A) with mean and variance matching the experimentally 
measured.  (B) Distribution of times from division to the priming event for cells stemming from P and L 
cells. Note that in the latter the priming event occurs prior to division. (C) Distribution of times from division 
to the priming event for cells stemming from AD and SD divisions. (D) Distribution of set times for a 
reporter with constant delay. (E) Lag time between the reporter onset in sibling cells. The simulations 
anticipate a high degree of synchronization. (F-H) Effect of heterogeneity in the reporter delay. (F) The 
distribution of delays of the reporter onset is assumed Gaussian. Variability in the reporter delay has little 
impact in the distribution of lag times in ACD and SCD originated cells (G) and in the synchronization of 
sibling cells (H) 
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Figure S10. Model results including cell misclassification. 
In order to account for the effect of possible misclassification biases in the distribution of lag times we 
performed an in silico misclassification experiment. We randomly sampled 11.6% of simulated cells 
stemming from SCD and classified them as stemming from ACD. The resulting distribution of reporter onset 
lag times for this latter group features a tail at low times that might partly account for the observed (cf. 
Figure 4C). This tail in the distribution, however, does not substantially affect the average lag time. 
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Figure S11. Representative in silico clone lineages generated. 
Temporal evolution of the expansion of five representative clones obtained with Monte-Carlo simulations of 
the model (q=0.2, θ=0.55). X axis indicates experimental time. All simulations start at time zero with one 
progenitor cell (P, green circle) whose cell cycle phase is set uniformly at random and run for 150 hours. 
Progenitor cells continuously divide according to the distribution of cell cycles in Figure S9A. Stochastic 
priming events are indicated by red diamonds. Events occurring early following cell division lead to cells 
exiting the cell cycle and differentiating (N cells, orange circles). Events taking place later on lead to primed 
cells that are already committed to complete the cell cycle (L cells, yellow circles) and that will give rise to 
two differentiated post-mitotic cells (N cells).  
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Supplementary Tables 
Table S1. Fraction of NEUROG3 over Pdx1tTA/+;tetO-H2B-GFP cells from immunostaining images 
after time-lapse imaging. 
  TL1 TL2 TL3 TL4 Mean SD Control* 
E14.5 
WT** 
Ngn3 # 228 333 298 243     154  
H2B-GFP # 7069 7090 5608 6644     6145  
Ngn3/GFP 0.032 0.047 0.053 0.037 0.042 0.0095 0.025 0.089±0.009 
*Explant control without imaging. 
**Ngn3/PDX1 measurements (Mean ± standard deviation) from E14.5 pancreata (n=4). 
 
Table S2. Data from NEUROG3+ cell tracking in time-lapse movies (Pdx1tTA/+;tetO-H2B-GFP). 
  TL1   TL2   TL3   TL4   Total   
Imaging 
duration 
(hr:mm) 
18:36   18:48   24:00    24:06 
 
    
total div* 221   546   250   611   1628   
Ngn3-prod. 
div* 19   38   15   30   102   
Back-traced Division Ngn3 # Division Ngn3 # Division Ngn3 # Division Ngn3 # Division 
Ngn3 
# 
Asym div 
(P/N) 24 24 24 24 21 21 36 36 105 105 
Sym div 
(N/N) 17 34 30 60 7 14 40 80 94 188 
sister lost 11 11 1 1 7 7 5 5 24 24 
sister dead 9 9 4 4 6 6 6 6 25 25 
No div   55   52   28   36   171 
lost   42   18   10   12   82 
                    
Total 61 175 59 159 41 86 87 175 248 595 
* Number of division counted in a cropped position. 
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Table S3. Data from in vivo clonal analysis (Hnf1bCreER;mT/mG). 
Sample ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 total 
No. Of Recombined 
cells* 18 65 18 61 45 95 60 40 57 40 39 60 38 65 48 61 19 31 118 63 108 16 1165 
No. of 2-cell clones 4 18 5 16 10 20 12 10 14 10 10 11 8 13 10 15 2 4 18 12 20 2 244 
SOX9+/SOX9+ 1 13 3 8 6 14 7 5 6 5 5 6 4 8 6 9 1 4 10 10 14 1 146 
SOX9+/NEUROG3+  0 0 0 1 4 0 3 2 4 3 2 1 1 2 1 5 0 0 1 1 3 0 34 
NEUROG3+/NEURO
G3+  0 2 0 2 0 1 0 1 2 0 1 1 1 1 2 1 0 0 6 0 0 0 21 
NEUROG3+/NEURO
G3-SOX9- 0 0 0 1 0 2 0 1 2 1 0 0 0 1 0 0 0 0 0 0 0 0 8 
SOX9+/SOX9-
NEUROG3- 2 1 0 3 0 0 1 0 0 1 1 2 2 1 1 0 0 0 1 0 1 0 17 
SOX9-NEUROG3-/             
SOX9-NEUROG3- 1 2 2 1 0 3 1 1 0 0 1 1 0 0 0 0 1 0 0 1 2 1 18 
*mostly 1-cell clones except 14 3-cell clones and 2 4-cell clones out of 1165 recombined cells. 
 
Table S4. Data from in vitro clonal analysis (Hnf1bCreER;mT/mG). 
Sample ID 1 2 3 4 5 6 7 8 9 10 11 Total Frequency 
2-cell clones 11 13 0 9 10 7 9 9 9 8 11 96          - 
SOX9 SCD 11 10 0 6 7 6 7 8 9 8 7 79 0.8229167 
NEUROG3/SOX9 
ACD 0 2 0 0 0 0 1 1 0 0 1 5 0.0520833 
NEUROG3 SCD 0 0 0 0 0 0 0 0 0 0 1 1 0.0104167 
SOX9+/SOX9- 0 1 0 2 2 1 1 0 0 0 1 8 0.0833333 
SOX9-/SOX9- 0 0 0 1 1 0 0 0 0 0 1 3 0.03125 
 
 
Table S5. Data from Neurog3-EYFP;Neurog3-RFP explant time-lapse. 
  exp1 exp2 exp3 Total avg stdev 
YFP+ # @t0 178 134 165 477 
RFP+ # @t0 153 110 141 404 
RFP+ # after t0 6 3 10 19 
potent. double (+)*# 159 113 151 423 
YFP+RFP- # @t0 19 21 14 54 
RFP+/YFP+ ratio @t0 0.86 0.82 0.85 0.84 0.02 
YFP+/RFP+ ratio @t0 1 1 1 1 
double (+)*/YFP+ 
ratio 0.89 0.84 0.92 0.88 0.04 
RFP-/YFP+ ratio 0.11 0.16 0.08 0.12 0.04 
*Potentially double positive cells that acquire RFP expression at later time points from time-lapse movies, 
although the cells were initially YFP+/RFP- at time 0. 
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Table S6. Data from RFP+ cell tracking in time-lapse movies (Pdx1tTA/+;tetO-H2B-GFP;Neurog3-RFP). 
  TL5   TL6   TL7   Total   
Imaging 
duration 
(hr:mm) 
48:30   47:54   48:42   
    
Back-traced Division RFP # Division RFP # Division RFP # Division RFP # 
Asym div 
(P/N) 11 11 9 9 7 7 27 27 
Sym div (N/N) 6 12 4 8 8 16 18 36 
sister lost* 3 3 5 5 3 3 11 11 
sister dead 3 3 1 1 2 2 6 6 
No division   49   17   20 86 
Lost**   146   160   103 409 
RFP+ cell 
division 2 4 0 0 1 2 3 6 
Total 25 228 19 200 21 153 65 581 
*Mostly due to low GFP signal. 
**Mostly due to moving out of Z position during backtracking. i.e. During the acquisition of images, the 
explants flatten, therefore, the majority of lost RFP cells appear during the flattening process over time. 
 
 
Table S7. Primary antibodies used for immunostainings. 
Epitope Species generated 
Dilution 
factor Provider 
Catalog 
number 
NEUROG3 goat   1:1,000 BCBC* AB2774 
SOX9 rabbit   1:2,000 Millipore AB5535 
aPKC rabbit   1:1,000 Santa Cruz sc-216 
E-CAD mouse   1:200 BD Trasduction Lab C20820 
MYC mouse   1:200 Invitrogen 13-2500 
GFP chicken   1:1,000 Abcam AB13970 
INSULIN guinea pig   1:50 Dako A0564 
GLUCAGON guinea pig   1:800 Linco 4031-01F 
*BCBC, Beta Cell Biology Consortium, funded by NIDDK U01DK072473. 
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